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Abstract of the Dissertation  
Characterization and Function of Islet Antigen Presenting Cells during NOD Diabetes  
by 
Stephen Ferris 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2017 
Professor Emil Unanue, Chair  
  
Here we characterized the initial antigen presenting cells (APCs) within the islet of 
Langerhans to ascertain their identity and functional role as it pertains to autoimmune diabetes. 
The activation of the adaptive immune system is induced by the innate immune system, and 
more specifically APCs. Therefore, it is crucial to identify the APCs that are initiating T1D in 
order to elucidate the break in tolerance and intervene in order to inhibit progression. We have 
found that there is a resident macrophage that is present in all strains of mice. This islet 
macrophage has a distinct transcriptional profile that is unique when compared to other non-
barrier tissue resident macrophages. The islet resident macrophage’s phenotype is akin to those 
macrophages found at barrier sites, i.e. the lung and the intestines. The barrier macrophages are 
constantly in contact with environmental pathogens, but the islet resident macrophage is located 
in tightly clustered mini-organs that are not in contact with barrier surfaces. We were able to 
show by RNAseq analysis that the islet resident macrophage is similar to macrophages treated 
with LPS and, thus, highly inflammatory. Furthermore, transcripts for the inflammatory 
cytokines TNFα and IL-1β found in islet macrophages were abundant and also were being 
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produced in high amounts as protein. However, we were unable to definitively ascertain any 
functional role these cytokines have whether that may be inflammatory or homeostatic. Finally, 
the islet macrophages found in NOD.Rag1-/- mice were homogenous, i.e. single cell qRT-PCR 
displayed similar gene transcripts being expressed across all cells examined. However, although 
~75% of the NOD islet macrophages expressed similar transcripts as the NOD.Rag1-/- 
macrophages, the remaining macrophages expressed an increase in inflammatory transcripts that 
are associated with interferon signaling. Finally, when compared to the non-diabetic B6.g7 islet 
macrophage, the NOD macrophage expressed differing chemokines that could be involved in 
chemotaxis of autoimmune cells into the islets.  
 In non-diabetic mouse strains, the only leukocyte found within the islets is the resident 
macrophage. In the NOD mouse, however, at approximately the age of weaning, a CD103+ 
dendritic cell (DC) is found within the islets. This DC population enters at a similar time that 
CD3ε+ T cells are entering, however, we find that the initial entry of the CD103+ DC is not 
dependent on CD3ε+ T cell entry because the CD103+ DCs represent a small fraction of the 
myeloid compartment even in NOD.Rag1-/- mice. As diabetes progresses, these CD103+ DCs 
increase and this increase is dependent upon autoreactive CD3ε+ T cell entry. By genetic 
deletion of the CD103+ DC subset of DCs (cDC1 DCs) by utilizing the Batf3-deficient mouse, 
diabetes was abolished. The cDC1 DCs were not present in the islets or in any tissue examined, 
as expected. The protection from diabetes produced by the loss of the cDC1 DCs was absolute. 
At no timepoint was there infiltration of autoreactive cells to the islet of Langerhans assayed by 
histology and flow cytometry. The CD3ε+ T cell infiltration never exceeded that of baseline seen 
in non-diabetic strains. The islet gene expression profile of the NOD.Batf3-/- mouse was 
essentially identical to the lymphocyte deficient NOD.Rag1-/- islets. The priming of autoreactive 
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CD8+ T cells was extinguished and priming of autoreactive CD4+ T cells was reduced by half. 
Transfer of naïve autoreactive T cells did not illicit entry into the islets or diabetes. However, 
diabetic splenocytes were able to confer diabetes when transferred into NOD.Batf3-/- mice. 
Therefore, the data strongly suggests the block in progression witnessed in the cDC1 DC 
deficient mouse is a lack of autoreactive T cell priming.  
 In conclusion, we have identified the major APCs residing within the islet of Langerhans 
in the NOD mouse. During the life of the mouse, there is found a resident macrophage resting in 
a basal inflammatory state. Upon weaning, a CD103+ DC enters the islet of Langerhans but only 
in the NOD strain. The NOD islet macrophage expresses aberrant chemokines when compared to 
non-diabetic strains, which may lead to the initial infiltration of either the CD3ε+ T cells or the 
CD103+ DCs. When the CD103+ DCs are absent, T1D is halted due to a block in T cell priming. 
Although the definitive trigger of diabetes is yet to be determined, we believe that within the 
interplay amongst the islet resident macrophage, the entering T cells, and CD103+ DC is the 
initiating events. Perturbing one, or all, of the arms of this triad will result in a block in diabetes. 
How they interact, activate, and propagate the process will serve as the basis for future studies 
within the lab. 
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Chapter 1 
A Brief overview of Type 1 Diabetes in mice and humans 
Brief Statement on Studying Autoimmunity 
There is a balancing act within the immune system. The immune system must be tolerant 
to self tissues but sensitive enough to eradicate invading organisms whether they are microbial, 
viral, fungal, etc. Autoimmunity occurs when there is a break down in self tolerance. This 
breakdown is manifested in many human autoimmune diseases such as multiple sclerosis (MS), 
type 1 diabetes (T1D), arthritis, lupus, and others. The conundrum in studying the pathology of 
said diseases is that animal models representing most of these diseases do not occur 
spontaneously. In many cases, forcing the immune system to become autoreactive is necessary to 
study the disease. For example, MS is mimicked by immunizing mice with a strong adjuvant in 
combination with self-myelin peptide that results in a similar, but distinct, central nervous 
system disease. This is termed experimental autoimmune encephalomyelitis. The usefulness of 
using this model is the study of the progression of disease post-initiation and has led to some 
crucial treatments. This model, however, does not occur spontaneously as is the case in the 
human MS disease. Therefore, the initiation events are a mystery. In the non-obese diabetic 
(NOD) strain of mice, these mice exhibit a spontaneous autoimmune T1D pathogenesis that is 
similar to human T1D. The importance of this mouse strain is that they spontaneously become 
diabetic, thus allowing research into the underlying mechanisms that lead to the initiation of 
autoimmune diabetes. Therefore, studying T1D in mice is useful in studying the underlying 
pathogenic initiating events in autoimmunity. 
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Type 1 Diabetes Description and History 
 Type 1 Diabetes is an autoimmune disease in which self-reactive T cells target and 
destroy the insulin producing beta cells that reside within a specialized mini-organ called the 
Islet of Langerhans (Van Belle et al., 2010; Todd, 2010). These islets are located anatomically 
within the pancreas.  The islet resident beta cells are critical for glucose regulation and storage 
through their ability to produce insulin (Lacy, 1967). The destruction of the beta cells halts the 
ability to regulate blood glucose as insulin is necessary for its clearance and storage. The result is 
ever increasing levels of blood glucose leading to kidney damage, neuropathy, and, if left 
untreated, death. The earliest description of T1D was termed Diabetes Mellitus and dates back to 
the early Egyptians, however we associate the nomenclature with the Greek term diabetes which 
translates into “to pass through” as it was known that a common association with diabetes is 
frequent urination. Mellitus, “from honey,” was added in the 1700s by a the British scientist 
Rolle to distinguish between Diabetes Mellitus and Diabetes Insipidus, a kidney or hormone 
disease also associated with frequent urination (Bockenhauer and Bichet, 2015).  This distinction 
was added because of the sweetness associated with the urine from a Diabetes Mellitus patient 
due to the elevated levels of glucose excreted in the urine. The discovery in the early 70s that 
T1D is an autoimmune disease was due to the evidence that autoimmune antibodies were 
directed to beta cell proteins (Bottazzo et al., 1974). Furthermore, treatment of recent diagnoses 
with immunosuppressives (i.e. anti-thymocyte immunoglobulin and cyclosporine A) delayed the 
progression of diabetes (Assan et al., 1986; Bach et al., 1990; Kolb et al., 1989). Along those 
lines, pancreatic isotransplants from a non-diabetic identical twin of a type 1 diabetic showed T 
cell infiltration into the donor graft corroborating the evidence that this was an autoimmune 
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mediated disease (Sutherland et al., 1984). The establishment that T1D was an autoimmune 
driven disease was a key event in understanding and studying the pathogenesis of the disease.  
 Another key advancement in the T1D field was the generation of the Non-Obese Diabetic 
mouse (NOD) strain. In 1980, Makino et al. generated the NOD mouse by interbreeding 
differing CST substrains of mice. The resulting NOD mouse strain was found to spontaneously 
develop diabetes. The discovery of a strain of mice that spontaneously developed an autoimmune 
disease set it apart from other models of autoimmunity. In the case of most models for studying 
autoimmunity, the disease must be elicited by a strong immunization of self with adjuvant, 
therefore limiting studies to the post-initiation events. These models are useful to study 
interventions post initiation but lack the ability to study the underlying mechanisms that lead to 
and produce the initial insult of disease. Therefore, the NOD mouse is the superior model in 
order to study autoimmune pathology. The final key distinction in this paper was the discovery 
of lymphocytic infiltration into and around the islets of Langerhans during the pre-diabetic stages 
of life of the mice, pointing to this mouse disease being autoimmune and therefore mimicking 
human T1D (Makino et al., 1980). The generation of this strain also allowed the field to delve 
into the underlying immunopathology of the disease and extrapolate findings while 
simultaneously translating them to the human disease.  
 The NOD mouse model of diabetes is similar in many regards to the human disease. In 
the mouse, the susceptibility factor that gives the highest propensity for disease pathogenesis is a 
variant major histocompatibility (MHC) class II allele I-Ag7. This class II allele is a variant of the 
mouse I-Ad with amino acid substitutions at positions 56 and 57 of the beta chain. The resulting 
class II allele shifts the highly conserved proline and aspartic acid to histidine and serine at the 
aforementioned positions (Acha-Orbea and McDevitt, 1987; Bell et al., 1987; Lee et al., 1987). 
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This substitution was subsequently found to be associated with human T1D patients harboring 
the DR4 or DQ8 MHC alleles (Todd et al., 1987). The risk of certain allelic combinations 
involving these MHC genes gives an odds ratio for developing T1D as high as 40 (Erlich et al., 
2008; Pociot et al., 2010). Through crystal structure analysis done by Daved Fremont in 
collaboration with our lab, it was identified that the I-Ad typical beta chain amino acid 57 
aspartic acid forms a salt bridge with the alpha chain amino acid 76 arginine. However, in the I-
Ag7 variant MHC class II, as in the human DR4 and DQ8, the aspartic acid is mutated to serine 
breaking the arginine pairing at the alpha chain at position 76 (Latek et al., 2000; Morel et al., 
1988). The consequences of this missing salt bridge were later discovered to alter the peptide-
binding repertoire of the MHC class II alleles. The preponderance of peptides that bound to the 
altered MHC class II allele now displayed an acidic amino acid at position 9, subsequently 
leading to a salt bridge between the peptide bound and the MHC itself at the alpha position 76 
arginine (Suri et al., 2005). Therefore, these slight alterations between the normal I-Ad MHC and 
NOD I-Ag7 structure drastically allowed for differential binding of peptides and an altered 
peptide-binding repertoire. Furthermore, it was shown in our lab that insulin degradation 
produced a specific peptide register on the I-Ag7 MHC class II protein. The displayed peptide is 
the register of amino acids 13-21 of the insulin beta chain molecule. However, when pulsed with 
degraded insulin, the insulin beta chain, or a peptide fragment spanning the 9-23 residues of the 
beta chain (B:9-23), not only was the 13-21 peptide presented but also a weaker binding 12-20 
peptide (Mohan et al., 2010, 2011, 2013). On its own, this data seems to be esoteric. However, it 
has been shown that insulin transcript and protein is expressed in thymic epithelial cells 
expressing the AIRE transcription factor that reside within the thymic medulla (Derbinski et al., 
2001). Therefore, only insulin protein is presented in the thymus and consequently only the 13-
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21 peptide register. Thus, if peptide fragments or degraded insulin is produced elsewhere, i.e. the 
islets, a different register could surface allowing for activation of a T cell that recognizes this 
register. Indeed, it was successively shown that the other register was presented in the islets of 
Langerhans and could activate 12-20 register specific T cells (Mohan et al., 2010). Thus, 
biochemical and cellular analysis was able to determine the role I-Ag7 may play in diabetes 
progression. The conundrum surrounding the class II association with T1D is that only 10% of 
those individuals harboring the DR4 or DQ8 mutation will develop diabetes (Todd, 2010). Along 
those lines, if the NOD I-Ag7 MHC locus is separated from the NOD genetic background and 
placed on a B6 background, the mouse does not become diabetic (Liu et al., 2009; Podolin et al., 
1993; Wicker et al., 1986, 1995). However, the necessity of I-Ag7 for initiating diabetes was 
shown by altering the NOD MHC locus to I-Ab or I-Ak with resulting mice never progressing to 
diabetes, albeit with minor insulitis (Wicker et al., 1995). Finally, transgenic expression of I-Ak 
into the NOD strain prevented diabetes development, showing I-Ak induced T cell tolerance 
could overcome the diabetogenic I-Ag7 MHC class II allele (Slattery et al., 1990).  In summary, 
these findings show that the diabetogenic allele I-Ag7 is necessary, but not sufficient for diabetes 
progression. Undeniably, there must be other genetic abnormalities found in the NOD strain that 
allow for the progression towards diabetes.  
In the NOD mouse strain, genetic loci within the mouse genome that are associated with 
diabetes progression have been identified. These are collectively termed the Insulin Dependent 
Diabetes (IDD) loci. The substitution of many of the NOD IDD loci to a non-diabetic strain loci 
allows for reduction in diabetes susceptibility (Chen et al., 2008; Eaves et al., 2002; Lyons et al., 
2001; Siegmund et al., 2000; Wicker et al., 1995). However, since the loci are generally larger, 
up to a centimorgan (cM) in length, the exact genes found within the IDD loci have not been 
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definitively identified as being involved in progression. These genes may all be slightly involved 
and altering a few would only alter diabetes little, if at all (Dugas et al., 2010; Fraser et al., 2015; 
Lord et al., 2001; Maier and Wicker, 2005; Wong et al., 2014). Therefore, their ability to initiate 
or be involved in diabetes is not well understood.  
Adaptive Immune System’s Role in T1D 
 To date, the majority of the studies of the NOD mouse have centered on the adaptive 
lymphocytes and their role in disease initiation. This should not be a surprise because the MHC 
Class II variant I-Ag7 is necessary for diabetes development pointing to abnormal CD4+ T cell 
selection and priming in NOD mice. Isolated cell transfers identified the effector cells involved 
as lymphocytes (Bach, 1994; Bendelac et al., 1987; Haskins and Wegmann, 1996; Wicker et al., 
1986; Wong et al., 1996). Indeed, the distinction that the adaptive immune response is critical is 
evidenced by the fact that lymphocyte deficient mice are protected from diabetes (Graser et al., 
2000; Serreze et al., 1994; Shultz et al., 2000; Wang et al., 1996). Furthermore, 
immunosuppressive therapy administered to mice exhibit clear reduction of incidence (Assan et 
al., 1986; Bach et al., 1990; Kolb et al., 1989).  Deeper characterization of the disease focuses it 
on being driven by autoimmune T cells as adoptive transfer of T cells, but not antibody or B 
cells, from diabetic donor mice elicits diabetes in immunodeficient recipient mice (Robinson et 
al., 1998; Wong et al., 2004). Interestingly, a B cell deficient patient harboring a mutation in 
Burton’s tyrosine kinase (Btk) succumbed to Type 1 Diabetes (Martin et al., 2001). Nevertheless, 
B cells are an important cell type involved in the progression in diabetes as B cell deficient mice 
have a reduced incidence of diabetes (Kitamura et al., 1991; Serreze et al., 1996). Whether this 
reduction is due to the improper formation of secondary lymphoid structures, reduced selection 
of autoreactive T cells, or loss of antibody production, is not well established.  Studies from our 
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and other labs have shown that insulin in particular is a key T cell autoantigen involved in 
diabetes progression. In humans, the establishment that development of insulin reactive 
autoantibodies in pre-diabetic patients results in a higher proclivity to succumb to overt diabetes 
points to insulin reactive T cells instigating an insulin reactive B cell response (Palmer et al., 
1983; Wegmann and Eisenbarth, 2000; Ziegler et al., 1989). Furthermore, the Eisenbarth 
laboratory published a seminal study showing the requirement for T cell reactivity to insulin 
during diabetes development. In this study, the authors deleted the two insulin genes, Ins1 and 
Ins2. To rescue the mouse from genetic insulin deficiency, and subsequent diabetes, they inserted 
a mutated insulin transgene under the control of the rat insulin promoter. The mutated insulin 
transgene had a single amino acid substitution in the beta chain resulting in the position 16 
tyrosine changed to alanine. The resulting mouse was termed the NOD.B16A mouse due to the 
beta chain substitution to alanine at position 16 (B16A). The mutated insulin from this mouse 
was shown to be functional in controlling levels of blood glucose. The resulting mice did not 
become diabetic (Nakayama et al., 2005). In the paper, the authors explained their findings being 
due to the mutated peptide not being capable of priming autoreactive T cells.  However, it is 
possible that the resulting mutation either disallowed the peptide involved in priming 
autoreactive CD4+ T cells to shift registers when degraded insulin is present, or, because of the 
transgenic insertion, insulin is now overexpressed in the thymus resulting in a greater ability to 
initiate T cell tolerance. Nevertheless, the findings show that T cell reactivity to insulin is a 
necessary step in diabetes progression.  
Therefore, the field focusing on the role of the T cell in T1D progression is indeed an 
important aspect of research. However, a crucial step in T cell activation is priming by the innate 
immune system. Even the most rudimentary courses in immunology teach that to generate an 
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adaptive immune response, the innate immune system must be stimulated by pathogen associated 
molecular patterns (PAMPs) or damage associated molecular patterns (DAMPs) through pattern 
recognition receptors (PRRs) (Beutler, 2009; Schaefer, 2014). Even with this general knowledge 
about the initiation of the adaptive response, the T1D field has been slow to study the innate 
immune system’s role in the progression of diabetes.  
Innate Immune System’s Role in T1D 
 To be brief, the innate immune system is composed of natural killer (NK) cells, innate-
like lymphocytes (ILCs), neutrophils, macrophages, dendritic cells (DCs), mast cells, basophils, 
and eosinophils. These cells sense external factors and initiate or alter the secondary or adaptive 
immune response. The diabetes field has little data on the innate immune system during disease 
pathogenesis. However, there are a number of studies that provide a stepping-stone for further 
investigations. Furthermore, questions arise as to the role of the innate immune system, and in 
particular antigen presenting cells, during progression of diabetes. These are: what cellular 
component of the innate immune system is involved in and crucial for the development of 
diabetes? What alteration in the NOD innate compartment allows for heightened activation 
leading to autoimmune pathology? When, if ever, can the innate compartment involved in 
diabetes progression be altered in order to delay or prevent the disease? These questions allow a 
foundational undergirding to study the innate immune compartments’ role in disease progression.  
As pertaining to the cellular components of disease progression, it first must be 
established what innate immune cells are found within the pancreatic islets of Langerhans. Early 
studies on innate immune cells within islets came from transplanting allogeneic islets. These 
studies identified cells within the islets that expressed major histocompatibility (MHC) 
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molecules. Thus, these MHC expressing cells allowed for efficient targeting of the islets for graft 
rejection (Lacy et al., 1979) . Depletion of these macrophages allowed for islet graft survival 
indicating that this APC was crucial in activating autoimmune T cells (Faustman et al., 1984). 
Along with these functional studies, histological and cytological experiments on pancreas 
sections and islets showed a resident myeloid population (Calderon and Unanue, 2012) with 
Hume defining them as macrophages by their expression of F4/80 (Hume et al., 1984). However, 
work from our lab described these cells to be dendritic cells (DCs) based on their high expression 
of CD11c, an integrin that is thought to be expressed mostly on DCs and not other APCs 
(Calderon et al., 2008, 2011). Work from other labs has corroborated the expression of CD11c+ 
cells inhabiting the islets (Melli et al., 2009). Furthermore, recent studies have described the 
islets at a very early age in the NOD mouse to have plasmacytoid dendritic cells (pDCs), B cells, 
and neutrophils (Diana et al., 2013). These three cell types were thought to interact with each 
other to generate a type 1 interferon signature, mostly through its production by the pDCs. 
Conversely, studies in this lab have been unable to find neutrophils in the islets at any time 
during diabetes progression, however pDCs and B cells can be seen in islets, albeit later than had 
been described in that paper (Carrero et al., 2013).  The discrepancy amongst different findings 
led us to investigate the characteristics and time of entry of hematopoietic cells from an early age 
to the development of diabetes in the NOD mouse. 
It is a crucial part of this thesis to finally determine the landscape of the early myeloid 
islet cells in order to proceed with experimental analysis on APC function and role during 
diabetes. To do this, one must take into account that the islet of Langerhans is separate from the 
pancreatic tissue (stroma) that surrounds it.  The stroma remains unaffected during diabetes, 
however, the myeloid and lymphoid compartments within the stroma contain leukocytes and 
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micro-lymphoid aggregates that alter the cellular phenotype of an islet preparation if not 
carefully separated. Thus, this may be the inherent reason as to why there is such discrepancy 
within the literature involving early innate leukocytic infiltrates into the islets. 
To initiate a T cell response, an antigen presenting cell (APC) must present peptides to T 
cells along with co-stimulation and helper cell driving cytokines (Reviwed in Chen and Flies, 
2013).  Therefore, it is paramount to understand the APCs involved in, and initiating, the process 
of diabetes. There are essentially two places for the initial presentation of diabetic antigens: the 
islets of Langerhans (islets) and the draining pancreatic lymph node (pLN).  These two 
anatomical sites harbor diverse subsets of antigen presenting cells that have not been sufficiently 
identified, characterized, or studied. Within the islets, we have discovered a resident macrophage 
population previously reported by Calderon et al. in 2011 to be dendritic cells (DCs) based on 
their expression of CD11c. However, recently it has been shown that these cells are indeed 
macrophages that are present within the islets at birth. These macrophages are the only 
hematopoietic cell within the islets in non-diabetic strains such as B6 and 129 (Calderon et al., 
2015). Furthermore, genetic depletion of macrophages in a non-diabetic strain using the op/op 
mouse attenuates the size and number of Islets. The op/op mouse expresses a non-functional 
CSF-1 and macrophages fail to develop in a number of organs, but most importantly, their islets 
lack macrophages (Banaei-Bouchareb et al., 2004; Mikkelsen and Thuneberg, 1999; Yamamoto 
et al., 2008). This finding points to a trophic or homeostatic role for the islet macrophage 
(Calderon et al., 2015). How do the beta cell and the islet macrophage interact to maintain this 
homeostasis? How the beta cell and the macrophages are interacting is not known, however, beta 
cells express high levels of vascular endothelial growth factor-A (VEGF-A) responsible for the 
development and maintenance of vascular structures. In a recent publication by the Power 
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laboratory, Beta cell proliferation was related to the presence of recent monocyte islet infiltrating 
cells that differentiated into macrophages in VEGF-A deficient mice (Brissova et al., 2014). In 
this paper, the authors ventured that macrophages inhabiting the islets produced a growth factor 
acting on the beta cells that allows them to proliferate and survive (Brissova et al., 2014; Xiao 
and Gittes, 2015). Yet another partner for the islets to interact with is the islet blood vessels. In 
recent findings within the lab done by Bernd Zinslemeyer, islet macrophages were always found 
in contact with the endothelial vasculature. Live images show filopodia extending between beta 
cells with some of them protruding into the vessel lumen. Macrophages also capture beta cell 
granules and can present antigens to diabetogenic T cells (Vomund et al., 2015). Therefore, the 
macrophage is in a position, if genetically predetermined, as is the case in the NOD strain of 
mice, to be involved in presenting antigens to autoreactive T cells, priming autoreactive T cells, 
and/or interacting with autoimmune infiltrating leukocytes within the circulation.  
It is clear that the macrophage within the islet is unlike other tissue-resident macrophage. 
The islet macrophage is M1 skewed and expresses high levels of MHCII by transcript and 
protein (Calderon et al., 2015). The role it plays in diabetogenesis is unclear. However, results in 
our lab have shown that the islet macrophage is picking up whole beta cell granules (Vomund et 
al., 2015). These beta cells contain up to 10,000 granules, each with up to 8 fg of insulin (Huang 
et al., 1995; Olofsson et al., 2002). This amount of insulin corresponds to an intragranular 
concentration of ~100 mM. Therefore, the endocytosis of a granule containing 100 mM insulin 
allows for an excess of insulin to flood endosomes, lysosomes, and the class II compartment. In 
vitro, it is difficult to replicate this sort of traffic of granules. Furthermore, it is even more 
difficult to obtain that concentration of insulin within the macrophage. Placed in the context of 
different epitope presentation, instead of free peptide being released by the beta cell, the sheer 
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amount of insulin could allow for aberrant presentation of the 12-20 B chain insulin epitope. 
Because the macrophage is the initial and resident APC within the islet and is picking up 
enormous amounts of insulin in the granules from beta cells, the inflammatory progression may 
begin here. Thus, the macrophage is the singular hematopoietic cell found in the non-diabetic 
islets. This allowed us to posit the question: Are there other antigen presenting cells residing in 
the NOD islet that could lead to initiation of or, at the least, progression of diabetes? 
 Previous studies have examined the NOD mouse APC compartment and found that, in 
general, there are abnormalities when compared to other strains of mice (Lau-Kilby et al., 2011). 
Discussed earlier was the function of macrophages and B cells in NOD diabetes progression. The 
other APCs capable of inducing an autoimmune response are DCs. There is now a general 
consensus amongst the DC field that there are two subtypes of DC: the plasmacytoid DC (pDC) 
and conventional DC (cDC) (Briseño et al., 2014). The pDC is so termed due to the plasma cell-
like morphology of the endoplasmic reticulum (Swiecki and Colonna, 2015). Plasmacytoid DCs 
are located in the blood and lymphoid tissue and are efficient producers of the type 1 interferons 
alpha and beta (IFNα/β) (Reizis et al., 2011; Swiecki and Colonna, 2015). Plasmacytoid DCs 
have not been extensively studied in the diabetes field. However, a recent study indicated that 
NOD diabetes was initiated by crosstalk between pDCs, neutrophils, and B cells within the islet 
microenvironment. In this paper, neutrophil extracellular traps (NETs) and soluble IgG secreted 
from activated B-1a cells residing in the peritoneal cavity activated pDCs within the islets to 
generate type 1 IFN and induce the autoimmune response (Diana et al., 2013). Depletion of any 
of the subsets or their subsequent downstream mediators reduced the incidence of diabetes. 
While it is not certain that the type of and amount of leukocytes found in the islets during the 
earliest stages of diabetogenesis found in this publication is correct (e.g. 20-50% CD45+ 
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cellularity at weaning), the role of pDC-derived interferon effecting diabetogenesis is critical to 
investigate. Along these lines, another group has shown that pDC production of type 1 IFN in the 
draining pancreatic lymph node (pLN) is crucial in diabetes initiation (Li et al., 2008). In this 
study, it was shown that there was an elevated type 1 IFN signature found in the CD4+ T cells 
isolated from the pLN of NOD mice early on in diabetogenesis (4 and 6 weeks of age).  
Blockade of the IFNα/β receptor before weaning significantly protected the mice from 
developing diabetes, increased the number of tolerogenic DCs, and increased the number of T 
cells producing the anti-inflammatory molecule interleukin (IL) 10 (Li et al., 2008). Therefore, 
pDCs in the nodes might be capable of inducing autoimmunity through aberrant production of 
type 1 IFN.  
 The literature on the role of cDCs during the progression of diabetes is also scarce and 
lacking in depth. The earliest studies on the DC compartment showed that isolated NOD bone 
marrow cultures were less proliferative and generated less cellularity when grown in macrophage 
colony stimulating factor (M-CSF) or granulocyte macrophage colony stimulating factor (GM-
CSF) when compared to non-diabetic strains (Serreze et al., 1993). Further analysis showed the 
CD8α+ DCs isolated from NOD mice were functionally different and were numerically less than 
non-diabetic cohorts (Marleau et al., 2008; Vasquez et al., 2004). The CD8α+ DC belongs to the 
cDC1 subset of DCs, and these DCs are capable of driving tolerance through generation of T 
regulatory cells (Tregs) (Darrasse-Jèze et al., 2009). There is a general consensus in the DC field 
that there are two cDC subsets: cDC1 and cDC2. The cDC1 subset is thought to be the cell type 
responsible for cross presentation and priming of CD8+ T cells (Briseño et al., 2014). Cross 
presentation is the term given to cells with the capability of taking up extracellular material, e.g. 
proteins, cellular debris, etc., and through an as of yet unknown intracellular pathway presenting 
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peptides derived from the uptake via MHC class 1 molecules (Belz et al., 2004; Dresch et al., 
2012; den Haan et al., 2000; Heath and Carbone, 2001; Joffre et al., 2012; Theisen and Murphy, 
2017). Indeed, the seminal paper published by the Murphy laboratory showed that the absence of 
this cell type through genetic ablation of the Basic helix-loop-helix ATF-like transcription factor 
3, or Batf3, resulted in complete lack of priming of CD8+ T cells. These mice were lacking the 
CD8α+ DCs located in the spleen and thymus. Subsequently, viral or cancer challenge of these 
mice failed to induce rejection of either the virus or the cancer cells (Hildner et al., 2008). 
Further studies showed that this subset consisted not only of CD8α+ cells, but also the CD103+ 
cells located in lymph nodes (Edelson et al., 2010, 2011). Finally, further characterization 
showed that these cDC1 cells homogenously express the chemokine receptor XCR1, although 
there is little evidence supporting a functional role of XCR1 in CD8+ T cell priming (Crozat et 
al., 2011; Dorner et al., 2009). Many other studies supported the fact that these cells are 
instrumental in inducing CD8+ T cell priming (Albert et al., 1998; den Haan et al., 2000; Iyoda 
et al., 2002; Pooley et al., 2001). This leads one to question the role of CD8+ T cells in diabetes. 
Indeed, the beta 2 microglublin (β2M) deficient mice do not develop diabetes and most 
importantly do not have noticeable leukocytic infiltration to the islets (Serreze et al., 1994). This 
points to the necessity of cDC1: CD8+ T cell interaction in the induction of diabetes. Another 
possible role for the cDC1 subset is the induction of tolerance. Dendritic cell deficient mice 
succumb to fatal autoimmunity (Ohnmacht et al., 2009) and deliverance of dying cells to 
dendritic cells induces peripheral CD4+ T cell tolerance (Liu et al., 2002).  Indeed, it was shown 
that the splenic CD205+ CD8α+ DCs were capable of inducing Foxp3+ T regulatory cells 
(Yamazaki et al., 2008). As stated earlier, the NOD mouse is numerically low in this cDC subset 
and this paucity could therefore lead to a breakdown in immune regulation. These cDC1 DCs, 
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when located in the thymus, were also described to select certain T cell receptors (TCRs) for 
Treg generation. When missing the cDC1 subset through Batf3-deficiency, a certain cohort of 
TCRs normally expressing Foxp3 were absent showing that this subset is crucial in inducing 
certain Tregs most likely through extracellular material uptake in the thymic medulla (Perry et 
al., 2014). However, in a subsequent paper published in the same journal, the data suggested that 
the cDC1 lineage had no effect on overall Treg numbers and phenotype (Malchow et al., 2016). 
Nevertheless, the dual nature of this subset of DC may point to differing roles in diabetogenesis. 
If these DCs are defective in any way in selecting certain Tregs, this could initiate diabetes. On 
the other hand, if the cells were crucial in priming auto reactive CD8+ T cells, their absence 
would block the initiation of diabetes and mimic the findings of the MHC class 1 null mouse and 
CD8+ T cell depletion studies.  
 The role of the cDC2 subset of DC is also uncertain, at best. These cells are not efficient 
at cross-presenting cell-associated antigens and express differing surface molecules to 
distinguish them, i.e. CD11b and DCIR2 (Price et al., 2015).  Their purported role in the immune 
system is to activate CD4+ T cells (Satpathy et al., 2012, 2013). Therefore, this DC subset could 
be involved in the initial priming of autoimmune CD4+ T cells. As stated earlier, the cDC2 
subset is found at a higher ratio compared to the cDC1 subset when NOD mice are compared to 
non-diabetic mouse strains (Marleau et al., 2008; Vasquez et al., 2004). The role these cells play 
in the advancement of diabetes is muddled by the fact that these cells share similar markers to 
infiltrating monocytes (Dong et al., 2016). During spontaneous NOD diabetes and upon 
activation and transfer of an activated diabetogenic CD4+ T cell, macrophages and monocytes 
accumulate in the islets over time (Calderon et al., 2008, 2011).  It is possible that the 
nomenclature is not correct in describing the infiltrating cells, and that is be another goal of this 
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thesis: to delineate the APC lineages involved in the initiation of diabetes. Nevertheless, 
targeting antigen to the marker DCIR2 via a coupled antibody allowed for protection of diabetes 
in the NOD mouse while targeting antigen to DEC205, a marker expressed on the cDC1 lineage, 
did not alter diabetes progression (Price et al., 2015). Therefore, these DCs can play a role in 
tolerance if forced into it by coupling antigens to a specific receptor expressed by the lineage. 
However, this does not explain their role during the development of spontaneous diabetes, nor 
does it definitively interrogate the cDC1 DCs because some cells of the cDC1 subset do not 
express the DEC205 molecule while it is also shared amongst macrophages and B cells (Gitlin et 
al., 2014; Kamphorst et al., 2010; Lahoud et al., 2012; Pasqual et al., 2015). Nevertheless, the 
role this cell plays in diabetogenesis may be important even if solely as an inhibitory DC target 
for translation to the clinic.  
 In conclusion, APCs initiate the adaptive response. While it is not clear what the APCs 
are in the islets during diabetes, this knowledge is crucial in understanding the initiating events 
and being able to formulate rational models of immune intervention. By identifying the APCs 
that are involved in diabetes and the role that they play in instigating the autoimmune response, a 
schematic can be unraveled that will illuminate pathways to inhibit disease progression.  
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Chapter 2 
A minor subset of Batf3-dependent antigen presenting cells is essential for the development 
of autoimmune diabetes 
Chapter 2 is taken directly from the first publication derived from this thesis. It was 
published in Immunity on October 15th 2014 by Stephen T. Ferris, Javier A. Carrero, James F. 
Mohan, Boris Calderon, Kenneth Murphy, and Emil R. Unanue. 
Abstract 
Autoimmune diabetes is characterized by inflammatory infiltration; however, the 
initiating events are poorly understood. We found that the islets of Langerhans in young 
nonobese diabetic (NOD) mice contained two antigen-presenting cell (APC) populations: a 
major macrophage and a minor CD103+ dendritic cell (DC) population. By 4 weeks of age, CD4+ 
T cells entered islets coincident with an increase in CD103+ DCs. In order to examine the role of 
the CD103+ DCs in diabetes, we examined Batf3-deficient NOD mice that lacked the CD103+ 
DCs in islets and pancreatic lymph nodes. This led to a lack of autoreactive T cells in islets and, 
importantly, no incidence of diabetes. Additional examination revealed that presentation of 
major histocompatibility complex (MHC) class I epitopes in the pancreatic lymph nodes was 
absent with a partial impairment of MHC class II presentation. Altogether, this study reveals that 
CD103+ DCs are essential for autoimmune diabetes development. 
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Introduction 
The progression of type 1 diabetes in non-obese diabetic (NOD) mice has been 
extensively investigated using a number of different approaches, with an emphasis on the 
involvement of different T cell subsets, effector molecules, and cytokines (Anderson and 
Bluestone, 2005). However, an evaluation of the role of specific antigen presenting cell (APC) 
subsets, particularly as it concerns the critical initial stage of presentation of beta cell antigens, 
has been examined in limited ways. Normal islets of Langerhans (islets) in all species, including 
the prediabetic NOD mouse strain, contain APCs that are required for normal islet function 
(Calderon and Unanue, 2012). These APCs take up secretory granules and are instrumental in the 
presentation of insulin peptides, a major antigenic determinant in NOD diabetogenesis (Mohan et 
al., 2010, 2013). Presentation of diabetogenic antigens in the draining pancreatic lymph nodes 
(pLN) is also seminal to diabetes development, strongly pointing to a translocation of some of 
the islet APCs into them (Gagnerault et al., 2002; Höglund et al., 1999; Kurts et al., 1997; 
Levisetti et al., 2004; Zhang et al., 2002).  
Diverse findings point out that CD4 T cell responses are a major component of the islet 
autoreactivity, particularly to insulin-derived peptides (Brezar et al., 2011; Daniel et al., 1995; 
Nakayama et al., 2005; Unanue, 2014; Wegmann et al., 1994; Zhang et al., 2008). These findings 
agree with the dependence on alleles of class II major histocompatibility complex (MHC) genes 
in disease susceptibility in both mouse and human type 1 diabetes. Although there is a strong 
influence of class II genes in both mice and humans, there is also a strong component of 
reactivity to peptides presented by class I MHC molecules for disease development. 
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Cooperativity between diabetogenic CD4 and CD8 T cells has been extensively studied in the 
NOD mouse model (Bendelac et al., 1987; Christianson et al., 1993; de Jersey et al., 2007; 
Krishnamurthy et al., 2006, 2008; Miller et al., 1988; Serreze et al., 2004). 
In the mouse, the Batf3 transcription factor regulates the differentiation of a subset of 
conventional dendritic cells (cDCs) that comprises the CD8α+ DC in secondary lymphoid organs 
and the tissue resident CD103+ DC (Edelson et al., 2010; Hildner et al., 2008; Mashayekhi et al., 
2011). This subset of cDCs is important in the presentation of class I-MHC bound peptides 
derived from microbes, dead cells, and cell bound antigens. This subset appears to be less 
involved in CD4 T cell responses. Reports examining mice with ablation of the Batf3 gene are 
enlightening in showing the role of the Batf3-dependent DC subset (herein termed the 
CD8α+/CD103+ DCs) in immune responses to viruses, tumors, and parasites (Belz et al., 2004, 
2005; den Haan et al., 2000; Liu and Nussenzweig, 2010; Pooley et al., 2001; Satpathy et al., 
2012). Previous studies show that the CD8α+/CD103+ subsets correspond to the same lineage of 
DCs (Edelson et al., 2010) 
We have evaluated here the effects of a Batf3 null mutation on the autoimmune diabetes 
of the NOD mouse. We first carried out a comprehensive cellular and gene expression analysis 
of the islet APCs of NOD mice, concluding that islets contained a small set of CD103+ DC 
together with a major component of macrophages. In NOD mice, there was an increase in the 
number of CD103+ DC in islets from the 4th to 12th week of age, coinciding with the entrance of 
CD4 T cells. This increase required autoreactivity to insulin. Next, we indicate that the absence 
of CD103+ DC in NOD.Batf3 -/- mice changed the islet genetic profile to one that resembled 
NOD.Rag1-/- mice. The NOD.Batf3 -/- mice lacked any evidence of autoreactivity and diabetes 
was absent. Therefore, a small subset of DC controls the development of diabetic autoimmunity. 
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Results 
The Batf3 null mice did not develop diabetes. 
A 129S6.Batf3-/- allele (Hildner et al., 2008) was backcrossed to the NOD background by 
speed congenic approaches and confirmed by microsatellite analysis (Table S1). Single 
nucleotide polymorphism (SNP) analysis showed that the NOD.Batf3-/- mice contained all the 
insulin-dependent diabetes (IDD) susceptibility alleles (Table S2). NOD.Batf3-/- mice developed 
normally, were resistant to diabetes, and no female mice developed disease. The cumulative 
incidence of diabetes in our female NOD colony is about 85% (Figure 1A).  NOD.Batf3+/- mice 
showed a similar incidence of diabetes. Histological analysis of the NOD.Batf3-/- mice at 
different ages showed normal islet morphology (Figure 1B-D). The islet in Figure 1B was 
representative of the typical NOD profile with intra-islet insulitis and peri-insulitis. The islets 
shown in Figure 1C-D are representative of at least 20 NOD.Batf3-/- pancreata examined. No 
lymphocyte infiltration was found in more than ~400 islets examined among the various 
samples.  
Examination of thymi, lymph nodes and spleens from NOD.Batf3-/- showed normal 
percentages and ratios of CD4+ and CD8+ T cells, but the CD8α/CD103+ DCs were low to 
undetectable (Figure 1E-I, Figure S1D-F). These results were comparable to those reported in 
129S6.Batf3-/- mice (Edelson et al., 2010; Hildner et al., 2008). The percentage of CD25+FoxP3+ 
positive T cells in the thymus, spleen, and mesenteric lymph node was identical between NOD 
mice and the NOD.Batf3-/- mice (Figure S1A-C). In summary, the only detectable immune cell 
defect in the NOD.Batf3-/- mice was the absence of the CD8α/CD103+ DC lineage.  
NOD islets of Langerhans contained macrophages and Batf3-dependent CD103+ DCs. 
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In order to place the findings related above to the events taking place in islets of NOD 
and NOD.Batf3-/- mice, it was necessary to examine clean islet APC profiles (Li et al., 2009). 
Islets from NOD contained two sets of APCs, the majority of them (80-90%) exhibited a 
macrophage profile when staining surface molecules: high surface expression of F4/80, CD11b, 
CD11c, and age-dependent surface expression of I-Ag7 (Figure 2A-D). These cells have been 
previously termed by us and others as islet DCs (Calderon et al., 2008; Ginhoux et al., 2009; 
Melli et al., 2009; Yin et al., 2012). However, a deeper analysis shows that they are 
macrophages. 
At 4 weeks of age, CD103+ DCs were found in small numbers, ranging from 2-7% of the 
islet myeloid cells (CD45+, CD11c+, MHC-II+) (Figure 2B). At this time, the percentage of 
CD45+ cells in islets ranged from 1-3% (Figure 2A). CD103+ DCs were CD11chi, expressed 
intermediate levels of CD11b and I-Ag7, but did not express F4/80 (Figure 2B-D). A small 
number of CD45+, CD11c+, MHC-II+, F4/80 negative, and CD103 negative cells were also found 
(Figure 2B).  
To further characterize the two sets of APCs and endocrine cells, qRT-PCR was 
performed on cells isolated from 10-12 week old mouse islets (Figure 2E-H, Figure S2A). 
Expression of CD3e, CD19, and Ins1 was absent from the myeloid populations ensuring the 
purity of our sorted populations (Figure 2E). Ins1 expression was solely found in the islets cells 
and Ptprc (CD45) was expressed in the myeloid populations (Figure 2E). Both the F4/80+ and 
CD103+ cells expressed Batf3, Clec9a, and Itgax (CD11c) (Figure 2F). The sorted F4/80+ cells 
expressed macrophage characteristic genes (Gautier et al., 2012): Emr1 (F4/80), Itgam (Cd11b), 
Lyz2, and Mertk, while expressing low to undetectable DC-linked genes such as Flt3, Itgae 
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(CD103), Xcr1, and Zbtb46 (Figure 2G-H). This expression profile contrasted with that of the 
CD103+ DC, which displayed high expression of Zbtb46, Xcr1, and Flt3, low expression of 
Itgam and Lyz2, and no detectable Emr1 (F4/80) (Figure 2G-H) (Crozat et al., 2011). Thus, the 
gene expression analysis together with the surface markers established the identity of the two 
major intra-islet myeloid cells as macrophages and CD103+ DCs. 
The CD103+ DCs were absent from islets of the NOD.Batf3-/- mice that contained only 
the macrophages. The third set of CD45+ cells (CD45+, CD11c+, MHC-II+, F4/80-, and CD103--) 
shown in the lower left quadrant in Figure 2B was also absent or reduced. This cell may 
represent an early stage of the CD103+ lineage in the islets, but regardless it was capable of 
presenting antigen as shown below. 
The islets of young NOD mice had a synchronous increase in CD103+ DC and T cells   
Two major changes took place in islets of NOD mice starting at 4-6 weeks of age. One 
was an increase in the number of CD103+ DCs peaking at 20% of the total myeloid population 
by the 8-12th week of age (Figure 3A,C). Second, coinciding with the increase in CD103+ DCs, 
was the appearance of CD3ε+ T cells within the islets (Figure 3B,D) (Carrero et al., 2013). No 
CD103+ myeloid cells were found in the islets of NOD.Batf3-/- mice at any time (Figure 3A,C). 
Islets from NOD.Batf3-/- mice did not contain intra-islet T cells but only the infrequent cells 
found as passenger leukocytes, their number never exceeded the baseline found in all NOD 
congenic strains (Figure 3B, D). 
In order to determine the ability of the CD103+ DC to promote T cell entry into islets, we 
utilized bone marrow chimeras to reconstitute the missing CD8α+/CD103+ DC lineage. 
NOD.Batf3-/- mice were irradiated at 3 weeks of age and NOD.Rag1-/- bone marrow was injected 
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to reconstitute the missing DC lineage without introducing Batf3 sufficient lymphocytes. The 
missing CD103+ DCs were reconstituted in both the islets and the pancreatic lymph nodes of the 
chimeras (Figure 3E, Figure S3). Most notably, the islets of the chimeric mice displayed 
lymphocyte infiltration (Figure 3E). In contrast, control NOD.Batf3-/-xRag1-/- bone marrow was 
incapable of reconstituting the CD103+ DCs or inducing lymphocyte infiltration (Figure 3E, 
Figure S3A). The pancreatic lymph node lymphocyte populations were unaffected by the bone 
marrow transfer (Figure S3B). This data reinforces the necessity of the CD103+ DCs for 
lymphocyte entry into islets and progression of type 1 diabetes.  
Non-diabetic NOD congenic strains contained low numbers of CD103+ DC throughout 
their life. 
To examine the relationship between the presence of lymphocytes and the rise in CD103+ 
DCs between the 4-12 week period, the NOD.Rag1-/- was examined. The myeloid (CD11c+, 
MHC-II, CD45+) fraction of the islets were mostly macrophages (~95%), but also showed the 
low basal number of CD103+ DC (~5%). Their islets did not show the increase in CD103+ DC 
that took place after 4 weeks of age in NOD mice (Figure 3A, C). 
In order to understand the correlation with CD103+ DC entry into islets with T cell 
pathogenicity, we examined the NOD.H4 mouse which has an intact lymphocyte compartment 
incapable of driving autoimmune diabetes (Podolin et al., 1993). Its genomic identity is derived 
from the NOD background except that it contains the H-2h4 MHC haplotype. The islets showed a 
low basal number of CD103+ DCs that never exceeded the 2-5% level of islet myeloid cells 
(Figure 3A,C); leukocytes within their islets mostly consisted of the F4/80+ macrophages (Figure 
3A). These small numbers of CD103+ DCs did not change with age. Like in other non-
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diabetogenic NOD congenic strains, lymphocytes were not present in the islets of NOD.H4 mice 
at 12 weeks, and the number of passenger T cells was about 4-6% of the very few islet CD45+ 
cells (Figure 3B, D). 
The NOD.B16A mouse was developed to examine the importance of insulin recognition 
in NOD diabetes (Nakayama et al., 2005). This strain lacks Ins1 and Ins2 gene expression and 
has an Ins2 transgene with a mutation of tyrosine 16 to alanine within the insulin beta chain. This 
mutation ablates T cell recognition of a majority of insulin reactive T cells. NOD.B16A mice do 
not develop diabetes. These findings support insulin autoreactivity as the likely initiating event 
of the diabetic process (Brezar et al., 2011; Jasinski and Eisenbarth, 2005; Unanue, 2014). We 
have reported that the NOD.B16A strain lacks the intra-islet lymphocytes that appear by the 4-6 
week of life in NOD mice. Moreover, insulin reactive CD4 T cells from a T cell receptor 
transgenic mouse do not enter their islets (Mohan et al., 2013). The islets of the NOD.B16A mice 
contained mostly macrophages with the low basal percentage of CD103+ DCs. These islets did 
not have the burst of CD103+ DCs in islets and only had the small number of passenger 
lymphocytes (Figure 3A-D). 
 These findings indicate that there is a low basal percentage of CD103+ DCs within the 
islets of all NOD congenic strains. In NOD, there is a rapid increase from the basal percentage 
that coincides with the infiltration of CD4+ T cells. From previous studies the entrance of CD4+ 
T cells precedes that of CD8+ T cells (Carrero et al., 2013). Both this basal percentage and the 
burst of CD103+ DCs were absent in mice lacking the Batf3 transcription factor. The increase 
above baseline of CD103+ DC was dependent on the presence of lymphocytes, since it was 
absent in NOD.Rag1-/- mice. Moreover, the increase in CD103+ DCs also required autoreactivity 
to insulin, e.g. it was absent in the NOD.B16A mice that did not go on to develop diabetes. 
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Reconstitution of the CD103+/CD8α+ lineage in the NOD.Batf3-/- mouse led to T cell and 
CD103+ DC entry into islets and diabetes development. Thus, for the autoreactive process to be 
activated there is an absolute requirement of both insulin reactive T cells and CD103+ DCs. 
The NOD.Batf3-/- mice displayed a transcriptional signature identical to the non-diabetic 
NOD.Rag1-/- mice. 
We performed gene expression analyses on RNA from NOD, NOD.Batf3-/- and 
NOD.Rag1-/- islets to determine if the block in diabetogenesis seen in the NOD.Batf3-/- mice had 
a unique gene expression signature. Previous studies showed that the islets of 4-6 week old NOD 
mice had an upregulation of inflammatory gene signatures enriched in interferon responsive 
genes (Carrero et al., 2013).  
The typical autoreactive gene signature of the early 6-8 week NOD mouse was absent 
from the islets of NOD.Rag1-/- and NOD.Batf3-/- mice (Figure 4). The gene expression 
differences by 6 weeks were represented as response to stress, immune response, and antigen 
processing and presentation signatures (Figure 4A,C). By 8 weeks of age, significant changes 
included inflammatory signatures compatible with immune system process and immune effector 
process signatures (Figure 4B,C). By 8 weeks of age, all major leukocyte subsets implicated in 
diabetes were represented in NOD mice (Carrero et al., 2013) but not in the islets of NOD.Batf3-
/- or NOD.Rag1-/- (Figure 4B). 
Islets from 6 week old NOD.Rag1-/- and NOD.Batf3-/- mice had virtually identical gene 
expression profiles. The only genes that were more expressed in 6 week old NOD.Rag1-/- mice 
when compared with NOD or NOD.Batf3-/- included the Mela, Reg3a, Reg3b, and Reg3g genes 
as well as a handful of islet-specific genes that did not fit a statistically significant grouping 
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(Figure 4C). These genes appear to be negatively influenced by the systemic presence of 
lymphocytes in mice, an issue that remains unresolved. 
In addition to microarray analyses, we performed qRT-PCR on cDNA from the islets of 
NOD and NOD.Batf3-/- mice. Transcripts that demonstrated inflammation of the islets, including 
Cxcl9, Gbp2, Icam1, and Vcam1 were all upregulated during the progression of diabetes (Carrero 
et al., 2013). These genes were upregulated as early as 4 weeks of age in NOD but not in 
NOD.Batf3-/- mice (Figure 5A). T cell associated genes (Cd3e; Figure 5A) were present starting 
at 4 weeks of age. No such increase was found in the islets from NOD.Batf3-/- mice. Coincident 
with T cell entry, we detected upregulation of Xcl1 and Xcr1 (Figure 5A). XCR1 was highly 
expressed on CD103+ DCs while XCL1 was produced by activated T cells (Crozat et al., 2010, 
2011; Dorner et al., 2009). This likely reflects the burst of CD103+ DCs found by flow cytometry 
in the experiments reported in Figure 3. Furthermore, there was upregulation of Ifng (Figure 5A) 
when both Cd3e and Xcl1 were upregulated, indicating the activation of T cells. These findings 
are consistent with our data showing the lack of increase of CD103+ DCs in conditions where 
anti-insulin T cells are not becoming activated or infiltrating islets (see Figure 3). The expression 
of interleukin-12 is one of the important functional hallmarks of the CD103+ DC (Mashayekhi et 
al., 2011). Il12b transcript expression was higher in the NOD than in NOD.Batf3-/- mice after 6 
weeks of age (Figure 5A). We were unable to reliably detect Il12a transcripts in our preparations 
(Figure 5A shows sporadic detection in ~2 out of 6-9 samples per time point). Finally, we 
analyzed canonical markers of myeloid cells (Lyz2) and B cells (Cd19). Consistent with our 
previous publication, Lyz2 (Figure 5A) and Cd19 (Figure 5A) expression increased at 8 weeks of 
age in NOD but not in NOD.Batf3-/- mice (Carrero et al., 2013).  
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Cytokine and chemokine transcript production was evaluated by qPCR on sorted islet 
cells from NOD.Rag1-/-, NOD.Batf3-/- (Figure 5B, S2A), and NOD (Figure 5C, S2B) mice at 10-
14 weeks of age. Cells from NOD.Rag1-/- mice were used to determine chemokine patterns in an 
uninflamed setting when compared to the NOD.Batf3-/- mice. No major differences were found.  
Purity was confirmed by gene transcript expression of Cd3e, Emr1, Ins1, and Xcr1 (Figure S4A). 
The CD45- component expressed Ccl2, Ccl19, Ccl21, and Ccl25 (Figure 5B). These correspond 
to ligands for CCR2, CCR5, CCR7, and CCR9. The islet macrophage expressed Ccl2, Ccl5, 
Cxcl9, and Cxcl10. These correspond to ligands for CCR1, CCR2, CCR3, CCR5, and CXCR3. 
No Xcl1 transcript was detectable (Figure 5B). Overall, this chemokine pattern corresponds to 
dendritic cell and T cell homing. 
To determine chemokine and cytokine transcript expression in an inflamed setting, NOD 
islet cells were sorted. To ensure cleanliness, Cd3e, Cd19, Emr1, Ins1, and Xcr1 gene transcripts 
expressed in T cells, B cells, macrophages, beta cells, and CD103+ DCs, respectively, were 
assayed and each gene transcript was solely expressed in the corresponding cell lineage (Figure 
S4B). The most notable changes in cytokine and chemokine patterns was the T cell production of 
Ifng, the T cell production of Ccl5 and Xcl1, particularly by the CD8+ subset, and the increase in 
production of chemokine transcripts by the macrophage component (Ccl2 and Cxcl9) and CD45- 
component (Ccl19 and Cxcl10) (Figure 5C). 
Figure 5D shows qPCR expression of genes for retinoic acid (RA) production: Aldh1a1 
and Aldh1a2. RA production has been associated with CD103+ CD11b+ DCs of the intestine, 
mesentery, and lung and linked to the conversion of T cells to the T regulatory cell lineage 
(Agace and Persson, 2012; Grainger et al., 2014). The expression of Aldh1a1 was undetectable in 
any of the APC populations in the islet while the expression of Aldh1a2 on the CD103+ DC 
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component was 5% of the mediastinal lymph node DC (lung DC) positive control (Figure 5D). 
This data affirms that the Islet CD103+ DC is not of the CD103+CD11b+ gut regulatory lineage. 
Antigen presentation in NOD.Batf3-/- mice in the islets and the pLNs was reduced. 
Antigen presentation was tested with known diabetogenic two CD4+ and one CD8+ T cell 
receptor (TCR) transgenic T cells in the pLN and the islet proper. The BDC2.5 TCR transgenic T 
cell (Katz et al., 1993) recognizes a beta cell antigen thought to be derived from chromogranin A 
(Stadinski et al., 2010).The CD4 T cell 8F10 recognizes the Insulin B chain peptide segment 12-
20 (Mohan et al., 2013). The CD8 TCR transgenic 8.3 recognizes a peptide from the islet-
specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) (Lieberman et al., 2003). 
To determine if the two APC of the islets in NOD could present diabetogenic peptides, we 
examined macrophages and CD103+ DCs sorted from islets of NOD mice. We have documented 
that the intra-islet APCs contained peptide-MHC complexes derived from beta cells and 
stimulated the BDC2.5 T cells as well as the 8F10 T cell (Calderon et al., 2008; Mohan et al 
2010).  Both APCs presented equally to either T cell (Figure S5). There was no presentation to 
8.3, which is an expected result (Tsai et al., 2008). 
CFSE labeled splenocytes from BDC2.5 TCR transgenic mice proliferated in the pLN of 
NOD mice but the degree of proliferation in the NOD.Batf3-/- mice was reduced to about half of 
that found in NOD mice (Figure 6A). A percentage of the injected T cells entered the islets of 
NOD mice where proliferation also took place (Figure 7A-B). However, there was no entrance of 
the labeled T cells into islets of NOD.Batf3-/- mice (Figure 7A). Lastly, islets were isolated, 
dispersed and their presentation to BDC2.5 was tested. The BDC2.5 T cell reacted equivalently 
to NOD and NOD.Batf3-/- dispersed islet cells (Figure 7C). Thus despite the macrophage 
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containing the relevant peptide-MHC complexes, in the absence of the CD103+ DC, the 
localization was impaired.  
The 8F10 TCR transgenic T cell does not proliferate in the pLN, but rather in the islets 
bypassing the pLN (Mohan et al., 2013). It entered and proliferated in the islets of NOD mice but 
did not enter the islets of the NOD.Batf3-/- mice (Figure 7D-E). The presentation from isolated 
islet cells of NOD.Batf3-/- was significantly reduced when compared to NOD (Figure 7F). Of 
note, sorted macrophage and DC populations from islets presented antigen to both the BDC2.5 
and 8F10 hybridoma indicating the presence of their cognate pMHC complexes (Figure S5A). 
CFSE labeled 8.3 T cells proliferated in the pLN of NOD mice, as expected (Lieberman 
et al., 2003). However, there was no proliferation in the lymph nodes of the NOD.Batf3-/- mice 
indicating a deficit in presentation of this class I peptide (Figure 6B).  [The 8.3 CD8 T cells did 
not migrate into NOD or NOD.Batf3-/- islets.] We were only able to detect presentation of IGRP 
peptides to the 8.3 hybridoma when sorted APCs were given exogenous peptide (Figure S5). 
The islets of the NOD.Batf3-/- mice were not receptive to the entrance of two CD4 T cell 
lines despite having presentation in the islets, albeit less efficiently in the case of the insulin 
epitope. The findings with the BDC2.5 CD4 T cells indicated that the presentation in the local 
draining node was reduced. With regards to MHC-I presentation, the NOD.Batf3-/- mice showed 
a major deficit in CD8 T cell presentation and priming. These findings support previous studies 
showing that cross-priming is required in diabetes (Yamanouchi et al., 2003). 
Finally, we examined the ability of T cells harvested from diabetic NOD mice to cause 
diabetes in NOD.Batf3-/- mice. Spleens from diabetic NOD mice contain activated diabetogenic T 
cells (Wicker et al., 1986). These splenocytes were transferred into irradiated NOD or 
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NOD.Batf3-/- mice. While about half of recipient NOD mice developed diabetes by the first 10 
days, it took 100 days for the NOD.Batf3-/- mice to become diabetic, about 10 fold longer (Figure 
7G). Thus, the results confirm that the NOD.Batf3-/- islets are less receptive to diabetogenic T 
cells. To determine if NOD.Batf3-/- mice had diabetogenic T cells we transferred splenocytes into 
NOD.Rag1-/- recipients. After 200 days post transfer, 40% of the recipient NOD.Rag1-/- mice 
became diabetic demonstrating that the defect in diabetogenesis in the NOD.Batf3-/- mouse is not 
intrinsic to the lymphocytes (Figure 7H). In sum the lack of diabetes in NOD.Batf3-/- mice is 
associated with the absence of the CD103+DC and not with a lymphocyte defect. We find 
defects in antigen presentation in islets and the pLN with a block in the entrance of diabetogenic 
T cells. 
Discussion: 
This work has established the importance of the CD103+/CD8α+ DC lineage in the 
initiation of type 1 diabetes. The absence of Batf3, and consequently this lineage, prevented the 
induction and subsequent immune infiltration of islets during diabetogenesis. Complementation 
of NOD.Batf3-/- mice with NOD.Rag1-/- bone marrow was sufficient to reconstitute the 
CD103+/CD8α+ lineage and correct the deficit.  From this and other experiments we concluded 
that: (i) the CD103+/CD8α+ DC lineage is required, and (ii) Batf3 deficiency had no effect on the 
diabetogenic capacity of lymphocytes.  
Islets of NOD mice contain a population of CD103+ DCs evident by the 3rd to 4th week of 
age along with resident macrophages, the latter representing the largest number of the islet 
APCs. For these findings on CD103+ DC to be meaningful, it was important to critically define 
the islet APC as well as the initial events at the time of the first entrance of lymphocytes. After 
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carefully isolating the islets making sure to eliminate lymphoid aggregates, only two sets of islet 
APCs were identified during the critical initiation of diabetes. Cell surface markers and gene 
expression analysis supported the separation of these resident myeloid cells into these two 
distinct lineages.  
Several crucial events in the islets characterize the initiation of diabetes. At about 3-4 
weeks of age, and only in NOD mice, three events take place: (i) an increase in the CD103+ DCs, 
(ii) the localization of CD4 T cells inside islets, presumably insulin reactive, and (iii) changes in 
gene expression. Notably, the installment of the diabetic process required two interconnected 
cells: the presence of the CD103+ DCs and of CD4 T cells recognizing immunogenic insulin. 
The absence of the CD103+ DC lineage in the NOD.Batf3-/- mouse resulted in a quiescent islet 
preventing the autoreactive diabetic process for the life of the mouse. Islets of NOD.Batf3-/- mice 
were comparable with those of the NOD.Rag1-/- mice that lack the gene signature that 
characterizes the initiation of diabetes. 
An important issue is the process whereby CD103+ DCs localize to the islets. Previous 
reports showed that CD8α+ and CD103+ DCs bear the XCR1 chemokine receptor and respond to 
the chemokine XCL1 (Crozat et al., 2010, 2011; Dorner et al., 2009). Our data showed that the 
islet CD103+ DCs are XCR1 positive and XCL1 was strongly expressed at the time that 
lymphocytes appeared in islets and more specifically by CD8+ T cells. It stands to reason that the 
expression of Xcl1 results in the increase in the CD103+ DCs. However, no Xcl1 was detectable 
in islets of mice that express the baseline number of CD103+ DCs such as in NOD.Rag1-/- mice. 
Analysis of NOD.Rag1-/- islet demonstrated the production of transcripts for chemoattractants 
responsible for DC and T cell homing. Previous studies have shown that these transcripts are 
specific to the pancreas of NOD but not in other strains of mice (Bouma et al., 2005). However, 
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their role remains unresolved. Their expression was low and, despite their presence, the islets of 
the NOD.Batf3-/- mice lacked DC or lymphocytes suggesting a non-chemokine driven process 
that drives early lymphoid and myeloid entry into islets 
Our data suggests that there are two processes that are influenced by the CD103+ DCs. 
First is the lack of lymphocyte entrance into islets missing the CD103+ DC. Because there is 
absence of T cells in the islets of the NOD.B16A mice, the anti-insulin CD4+ T cells are a major 
autoimmune driver among those entering early into islets. These anti-insulin CD4+ T cells enter 
islets of NOD mice in the absence of the pLN (Mohan et al., 2013), but were not found in the 
NOD.Batf3-/- mice. This lack of entrance was confirmed in the experiments transferring CFSE-
labeled anti-insulin CD4+ T cells into the NOD.Batf3-/- mice. The absence inflammation in islets 
from NOD.Batf3-/- mice occurred despite the presentation of diabetic peptides by the resident 
macrophages and the presence of diabetogenic T cells in the spleen. Thus, the CD103+ DC is 
essential for entrance of anti-insulin CD4+ T cells that initiate diabetogenesis. The CD103+ DC 
may be necessary for the islet to be receptive to T cell entrance through ways that we are now 
investigating. 
Second, as one probes the underlying changes in the NOD.Batf3-/- mice using the IGRP 
CD8+ reactive T cells, an absence of presentation of class I MHC epitopes is evident in the 
draining pLN. Therefore, the absence of CD103+ DC also results in the ablation of the CD8+ T 
cell response, which constitutes the effector T cell in diabetes. The involvement of CD8+ T cell 
in NOD autoimmunity has been recognized since early studies in which spleen cells transferred 
diabetes into non-diabetic NOD mice, although these required the presence of both CD4+ and 
CD8+ T cells. The requirement of CD8+ T cells was also noted in mice lacking beta 2-
microglobulin and in studies showing that CD8+ T cells directed to beta cell antigens can 
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participate in the diabetic process (de Jersey et al., 2007; Kay et al., 1996; Serreze et al., 1994, 
2004; Wang et al., 1996; Wicker et al., 1994). We posit that the CD103+ DC is the essential APC 
for diabetogenic class I MHC epitopes. This is based on the strong findings with the CD8 TCR 
transgenic T cell recognizing a peptide of IGRP. There was no presentation in the pLN, a site 
thought to be crucial for the selection and activation of CD8+ T cells (Höglund et al., 1999; Kurts 
et al., 1997; Zhang et al., 2002) . 
In summary, the data allows us to posit a model for the initiating events of the 
autoreactive process in islets of Langerhans. The first set of CD4+ T cells that enter islets are the 
insulin reactive T cells, those akin to the 8F10 TCR transgenic mouse (Mohan et al., 2013). 
These T cells initiate the autoimmune process, enter islets spontaneously without the need for 
priming in the pLN, and require both the display of immunogenic insulin and the presence of 
CD103+ DC [e.g., the findings in the NOD.B16A and NOD.Batf3-/- mice (Mohan et al., 2013; 
Nakayama et al., 2005)]. Once insulin reactive T cells encounter CD103+ DC, an amplification 
loop begins: a burst of CD103+ DCs enters islets, antigen presentation increases in the pLN, 
additional inflammatory cells enter islets, and, importantly, the autoreactive CD8+ T cells are 
primed and activated. This scenario takes place starting at about the fourth week of life and 
increases very rapidly during a limited time period, after which the diabetogenic process is in full 
operation and difficult to control. The pLNs are not required beyond three weeks of age as their 
removal does not halt the diabetic process (Gagnerault et al., 2002). This working scenario sets 
the base for future investigations. 
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Materials and Methods 
Mice 
NOD/ShiLtJ (NOD), NOD.129S7(B6)-Rag1tm1Mom/J (NOD.Rag1-/-), NOD.Cg-
Tg(Ins2*Y16A)1EllIns1tm1JjaIns2tm1Jja/GseJ (NOD.B16A), NOD.Cg-H2h4/DilTacUmmJ 
(NOD.h4), NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/DoiJ (BDC 2.5), NOD.Cg-
Tg(TcraTcrbNY8.3)1Pesa/DvsJ (8.3) mice were obtained from the Jackson Laboratory. 
NOD.Batf3-/- mice were generated by breeding the 129S-Batf3tm1Kmm/J mouse obtained from 
Dr. Kenneth Murphy to NOD. Speed congenics was utilized selecting for the highest percentage 
of NOD microsatellite markers at each generation resulting in 100% NOD microsatellite markers 
at the sixth generation of backcross. SNP analysis by the Jackson Laboratory confirmed the IDD 
loci were of the NOD background.   NOD.Batf3-/-xRag1-/- were generated by intercrossing 
NOD.Batf3-/- with NOD.129S7(B6)-Rag1tm1Mom/J.  For bone marrow reconstitution, donor 
NOD.Rag1-/- and NOD.Batf3-/-xRag1-/- were administered 150 mg/kg 5-fluorouracil (Sigma-
Aldrich, St. Louis, MO) by intraperotineal injection. The bone marrow was harvested 5 days post 
5-fluorouracil injection and transferred intravenously into 300 cGY treated 3 week old 
NOD.Batf3-/- recipients. All mouse experiments were approved by the Division of Comparative 
Medicine of Washington University School of Medicine (Association for Assessment & 
Accreditation of Laboratory Animal Care [AAALAC] accreditation number A3381-01).  
Histology and islet Isolation 
Pancreata were sectioned and stained by conventional techniques. For islet isolation, the 
pancreata were perfused (5 mL HBSS without calcium supplemented with collagenase), 
removed, and digested in a 37 °C water bath for 15 min. After shaking for 90 seconds, the 
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pancreata were washed 3 times and passed through a 70 µm filter. The remains were flushed 
from the filter and islets were handpicked using the zinc-chelating dye dithizone (Sigma-Aldrich; 
200 µg/mL 10% DMSO PBS) as a marker of islets.  
Flow Cytometry and Cell Sorting 
Flow cytometry was performed using a FACSCanto II (BD Biosciences, Franklin Lakes, New 
Jersey) and data was analyzed using FlowJo software (Tree Star Software, Ashland, OR). See 
Supplemental Information for complete antibody list. Islets were harvested as described 
previously and dispersed via Cell Dissociation Solution Non-Enzymatic (Sigma-Aldrich) for 5 
min at 37°C. Single cell suspensions were treated with 2.4G2 conditioned media (PBS, 1% 
bovine serum albumin, and 50% 2.4G2 in DMEM) at 4 °C for 15 min to block FC receptors. 
Cells were then stained with fluorescent antibodies and sorted via FACSAria II (BD 
Biosciences).  
Diabetes Monitoring 
Blood glucose was monitored daily or weekly and after two consecutive readings of ≥250 mg/dL 
mice were considered diabetic (Chemstrip 2GP, Roche Diagnostics, Indianapolis, IN).  
RNA Isolation, Real Time PCR, and Micro Array Analysis 
RNA isolation and qRT-PCR was performed as in (Carrero et al., 2013) with minor 
modifications (see supplemental materials and methods). RNA (50 ng) was amplified using 
Ovation PicoSL WTA System V2 (NuGEN, San Carlos, CA, USA) following the manufacturer’s 
instructions. Amplified RNA (100 ng) was labeled using Affymetrix GeneChip Whole Transcript 
Sense Target Labeling Assay following the manufacturer’s instructions (Affymetrix, Santa Clara, 
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CA, USA). Labeled RNA was hybridized to Mouse Gene 1.0 ST microarrays using a GeneChip 
Fluidics Station 450 (Affymetrix). Microarrays were scanned using a GeneChip Scanner 3000 
7G (Affymetrix). All GeneChip processing steps were performed by the Laboratory for Clinical 
Genomics at Washington University School of Medicine. 
In Vivo T Cell Proliferation and Antigen Presentation Assays 
8F10, BDC2.5, and 8.3 TCR transgenic mouse spleens were harvested and dispersed into single 
cell suspensions. CD4 or CD8 positive cells were selected via magnetic microbead cell 
separation (Miltenyi Biotech, San Diego, CA) according to the manufacturer’s protocol. The 
cells were then stained with 1 µM CFDA SE (Life Technologies) for 15 min at 37 °C and 
immediately quenched with 4 °C DMEM supplemented with 10% FCS. 5-10 x 106 cells were 
transferred via intravenous injection into recipient mice. After 3-7 days, islets, draining 
pancreatic lymph nodes, and inguinal lymph nodes were harvested, dispersed into single cell 
populations, and stained with fluorescent antibodies.  Flow cytometry was performed and 
analyzed as described above.  For antigen presentation assays, T cell hybridomas (5 x 104 per 
well) were cultured with dispersed islet cells (5 x 104 per well) and with peptide pulsed APC (5 x 
104 or 105 per well) as controls. After incubating for 18 hours, the culture supernatant of each 
well was assayed for IL-2 production through use of the IL-2 dependent cell line CTLL-2. 
Proliferation of CTLL-2 was assessed by [3H] thymidine incorporation.  
Statistical Analysis 
Mann–Whitney U test was used to determine the level of significant differences between 
samples and was plotted using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). 
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Antibodies 
The following antibodies were purchased from BioLegend (San Diego, CA): FITC/PE/PerCP-
Cy5.5 anti-B220 (RA3-6B2), PE anti-CD103 (2E7), PE-Cy7 anti-CD11b (M1/70), APC-Cy7 
anti-CD11c (N418), APC anti-CD205 (NLDC-145), PE-Cy7 anti-CD4 (RM4-5), BV510/APC 
anti-CD45 (30-F11), Pacific Blue anti-CD45.2 (104), FITC/PerCP-Cy5.5 anti- CD8α (53-6.7), 
PerCP-Cy5.5/APC anti-F4/80 (BM8), Alexa Fluor 488 anti-I-Ak (40F), Alexa Fluor 647 anti-
Siglec H (ebio440c), and PE anti-VB8.1/8.2 (KJ16-133.18). The following antibodies were 
purchased from eBioscience (San Diego, CA): APC anti-CCR7 (4B12), FITC/V450 anti-CD19 
(1D3), APC anti-CD25 (PC61.5), PerCP-Cy5.5 anti-CD45.1 (A20), PerCP-Cy5.5 anti-CD45.2 
(1D4), and PE anti-FoxP3 (FJK-16s). The following antibodies were purchased from BD 
Biosciences:  FITC/APC anti-CD3e (145-2C11), V450 anti-CD45.1 (A20), FITC anti-I-AKß 
(10-3.62), and PE anti-Vß4 (KT4). Alexa Fluor 488/Pacific Blue I-Ag7 (AG2.42.7) was made in 
our laboratory (Suri et al., 2002) . 
RNA Isolation and Real Time PCR 
For whole islets and sorted cell populations, total RNA was isolated using the Ambion 
RNAqueous-Micro Kit (Life Technologies, Carslbad, CA) following the manufacturer’s 
instructions. RNA was quantified by OD260 using Nanodrop (Thermo Fisher Scientific, 
Waltham, MA). For microarray analysis, RNA integrity and quantification was further validated 
using a Bioanalyzer 2100 or a Tapestation 2200 (Agilent Technologies, Santa Clara, CA). cDNA 
was made from total RNA using TaqMan Reverse Transcription Reagents (Life Technologies) 
following the random hexamer protocol. Primers for quantitative RT-PCR were designed using 
the PrimeTime predesigned qPCR assays (IDT DNA, Coralville, IA), except for the Ccl2, Ccl5, 
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Ccl19, Ccl21, Ccl25, and Cxcl10 probes, which were designed using Primer Bank 
(http://pga.mgh.harvard.edu/primerbank/). TaqMan primers and probes for detecting 18S rRNA 
was obtained from Life Technologies. PrimeTime primers employed 5’-nuclease detection 
technology and Primer Bank primers employed SYBR Green I detection technology. PCR was 
performed using SSOFast Probes Supermix or SsoFast EvaGreen Supermix  (Bio-Rad, Hercules, 
CA) on a StepOnePlus Real-Time PCR system running StepOne Software. Quality control and 
relative expression quantification for qPCR was performed by the StepOne 2.1 software. 
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Figure Legends 
Figure 1. Absence of diabetes or immunological infiltrates in NOD.Batf3-/- mice. 
(A) Diabetes incidence in female NOD (n=24), NOD.Batf3-/- (n=24), and NOD.Batf3+/- (n=8). 
Hematoxylin and eosin staining of (B) a 6 week female NOD islet, (C) a 6 week female 
NOD.Batf3-/- islet, and (D) a 52 week female NOD.Batf3-/- islet. Scale bars represent 100 µm. 
Flow cytometric profiles of CD4 and CD8 T cells from NOD and NOD.Batf3-/- (E) thymocytes 
and (F) splenocytes, respectively. Percentage of CD103+ and CD11b low to negative cells of (G) 
pLN and (H) mesenteric lymph nodes (gated on CD45+, CD11c+, MHC-II+). (I) Percentage of 
DEC205+ (CD205) and CD8α+ cells of spleen (gated on CD45+, CD11c+, MHC-II+ cells). All 
flow cytometry plots are representative of two or more independent experiments.  
Figure 2. Two sets of myeloid cells are identified in NOD mice islets. 
(A) Gating strategy for dispersed islets. (B) F4/80 and CD103 staining of myeloid cells from 4 
week and 8 week NOD (left) and NOD.Batf3-/- (right) islets as gated in panel (A). (C) CD11b 
and (D) MHC class II flow cytometry of F4/80+ (Red), CD103+ (Blue), or unstained (Green) 
islet myeloid cells as gated in panels (A). Representative flow cytometry plots and cumulative 
data from two or more independent experiments with each experiment pooling two or more 
mouse islets per sample.(E-H) Quantitative RT-PCR (qPCR) was performed on sorted 
populations of islet cells. Islets represent large and granular CD45- cells. F4/80+ and CD103+ 
were gated as shown in Figure S2A. All qPCR is represented relative to the expression of 18s 
rRNA (ΔCt). All qPCRs represent data from 2 biological replicates of 10-15 pooled female NOD 
mouse islets each performed in duplicate (error bars, SD). All mice used for qPCR were 10-12 
weeks old. 
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Figure 3. Lymphocyte infiltration is absent in NOD.Batf3-/- mice islets.  
Flow cytometric analysis of (A) CD103+ myeloid cells gated as in Figure 2A and(B) CD3ε+ 
lymphocytes (gated on CD45+ cells) from 12 week NOD, NOD.Batf3-/-, NOD.B16A, NOD.H4, 
and NOD.Rag1-/- islets. (C) Representative graph of data from (A) including time course of NOD 
from 3 to 12 weeks of age. (D) Representative graph of data from (B) including NOD time 
course from 3 to 12 weeks of age. Representative flow cytometry plots and cumulative data from 
three or more independent experiments with each experiment pooling two or more mouse islets 
per sample (error bars, SD). (E) Flow cytometry of islet lymphocyte and myeloid cells from 
NOD, NOD.Batf3-/-, and NOD.Batf3-/- that received either NOD.Rag1-/- or NOD.Batf3-/-xRag1-/- 
bone marrow 23 weeks prior to being harvested. 
Figure 4. Gene expression analysis reveals a quiescent state in NOD.Batf3-/- mice islets. 
(A-B) Microarray analysis of the islets of NOD, NOD.Batf3-/- and NOD.Rag1-/- mice. Scatter-
plots of the normalized probe intensity of all annotated microarray signals are shown for whole 
islet preparations. Each dot represents the mean of 3-6 independent biological replicates. 
Numbers labeled in red are those that are at least 2-fold different at a 99% confidence interval by 
moderated t test. Data are plotted at a log2 scale. (A) 6 week and (B) 8 week comparisons of 
NOD vs. NOD.Rag1-/- (left), NOD vs. NOD.Batf3-/- (middle), and NOD.Batf3-/- vs. NOD.Rag1-/- 
(right). Several significantly different genes are highlighted in green. (C) Gene Ontology (GO) 
analysis of the differentially expressed genes between NOD and either NOD.Rag1-/- or 
NOD.Batf3-/- at 6 or 8 weeks of age. Corrected hypergeometric p values were calculated using 
the genes selected in the scatter plots shown in panels A-B. 
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Figure 5. Real time PCR shows progression of inflammation in NOD but not NOD.Batf3-/- mice 
islets. 
(A) Taqman qPCR quantification of the indicated genes. Bars represent the mean of the ΔCt 
value of the gene of interest normalized to an Actb control. All values were adjusted by 
multiplying by a factor of 105 to facilitate visualization. Bars represent the mean +/− S.D. of 6 
biological replicates performed and tested in duplicate. P values were calculated using Mann-
Whitney U test. (B-D) The indicated populations were sorted from (B) NOD.Rag1-/- and 
NOD.Batf3-/-, (C-D) NOD mouse islets as in Figure S2B, and (D) CD11c+ MHC-II+ cells from 
mediastinal lymph nodes.  Taqman or SYBR Green I qPCR was used to quantify the indicated 
genes. Bars represent the mean +/− S.D. of 2 biological replicates performed and tested in 
duplicate. 
Figure 6. TCR transgenic T cells proliferate more effectively in the pancreatic lymph nodes of 
NOD than NOD.Batf3-/- mice. 
CFSE dilution of transferred (A) BDC2.5 NOD CD4+ T cells and (B) 8.3 NOD CD8+ T cells 
isolated from the pancreatic lymph nodes and inguinal lymph nodes from recipient 8-12 week 
NOD or NOD.Batf3-/- mice. Cells were assayed 3 days post transfer. Dots represent individual 
mice. P values were calculated using Mann-Whitney U test (*** P < 0.005). 
Figure 7. TCR transgenic T cell entrance into NOD or NOD.Batf3-/- islets and splenocyte 
transfer into recipients. 
(A) Percentage entering islets and (B) CFSE dilution of CD45.1/2 BDC2.5 NOD CD4+ T cells 
(both at day 3 post transfer). (D) Percentage entering islets and (E) CFSE dilution of CD45.1/2 
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8F10 NOD CD4+ T cells transferred into 6-12 week NOD or NOD.Batf3-/- mice (both at day 7 
post transfer). Dispersed islet cell presentation to (C) BDC2.5 hybridoma and (F) 8F10 
hybridoma as measured by CTLL-2 assay for IL-2. Each dot represents an independent T cell 
assay. Representative flow cytometry plots and cumulative data from two or more independent 
experiments. P values were calculated using Mann-Whitney U test (** P<0.005). (G) Diabetic 
NOD splenic T cells were isolated using CD90.2 magnetic beads and then 107 cells were 
transferred to the indicated irradiated (600 cGy) recipients. (H) 10-12 week old NOD or 
NOD.Batf3-/- splenocytes (107) were transferred into NOD.Rag1-/- recipients. Recipient mice in 
(G) and (H) were then monitored for diabetes. Diabetes incidence was monitored as indicated in 
the main methods section. 
Supplementary Figure Legends 
Figure S1. Characterization of NOD and NOD.Batf3-/- T regulatory cell and dendritic cell 
populations. Percentage of FoxP3+ CD4+ CD3e+ CD25+ cells in the (A) thymus, (B) pancreatic 
lymph nodes, and (C) mesenteric lymph nodes harvested from NOD and NOD.Batf3-/- mice 
(Gated on CD45+). Percentage of CD11b+ CD103- (upper left quadrant), CD11b+ CD103+ 
(upper right quadrant), and CD11b-/lo CD103+ (lower right quadrant) cells in the (D) pancreatic 
lymph nodes and (E) mesenteric lymph nodes harvested from NOD and NOD.Batf3-/- mice 
(gated according to the strategy indicated in Figure 2).  (F) Representative graph of data from 
(D-E). All mice were 6 weeks old. Representative flow cytometry plots and cumulative data 
from three biological replicates. (error bars, SD). 
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Figure S2. Gating strategy for sorting mouse islets. Single cell suspensions from islets of 
Langerhans gated in the order listed in the Figure. (A) Myeloid and (B) lymphoid cell 
populations were sorted as shown. 
Figure S3. Bone marrow reconstitution of NOD.Batf3-/- mice. (A) Flow cytometry gating 
strategy and islet myeloid population and (B) pancreatic lymph node analysis from the NOD, 
NOD.Batf3-/-, and NOD.Batf3-/- that received either NOD.Rag1-/- or NOD.Batf3-/-xRag1-/- bone 
marrow 23 weeks prior to being harvested (see Figure 7G). 
Figure S4. Quantitative RT-PCR of selected cell specific markers. (A) NOD.Rag1-/-, 
NOD.Batf3-/-, and (B) NOD islet cells were sorted and analyzed as in Figure 5. 
Figure S5. Presentation of diabetogenic epitopes to T cell hybridomas by sorted islet APC 
subsets. CD103+, F4/80+ or CD103-F4/80- APCs were isolated from the islets of 10 week NOD 
female mice according to the gating strategy indicated in Figure 2. The indicated T cell 
hybridomas (5x104) were incubated with the indicated APC subset (1x103) overnight and then 
assayed for IL-2 production as described in the main methods.  APC were either (A) left 
untreated or (B) pulsed with 10µM cognate peptide. 
Table S1. Microsatellite validation of 129.Batf3-/- backcross to the NOD background. Three 
control strains (129X1, 129S6, and 129P2) and 8 NOD.Batf3-/- mice at generation N6 were 
assayed using 111 PCR probes to the indicated microsatellites. Yellow shading indicates 129S6 
loci and purple indicates NOD loci. Numbers in the box are the size of the expected fragments. 
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Table S2. Single nucleotide polymorphism analysis of 23 IDD loci in NOD.Batf3-/- compared to 
129 and NOD. The indicated IDD loci were tested for 129S6 vs. NOD sequence identity by the 
Jackson Laboratories.  See http://jaxservices.jax.org/genome/snp.html for details. 
Supplemental Material Reference 
Suri, A., Vidavsky, I., Drift, K. van der, Kanagawa, O., Gross, M.L., and Unanue, E.R. (2002). 
In APCs, the Autologous Peptides Selected by the Diabetogenic I-Ag7 Molecule Are Unique and 
Determined by the Amino Acid Changes in the P9 Pocket. J. Immunol. 168, 1235–1243. 
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Table	S1.	Microsatellite	validation	of	129.Batf3-/-	backcross	to	the	NOD	background.	
Three	control	strains	(129X1,	129S6,	and	129P2)	and	8	NOD.Batf3-/-	mice	at	generation	N6	were	assayed	using	111	PCR	probes	to	the	indicated	microsatellites.	Yellow	shading	indicates	129S6	loci	and	purple	indicates	NOD	loci.	Numbers	in	the	box	are	the	size	of	the	expected	fragments.
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Supplemental Table 2 
SNP_ID RS_ID CHR MB_Position 129S6 NOD/LtJ NOD.Batf3-/-	Mouse #: 1 2 3 4 5 6 7 8 9 10
01-005230167-M rs3708040 1 5.22 T C Idd5.1 Idd5.3 Idd5.2 Idd5.4b C C C C C C C C C C
01-022154835-M rs3711079 1 21.93 T C Idd26 C C C C C C C C C C
01-070529579-G rs13475912 1 69.92 A G Idd5.4a G G G G G G G G G G
01-080181487-M rs3677697 1 79.3 T A Idd5.4 A A A A A A A A A A
02-043953410-M rs3678765 2 43.34 T C Idd13 C C C C C C C C C C
03-007561998-N rs4223706 3 7.55 T C Idd3 Idd17 Idd10 Idd18.4 Idd18.2 Idd18.3 Idd18.1 C C C C C C C C C C
04-003163167-M rs3694594 4 3.65 T G Idd9.1 Idd25 Idd9.2 Idd9.3 G G G G G G G G G G
04-009404597-G rs13477554 4 9.88 G A Idd11 A A A A A A A A A A
05-009804084-N rs4225033 5 4.08 A G Idd15 G G G G G G G G G G
06-006170915-M rs3700900 6 6.39 A T Idd20 Idd19 Idd6.2 Idd6.3 Idd6.1 T T T T T T T T T T
M-05782_1 rs3023106 7 3.79 G T Idd7
07-026985215-M rs3724525 7 37.26 T G Idd	not	assigned G G G G G G G G G G
07-028240185-M rs3696033 7 38.5 A A Idd27 A A A A A A A A A A
08-003089774-M rs3701395 8 3.19 C T Idd8 Idd22 T T T T T T T T T T
09-063923771-M rs3656848 9 63.2 G A Idd2 A A A A A A A A A A
11-008353761-M rs3685325 11 8.35 C G Idd4.1
11-012224593-M rs3663826 11 12.19 A G Idd4.3 G G G G G G G G G G
13-091042598-M rs3675592 13 94.48 A G Idd14 G G G G G G G G G G
14-005055006-M rs3689508 14 10.59 A T Idd12 T T T T T T T T T T
17-003335010-M rs3694565 17 5.89 C G Idd16 Idd1 Idd24 G G G G G G G G G G
17-021662242-G rs13479580 17 22.99 C T Idd23 T T T T T T T T T T
18-005066417-M rs3706767 18 5.21 C T Idd21.2 T T T T T T T T T T
18-017475340-N rs3090636 18 17.56 C A Idd21.3 Idd21.1 A A A A A A A A A A
The	indicated	IDD	loci	were	tested	for	129S6	vs	NOD	sequence	identity	by	the	Jackson	Laboratories.		See	http://jaxservices.jax.org/genome/snp.html	for	details.
Supplemental	Table	2.	Single	nucleotide	polymorphism	(SNP)	analysis	of	23	IDD	loci	in	NOD.Batf3-/- compared to 129S6 and NOD. 
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Chapter 3 
The islet resident macrophage is in an inflammatory state and senses microbial products in 
blood. 
Chapter 3 is taken directly from the second publication derived from this thesis. As of 
writing this thesis it was accepted for publication on May 9th 2017 in the Journal of Experimental 
Medicine and is in-press.  The authors are Stephen T. Ferris, Pavel N. Zakharov, Xiaoxiao Wan, 
Boris Calderon, Maxim N. Artyomov, Emil R. Unanue, and Javier A. Carrero. 
Summary 
Macrophages in pancreatic islets express a gene signature of activation consistent with 
barrier macrophages. Macrophages are poised to react to blood inflammatory stimuli. In NOD 
mice, an additional immune activation signature is observed as early as 3 weeks of age. 
Abstract 
We examined the transcriptional profiles of macrophages that reside in the islets of 
Langerhans of NOD, NOD.Rag1-/-, and B6.g7 mice at three weeks of age. Islet macrophages 
expressed an activation signature with high expression of Tnf, Il1b, and MHC-II both at the 
transcript and protein levels. These features are common with barrier macrophages of the lung 
and gastrointestinal tract. Moreover, injection of lipopolysaccharide induced a rapid 
inflammatory gene expression, indicating that blood stimulants are accessible to the 
macrophages and that these macrophages can sense them. In NOD mice, the autoimmune 
process imparted an increased inflammatory signature, including elevated expression of 
chemokines, chemokine receptors, and an oxidative response. The elevated inflammatory 
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signature indicates that the autoimmune program was active at the time of weaning. Thus, the 
macrophages of the islets of Langerhans are poised to mount an immune response even at steady 
state, while the presence of the adaptive immune system elevates their activation state. 
Introduction 
An emerging theme in macrophage biology is that each tissue macrophage is adapted to 
its local environment and provides homeostatic support (Amit et al., 2016). While all the tissue 
macrophages share core gene transcripts, including the transcription factor Spi1 (PU.1), and cell 
surface receptors such as Mertk (Mer) and Fcgr1 (CD64), a comparison of different organs 
reveals substantial differences that may relate to a specific function (Gautier et al., 2012). 
Macrophages share a common set of enhancers but these are differentially expressed in a tissue 
specific manner leading to their specialization (Kaikkonen et al., 2013; Lavin et al., 2014). For 
example, red pulp macrophages are specialized to dispose of effete red blood cells by sensing 
heme and inducing Spic (Haldar et al., 2014). Understanding how the phenotypic qualities of 
many tissue macrophages originate and are influenced by their surrounding tissues is a work in 
progress. 
The pancreas contains distinct resident macrophages in the exocrine and endocrine 
regions (Calderon et al., 2015). In each anatomical site, the macrophages differ in their 
embryonal origin and in their activation status. In an analysis performed in C57BL/6 mice, the 
inter-acinar macrophages were found to express genes and cell surface markers that categorize 
them as M2-like (anti-inflammatory) and tissue supportive. In contrast, the macrophages in the 
islets of Langerhans expressed M1-like transcripts typically associated with inflammatory 
macrophages. The islet macrophage has a homeostatic role as shown in the op/op mouse that 
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lacks functional CSF-1 protein. In these mice, the islets lack macrophages and develop poorly 
(Banaei-Bouchareb et al., 2004; Calderon et al., 2008, 2015). Also, the islet macrophages are 
intimately associated with intra-islet vessels and in close contact with beta cells (Calderon et al., 
2011). Islet macrophages take up dense core granules and can present the contents of the islet 
granule to islet reactive CD4+ T cells (Vomund et al., 2015). 
There has been confusion in the field about the identity of tissue resident macrophages 
and dendritic cells (DCs). The main reason has been the long-standing assumption that 
expression of CD11c and high MHC-II were specific markers of DC and that high F4/80 was a 
signature of the macrophage. In fact, CD11c and class II MHC expression are not definitive 
markers, many tissue resident macrophages express CD11c and class II MHC, and F4/80 levels 
vary across the macrophage lineage. Recent data has identified more faithful markers for both 
cells. In the case of macrophages, the cell surface receptors MerTK and FcγRI are among the 
most reliable markers (Gautier et al., 2012). In the case of DCs, the conventional DCs are best 
defined by a group of genes that includes Zbtb46 and Flt3, while the plasmacytoid DC (pDC) 
lineage is best defined by expression of B220, PDCA, and SiglecH (Miller et al., 2012).The islet 
macrophages are positive for expression of canonical macrophage proteins or genes such as 
MerTK, FcγRI, Sfpi1, but do not express the DC markers Zbtb46, Flt3, B220, and Siglec H 
(Calderon et al., 2015; Ferris et al., 2014).  
 Comparing the islet macrophages from non-diabetic mice with early pre-diabetic mice is 
important. The macrophages constitute the majority of the leukocytes found in islets at steady 
state and they can act as a potential modulator of T cell activation in vivo. Our studies therefore 
focus on the three week old mouse, a time before there is overt lymphocytic infiltration of islets. 
Overall, the role of the macrophage in the autoimmune diabetic process is not well understood. 
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In the NOD mouse, a strain that develops spontaneous diabetes, the first inflammatory 
transcriptional signatures that can be detected can be mapped back to myeloid cells generally and 
macrophages specifically (Carrero et al., 2013). At this early stage in NOD diabetogenesis, a 
second myeloid cell, the Batf3-dependent XCR1+ DC, enters the islets, but the relationship 
between the two cells is not known. The importance of myeloid cells in diabetogenesis is 
reinforced by the finding that the NOD.Batf3-/- mice lacking XCR1+ DCs never develop diabetes 
(Ferris et al., 2014).  
Islet macrophages from two strains of non-diabetic mice were in an activated state 
comparable to other barrier macrophages, such as those found within the lung and the intestine. 
They expressed high class II MHC complex (MHC-II), TNFα, and IL-1β, all at the transcript and 
protein level, as well as a host of other inflammatory mediators and sensors. Importantly, the 
islet macrophages are sampling blood contents, as there was increased expression of 
inflammatory transcripts following treatment with intravenous lipopolysaccharide (LPS). In the 
NOD mouse, the islet macrophage was sensitive to the presence of an adaptive immune system, 
having an increased expression of inflammatory transcripts. Interferon inducible gene signatures 
were identified in macrophages from 3 week-old NOD mice, clearly indicating that the diabetic 
process was already underway very early in the life of the mouse. Finally, in a deeper analysis of 
the islet macrophages, a quarter of the NOD macrophages had increased inflammatory 
transcripts above those found in the basal state.  
Results 
Core features of the NOD, NOD.Rag1-/-, and B6.g7 islet resident macrophages  
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We isolated 3 week old islet macrophages (CD45+F4/80+MHCII+) using the gating 
strategy shown in Figure S1A. Note that 85-95% of the CD45+ cells in the islets of the 3 week 
old NOD mice are macrophages, the remaining cells are mostly CD3ε+ T cells (see also Melli et 
al., 2009). [Previous reports showed that islets at 3 weeks or earlier contained B cells, 
neutrophils, and pDCs (Diana et al., 2013; Diana and Lehuen, 2014). However, our experimental 
analysis did not reproduce these findings (See Figs. S2 and S3)]. 
We compared macrophages isolated from NOD, NOD.Rag1-/-, and B6.g7 mice pancreatic 
islets for their gene expression profiles and cell surface marker expression.  Examination of the 
NOD.Rag1-/- and B6.g7 mice established their basal features independent of autoimmune 
inflammation. All mice used in this study were housed in an advanced pathogen-free barrier 
facility, develop normally, and did not have any indication of infections.  
 We also included lung macrophages and pancreatic lymph node XCR1+ DCs 
(CD45+CD11c+MHC-II+CD172anegCD11bnegXCR1+) for additional comparisons (Figs. S1B-C). 
A preliminary analysis of the islet macrophage data using the Immunological Genome Project 
(Immgen) "My Geneset" tool showed that the lung and intestinal macrophages most closely 
resembled those of the islet (Heng et al., 2008). We chose the lung macrophage to determine 
both common and unique gene expression signatures of the islet macrophage when compared to 
other tissue macrophages. (There are two annotated lung macrophages in Immgen: the "lung 
CD11b+ macrophage" that is CD11bhiCD11c+MHCII+CD103negCD24neg and the "lung 
macrophage" that is CD11c+MHCIInegCD11bnegCD103negSiglecF+. Our preliminary analysis 
showed high similarity between the islet macrophage and the "lung CD11b+ macrophage" 
leading us to examine that population.) The XCR1+ DCs represent a different phagocyte lineage 
that is highly relevant for the initiation of diabetes (Ferris et al., 2014). The absence/paucity of 
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these DC in islets at the 3-week window made it difficult to analyze them, so instead we isolated 
them from the pancreatic lymph node based on their expression of XCR1. This combination of 
tissues and cell types allowed us to interrogate several questions about the transcriptional profile 
and biology of the islet macrophage.  
The top expressed transcripts in 3 week old islet macrophages showed similar values 
(Figs. 1A-C). Housekeeping genes, such as transcriptional regulators and cell structural genes, 
i.e., Actb, Fosb, and Hspa5, were comparably expressed (Fig. 1A, Table S1). Most canonical 
myeloid genes were comparably transcribed in both islet macrophage and in lymph node DCs 
(Fig. 1B; Gautier et al., 2012). Included in this group were the MHC-II antigen presentation 
genes H2-Aa, H2-Ab1, H2-Eb1, and Cd74. The islet macrophages do not initially express 
uniformly high MHC-II on their surface (Calderon et al., 2015). At 2 weeks of age they have 
varying levels of MHC-II on their surface. However, by 4 weeks of age, MHC-II expression 
becomes uniformly high (Fig. S1D). Unlike DCs, high expression of MHC-II genes is not a basal 
condition in all tissue-resident macrophages. Microglia, the large peritoneal macrophages, and 
alveolar macrophages express low levels of MHC-II genes and the master regulator Ciita (Fig. 
S1E shows data from Immgen).  
Three additional classes of genes integral to the initiation of an adaptive immune 
response were expressed highly in islet macrophages: (i) costimulatory molecules, (ii) pattern 
recognition molecules (toll-like receptors, TLRs), and (iii) chemokines (Fig 1D-G).  
(i) The most notable co-stimulatory genes were the activating ligands Cd86 and Pvr (CD155) 
and the inhibitory ligands Lgals3 (Galectin-9) and Cd274 (PD-L1) (Fig. 1D); 
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 (ii) Most TLR genes and adaptor proteins were expressed at high levels, including Tlr1, Tlr2, 
Tlr3, Tlr4, Tlr6, Tlr7, Tlr8, Tlr9, Tlr12, and Tlr13 allowing the islet macrophages to sense 
different microbial patterns (Fig. 1E)(Kawai and Akira, 2011; Koblansky et al., 2013; Oldenburg 
et al., 2012). In contrast, the XCR1+ DC had reduced/absent expression of most of the TLRs 
except for Tlr3, Tlr9, and Tlr11. 
(iii) The chemokine expression consisted of genes capable of attracting myeloid cells (Ccl3, 
Cxcl14), macrophages (Ccl9, Cxcl14), neutrophils (Cxcl1, Cxcl2), NK Cells (Ccl3), NK T cells 
(Cxcl16), T cells (Ccl4, Cxcl9, Cxcl10, Cxcl16) and Treg T cells (Cxcl9) (Fig. 1F)(Castellino et 
al., 2006; Dufour et al., 2002; Griffith et al., 2014; Kurth et al., 2001; Matloubian et al., 2000; 
Yamada et al., 2012; Zhao et al., 2003). Finally, islet macrophages expressed chemokine 
receptors found in inflammatory leukocytes (Ccr2, Ccr5), developing leukocytes (Cxcr4), barrier 
macrophages (Ccr2, Ccr5, Ccrl2, Cx3cr1, Cxcr4), and microglia (Cx3cr1), but whose combined 
pattern of expression most resembled barrier macrophages (Fig. 1G)(Gautier et al., 2012; Griffith 
et al., 2014). 
Several myeloid genes were differentially expressed in the islet macrophages compared 
to the lymph node DC. Among these were Atf3, Rasgef1b, and Rgs1 (Fig. 1B). Atf3 is 
downstream of TLR4 signaling and acts as a negative regulator of cytokine transcript expression 
following LPS treatment (Gilchrist et al., 2006). Rasgef1b encodes a guanine-nucleotide 
exchange factor induced by TLR signaling and believed to activate Ras-like proteins (Andrade et 
al., 2010). Rgs1 encodes a regulator of G-protein coupled signaling that antagonizes chemokine 
receptor signaling (Moratz et al., 2004; Reif and Cyster, 2000). Genome-wide association studies 
have linked Rgs1 to celiac disease and type I diabetes, but its exact function in autoimmunity is 
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poorly defined (Smyth et al., 2008). All three of these genes (Atf3, Rasgef1b, and Rgs1) are also 
highly expressed in lung and intestinal macrophage (Heng et al., 2008).  
For validation purposes, we identified a number of cell surface receptors using the 
Panther classification system (Mi et al., 2013, 2016). In this way, CD44, CD53, CD83, and TLR-
7 were identified and validated by flow cytometry as shown in Figure S1F.  
NOD islet macrophages expressed higher levels of inflammatory transcripts than 
NOD.Rag1-/- at 3 weeks of age. 
We compared the gene expression profiles of the NOD, NOD.Rag1-/-, and B6.g7 islet 
macrophages, the CD11b+ lung macrophage, and the XCR1+ DC. Principal component analysis, 
based on the top 5% of gene expression variance, clustered the islet macrophages tightly along 
the first and second components, and related them more closely to the CD11b+ lung macrophage 
than to the lymph node XCR1+ DCs. (Fig. 2A). Pearson correlation and hierarchical clustering 
reinforced this point demonstrating the similarity between NOD, NOD.Rag1-/-, and B6.g7 
macrophages (Figs. 2B-C).  
The NOD macrophage at 3 weeks contained an added activation signature not found in 
the NOD.Rag1-/- macrophage. Using DESeq2, we found 542 genes differentially expressed at 2-
fold counts and adj. P-val ≤ 0.05 (Fig. 2D-E). Of these, 314 were upregulated in NOD and 228 
were upregulated in NOD.Rag1-/- (Fig. 2D).  
By hypergeometric analysis, the major Gene Ontology (GO) pathways enriched in NOD-
upregulated genes mapped to Signal transduction, Cellular biosynthetic process, Inflammatory 
response, Response to external stimulus, and Defense response (Fig. 2F). The top C2 pathways 
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(Curated Gene Sets) enriched in NOD macrophages mapped to KEGG oxidative 
phosphorylation, KEGG huntingtons disease, Naba matrisome associated, and KEGG 
cytokine/cytokine receptor interaction (Fig. 2F)(Kanehisa and Goto, 2000; Mootha et al., 2003). 
We performed gene set enrichment analysis using Broad Institute software (GSEA, 
(Subramanian et al., 2005)) and this revealed a correlation of the NOD upregulated genes with 
the GO MsigDB biological process gene signatures that associate with protein synthesis 
machinery, oxidative phosphorylation, inflammation, cellular response to reactive oxygen 
species, and cell proliferation (Fig. 2G) [P-val < 0.002 and FDR q-val < 0.05: Protein Folding 
(GO Term:0006457), Translational Initiation ((GO Term: GO:0006413), Response to Oxidative 
Stress (GO Term: 0006979), Cellular Biosynthetic Process (GO Term:0044249), Behavior (GO 
Term:0007166), Inflammatory Response (GO Term:  0006954)].  
These findings show that the NOD macrophages are transcriptionally and metabolically 
more active than their NOD.Rag1-/- counterparts. First, the behavior and inflammatory response 
grouping contained NOD-upregulated genes involved in chemotaxis, including the chemokine 
receptors Ccr1 and Ccr7 as well as the chemokines Ccl5, Cxcl2, and Cxcl9 (Figs. 2H-I). Second, 
the islet macrophages displayed an upregulation of interferon inducible genes, including Cxcl9 
and Ccl5, along with early innate immune mediators such as Cd40 Figs. H-I). A majority of 
these genes are associated with pathogen associated molecular pattern (PAMP) signaling and are 
discussed in greater detail in a later section. Third, the response to oxidative stress signature 
contained upregulated genes encoding proteins with an antioxidant role in cells (Fig. 2J). For 
example, Sod1 encodes superoxide dismutase 1 one of two enzymes responsible for converting 
superoxide radicals to molecular oxygen and hydrogen peroxide (Fridovich, 1995). Prdx2 and 
Prdx5 encode peroxiredoxin 2 and peroxiredoxin 5 antioxidant enzymes that reduce hydrogen 
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peroxide and alkyl hydroperoxides (Wood et al., 2003). Finally, the oxidative phosphorylation 
gene signature contained genes whose products are components of the four major complexes of 
the mitochondrial electron transport chain as well as the ATP synthase complex (Fig. 2K). 
Combined, these findings point to an increase in the oxidative activity of the NOD macrophages 
compared to those of the NOD.Rag1-/- macrophages. 
NOD macrophages at 3 weeks of age already display transcriptional signatures of diabetes 
progression 
We examined whether transcripts found during diabetes progression might be 
upregulated in the 3-week-old NOD macrophage (Fig. 3A). We did this by comparing the islet 
macrophage transcriptional signature to our previous chronological analysis of whole islets in 
NOD diabetes (Carrero et al, 2013). Our previous dataset contains the whole islet transcriptional 
analysis of T1D progression in the NOD mouse from 2 weeks of age until the onset of diabetes 
(~20–30 weeks). This dataset also included control samples from mice that never developed 
diabetes: B6.g7, C57BL/6 and NOD.Rag1-/-. We calculated Pearson correlation of whole islet 
transcriptomes based on the transcripts differentially upregulated in NOD macrophages (the 314 
genes described in Fig. 2D-E, adj. P-val ≤ 0.05 and MLE-adjusted fold-change ≥ 2). Those same 
314 genes were used to calculate Pearson's correlation between whole islet transcriptomes that 
ranged between two weeks of age and diabetic onset. We found a gradually increasing and 
positive correlation from two weeks to diabetic onset (Fig. 3A).  
The upregulated transcripts parsed into two clusters that showed significant enrichment in 
MsigDB Canonical (C2) and GO biological pathways (C5BP) database (Fig. 3B, see also Fig. 
S4A). Cluster I included genes that are progressively upregulated during NOD diabetes (e.g., 
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Cxcl9, S100a4, and Ptgs2). These were enriched by hypergeometric test for inflammatory 
pathways namely Defense Response, Immune System Process, and Cytokine/Cytokine Receptor 
interaction (Fig. 3C, Fig. S4B). Cluster II, in contrast, consisted of genes upregulated enriched in 
developmental pathways, such as Cellular Biosynthetic Process, Translation, and Oxidative 
Phosphorylation. These genes were upregulated in the islets of 2 week old mice and recently 
diabetic NOD mice (Fig. 3B, D, Fig. S4C). These transcripts indicate increased cellular activity 
likely accountable by some level of replication. 
 
Inflammatory transcripts in the islet macrophage are the hallmark features of a barrier 
macrophage. 
GSEA of the genes differentially expressed between NOD and NOD.Rag1-/- (see Fig. 2G) 
revealed a correlation with gene signatures identified in cultured bone marrow-derived 
macrophages treated with LPS (Dataset, GSE14769 Samples, Unstim vs 40min LPS BMDM 
DN, Immunologic C7 MsigDB)(Litvak et al., 2009). Similar findings were made interrogating 
datasets from macrophages treated with different inflammatory stimuli. In total, we found a 
significant enrichment score for genes expressed following LPS, TNFα, and IL-1 treatment of 
macrophages (Fig. 4A).  When further compared to Immgen datasets, the macrophages that 
displayed genes upregulated in an LPS signature were all barrier macrophages and exposed to 
either intestinal or airborne stimuli. This association was revealed both by hierarchical clustering 
(Fig. 4B) and by correlation analysis. Both techniques grouped the intestinal and CD11b+ lung 
macrophages together and showed that barrier macrophages as a group had a higher enrichment 
score for LPS signatures than the non-barrier macrophages (Fig. S4D).  
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The presence of gene signatures induced by LPS, TNFα, and IL-1 were found highest in 
the CD11b+ lung macrophages, NOD, NOD.Rag1-/-, B6.g7 islet macrophages, but not in bone 
marrow macrophages (Fig. 4C-D). This indicated that at steady state, the islet macrophage was 
in an activated state comparable to those at a barrier surface. 
The similarities between the islet resident macrophage to barrier macrophages led us to compare 
our own gene expression profiles between the islet and the CD11b+ lung macrophage to identify 
islet macrophage-enriched signatures. The top statistically significant canonical signature by 
GSEA that distinguished the islet macrophage from the CD11b+ lung macrophage was Lysosome 
(FDR < 1.0E-5, P-val < 1.0E-5; Figs. 4E-F). The Lysosome signature included genes encoding 8 
cathepsins (A/B/C/D/H/O/S/Z), Laptm4b and Laptm4a (lysosomal protein transmembrane 4 
Alpha and Beta), and Lgmn (Legumain cysteine protease). This gene signature suggested a 
higher lysosomal activity in the islet macrophages than in the CD11b+ lung macrophages (Fig. 
4F)(Ewald et al., 2011). The lysosomal gene signature was found in all islet datasets indicating 
that heightened lysosomal function was a steady-state feature of islet macrophages.  
Inflammatory mediator production by the islet macrophages 
Intracellular flow cytometry showed production of IL-1β and TNFα confirming the 
RNAseq analysis (Fig. 5A). About half of the NOD.Rag1-/- islet macrophages were producing 
detectable levels of TNFα and IL-1β without any stimulation. Activation with phorbol 12-
myristate 13-acetate (PMA) and ionomycin led to a limited increase in TNFα and IL-1β proteins, 
revealing that they were at or near maximal production (Figs. 5A-B). For comparison, the 
CD11b+lung macrophage produced almost no detectable TNFα but equivalent IL-1β (Figs. 5A-
B). Even when pulsed with PMA/ionomycin, the CD11b+ lung macrophage TNFα cytokine 
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production never reached that of steady state islet macrophage levels (Fig. 5B). Their production 
of IL-1β protein was equivalent to the islet macrophage and did not increase when pulsed with 
PMA/ionomycin (Figs. 5A-B). 
Activation of IL-1β from its pro-form to its active form requires processing by an active 
inflammasome-family caspase (Dinarello, 2009). Islet macrophages from NOD and NOD.Rag1-/- 
expressed a detectable level of active-caspase-1 when examined with the fluorescent form of the 
caspase substrate YVAD. The CD45-negative fraction, i.e., the endocrine cells, were negative 
(Fig. 6A). 
The data indicates that the islet macrophages are making some level of both active-IL-1β 
and TNFα. Since both receptors converge on the NF-κB-pathway we analyzed our transcriptional 
data, searching for NF-κB family members expressed in the whole islet. The only members of 
the transcription factors/coactivators contained in the NF-κB and Rel-family detectable above 
background were Nfkb1 (p105/p50) and Rela (p65) (Carrero et al., 2013). Therefore, we 
examined the nuclear localization of the NF-κB component RelA/p65 (Rütti et al., 2016). 
Staining for RelA/p65 revealed a predominantly cytosolic pattern of staining in NOD islets at 6 
weeks of age (Fig. 6B, top). As a positive control, islet cells treated with IL-1β induced nuclear 
localization (Fig. 6B, bottom). The data shown in Figure 6B was generated using islets cultured 
in IL-1β for ~16 hours to allow for signaling. Therefore, despite the expression of IL-1β and 
TNFα by islet macrophages, there was limited detectable nuclear NF-κB in the endocrine 
pancreas. This data indicates that despite the levels of cytokine being made by the islet 
macrophages, the beta cells are not strongly signaling.  
Islet macrophages respond to blood-borne stimuli  
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A blood borne stimulus might be able to induce part of activation profile in the 
macrophage, as suggested by the expression of Tnf, Il1a, and Il1b transcripts. This idea is 
supported by our previous report that the islet macrophage extended filopodia into the lumen of 
the blood vessel and could interact with blood-borne particles (Calderon et al., 2011). 
To determine if a blood borne TLR-agonist could stimulate the islet macrophage, we 
injected LPS at low concentrations that would not induce systemic effects. LPS was injected 
intravenously into 3 week old NOD and NOD.Rag1-/- mice. Islets were isolated three hours later 
and the islet macrophage was sorted using the strategy outlined in Figure S1. Transcripts 
associated with signaling of TLR4 were assayed via quantitative reverse transcription 
polymerase chain reaction (qRT-PCR). The transcripts for Cxcl9, Ccl5, Il12b, Nos2, and Il6 were 
significantly upregulated following LPS injection of NOD.Rag1-/- mice, but not after control 
phosphate buffered saline (PBS) injection (Fig. 6C). Cxcl9, Ccl5, and Il12b were upregulated in 
the NOD. Notably, the NOD displayed higher baseline expression than the NOD.Rag1-/- mice for 
all markers examined. This was not surprising, as some of these markers were the most 
differentially expressed between NOD and NOD.Rag1-/- mice by RNAseq (Fig. 2D). In sum, the 
islet macrophage is accessible and reacting to circulating LPS, a strong representative PAMP. 
Single cell analysis of islet macrophages reveals heterogeneity in the NOD but not the 
NOD.Rag1-/- 
We examined if the inflammatory gene expression differences between NOD and 
NOD.Rag1-/- islets was due to homogeneous or heterogeneous autoimmune activation of the 
NOD macrophages. To interrogate transcriptional heterogeneity at the cellular level, we 
examined individual macrophages from NOD and NOD.Rag1-/- islets. Macrophages were sorted 
 
 
88 
directly into RNA lysis buffer, cDNA was synthesized and preamplified, and qRT-PCR was 
performed for 95 different markers using the Fluidigm Biomark HD system. The starting cell 
inputs were 184 NOD and 95 NOD.Rag1-/- macrophages. After outlier detection using the 
Singular analysis software, 143 NOD and 79 NOD.Rag1-/- were kept for further analysis. 
By principal component analysis, the majority of macrophages from both mice clustered 
together except for a subset in the NOD samples represented by 42/184 (22.8%) (outlined in Fig. 
7A). Furthermore, all of the cells contained in the NOD outlier population expressed high levels 
of Cxcl9. The population level macrophage RNASeq data showed that Cxcl9 was the most 
differentially expressed gene between the NOD and NOD.Rag1-/- samples and the expression of 
this chemokine was only detected in the NOD outlier population (See Fig. 2 and Table S1). 
The combination of ANOVA and fold change analysis was performed on the normalized 
expression values (log2ex) of the single macrophage PCR data (Fig. 7B). We identified several 
genes previously shown to be differentially expressed between NOD and NOD.Rag1-/- samples 
by RNASeq, including Ccl5, Cxcl9, Ly6a, Cd38, and Dnase1l3. However, Cxcl9 was the most 
significant differentially expressed gene. In total, 26/95 genes interrogated by single cell qRT-
PCR were differentially expressed between NOD and NOD.Rag1-/- samples at 2-fold change and 
P value < 0.01. Selection of these genes revealed a cluster enriched in only NOD and not 
NOD.Rag1-/- samples (See Fig. S5A, left side of the heat map, for the heat-map of the entire 
dataset see Fig. S5B). 
In brief, the islet resident macrophages in the NOD.Rag1-/- mouse were homogeneous. In 
the NOD mouse at three weeks, there was heterogeneity in their activation state. There was a 
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major set identical to the NOD.Rag1-/- macrophage, but also a second that expressed the same 
upregulated transcripts revealed by the RNAseq analysis. 
Discussion 
We made three key findings that place the resident macrophage in a unique position to 
regulate islet function. First, the islet macrophages are in an activated state comparable to 
macrophages exposed at barrier surfaces. This result leads to the obvious question, why are these 
macrophages in such a state? The islet is a mini-organ that is constantly responding to a number 
of stimuli that vary and oscillate, such as blood glucose, the most prevalent bioactive molecule. 
We have reported that the macrophages capture dense core granules and therefore, must be 
exposed to the products of the beta cell (Vomund et al., 2015). We also showed here how blood 
products, in our example a low dose of LPS, were accessible to the islet macrophage. In a 
previous report we indicated that the islet macrophages extended filopodia into the blood vessel 
lumen, which could be the interacting structure with the circulation (Calderon et al., 2011). In 
essence, the islet macrophages may be activated by intra-islet components as well as by blood 
products. 
A second finding, as mentioned above, is the capacity of the islet macrophages to sense 
blood-borne stimuli. This finding opens the question of the biological significance of such 
sensing as well as on the repertoire of stimulants, an issue that needs critical evaluation. One 
needs to keep in mind that the Tlr2-/-, Tlr9-/- and, Myd88-/- mice have reduced incidences of 
diabetes (Kim et al., 2007; Tai et al., 2016; Wen et al., 2008). It is tempting to postulate that 
during weaning, profound changes occur in the islet macrophage as was evident by MHC Class 
II expression. This occurs at a time when the islet is subjected to more demands for growth as 
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well as to a new intestinal flora. It is possible the islet macrophage senses systemic inflammation 
as suggested by the modulation of type 1 diabetes by gut flora and systemic infections (Christen 
and von Herrath, 2011; Markle et al., 2013; Wen et al., 2008; Yurkovetskiy et al., 2015). We 
speculate that through this sensory function the macrophages plays a protective role for the islets 
against blood-borne pathogens. Finally, one component that may contribute to the NOD 
macrophage activation compared to NOD.Rag1-/- mice is the presence of antibodies particularly 
those derived from the mother. Evidence in favor of this is that the wild type heterozygote pups 
born from B cell deficient mice (µMT) display decreased incidence and penetrance of diabetes 
(Greeley et al., 2002). 
The third finding is that there are genes characteristic of diabetes progression being 
expressed in three-week-old islet macrophages. This implies that even without overt lymphocyte 
infiltration of the islet or destruction of beta cells, the adaptive immune system is enforcing a 
degree of activation on the islet macrophage. Thus, superimposed on the basal activation state, 
the diabetes susceptible traits impose a further activation program that is likely to be critical for 
the development and progression of the disease. The single cell analysis of the islet resident 
macrophages showed that only a subset of the NOD macrophages was more inflamed than those 
of the NOD.Rag1-/-. We cannot conclusively state which signal/cell type is responsible for the 
activation of the macrophage in a young NOD mouse, but the presence of an interferon signature 
points to an activated diabetogenic T cell acting on the islets at these early times. We have found 
a few T cells in islets at this early time period. Also, upregulation of the oxidative 
phosphorylation in NOD macrophages, as well as self-defense antioxidant enzyme expression 
(Response to Oxidative Stress, GO Term: 0006979), suggests antimicrobial generation of 
reactive oxygen species (ROS). Higher ROS synthesis in NOD macrophages compared to 
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NOD.Rag1-/- might be a result of synergistic action of adaptive and innate immune response (T 
cell and macrophage activation) as opposed to only an innate response in NOD.Rag1-/-. During 
diabetogenesis, it is the lymphocytic infiltrate that is most likely responsible for the cell division 
and cellular activity signature in whole islets. Activated macrophages are known to express 
genes responsible not only for cytokine and chemokine production, but also for cell cycle 
progression and proliferation (Buxade et al., 2012).  
Since the NOD macrophage autoimmune activation is dependent on the presence of the 
adaptive immune system, it is likely that there is heterogeneity in immune components within a 
single islet or among them, with some affected and others not. Resolving this will require 
isolating single macrophages from individual hand-picked islets, a difficult task based on current 
technologies. However, this will be an important issue to tackle, as it will instruct us to the nature 
of the activation of the earliest sensors of autoimmune diabetes, the macrophage, as well as the 
distribution of islet involvement in the autoimmune process. Thus, intervention and identification 
of those who are to progress to diabetes must be done much earlier than diagnosis in order to 
intervene and prevent diabetes. 
The islet macrophages express IL-1β and TNFα at the steady state. Expression of IL-1β and 
TNFα (and other cytokines) is a complex process (Aggarwal, 2003; Dinarello, 2009; Pasparakis, 
2009). It involves a number of transcriptional regulators that modulate the level and time of 
expression of the gene (Amit et al., 2009; Foster et al., 2007; Kotas and Medzhitov, 2015; Yosef 
and Regev, 2011, 2016). This regulation is of particular relevance. As noted earlier, Atf3 is 
expressed by the macrophages indicating a degree of regulation of TLR signaling. Regarding IL-
1β, we find an intermediate expression of active caspase-1, but failed to detect RelA by nuclear 
staining in the beta cells. However, we may well be missing a low level of activation and are 
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guarded in concluding a lack of IL-1β signaling in the beta cell. Indeed, it is still likely that there 
is a level of homeostatic role for IL-1R signaling in endocrine function. For example, the p85α 
component of the PI3-kinase is activated by IL-1R signaling (Reddy et al., 1997). Deficiency of 
p85α leads to reduced insulin secretion following glucose challenge (Terauchi et al., 1999). Also, 
IL-1β treatment of islets instigates downregulation of the glucose transporter GLUT2 and 
glucokinase (Park et al., 1999). Finally, IL-1R1-deficient mice develop late-onset obesity (García 
et al., 2006). In sum, IL-1 production by the islet macrophage may be one component in its 
general role as a modulator of glucose homeostasis influencing the pancreas, fat depots, and 
central nervous system (Del Rey et al., 2006; Dror et al., 2017). Concerning its role in the 
autoimmune process, much has been discussed on IL-1’s role in diabetes initiation based largely 
on the harmful effects of IL-1 on long term cultures of beta cells (Mandrup-Poulsen et al., 2010). 
However, a role in diabetes progression in the NOD mouse model is not evident. Genetic 
ablation of caspase-1 does not alter diabetes development (Schott et al., 2004). IL-1R deficiency 
delays progression to diabetes, albeit modestly (Thomas et al., 2004). Insofar as TNFα, its effects 
are pleiotropic but are also under strict control. TNFα can affect not only beta cells but also the 
vascular endothelium and T cells. In contrast to IL-1β, TNFα has complex effects on diabetes 
development, most likely on the effector stage of the disease by not only modifying beta cells, 
but also T cells (Chee et al., 2011; Kägi et al., 1999; Pakala et al., 1999; Wu et al., 2002; Yang et 
al., 1994). 
The data indicates that the islet macrophage is subjected to stimuli derived from beta cells 
as well as by blood products (Calderon et al., 2011; Vomund et al., 2015). Therefore, this could 
lead to a transcriptional program that is complex, representing the diverse stimuli, and these 
responses need to be integrated. In the absence of macrophages as in the op/op mouse the 
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development of islets is impaired (Banaei-Bouchareb et al., 2004). Studies are now under-way in 
our laboratory to determine the activation state of islet macrophages derived from different 
strains and ages of mice and under different biological conditions. The islet macrophages of all 
strains examined contain macrophages with core features similar to NOD.Rag1-/-. In contrast, the 
signature of diabetic inflammation that includes Cxcl9 and other interferon inducible genes, has 
only been found in NOD, and not in any of the control strains. 
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Materials and Methods 
Mice 
NOD/ShiLtJ (NOD), NOD.129S7(B6)-Rag1tm1Mom/J (NOD.Rag1-/-), and B6.NOD-(D17Mit21-
D17Mit10)/LtJ (B6.g7) originally obtained from the Jackson Laboratory, were bred and 
maintained under specific pathogen free conditions in our animal facility. All experiments were 
approved by the Division of Comparative Medicine of Washington University School of 
Medicine in St. Louis (Association for Assessment and Accreditation of Laboratory Animal 
Care, accreditation number A3381-01).    
Antibodies 
The following antibodies were purchased from BioLegend (San Diego, CA): FITC/PE/PerCP-
Cy5.5 anti-B220 (RA3-6B2), PE-Cy7 anti-CD11b (M1/70), PE/APC-Cy7 anti-CD11c (N418), 
PE/APC anti-CD274 (10F.9G2), PE-Cy7 anti-CD4 (RM4-5), APC-Cy7 anti-CD44 (IM7), 
BV510/APC anti-CD45 (30-F11), FITC anti-CD53 (OX-79), FITC/PerCP-Cy5.5 anti- CD8α 
(53-6.7), PE-Cy7 anti-CD83 (Michel-19), FITC/APC anti-F4/80 (BM8), APC anti-TNFα (MP6-
XT22). The following antibodies were purchased from eBioscience (San Diego, CA): Fixable 
viability dye eflour780 and PerCP efluor710 proIL-1β (NJTEN3). The following antibodies were 
purchased from BD Biosciences (San Jose, CA): FITC/APC anti-CD3e (145-2C11), PE anti-
IFNγ (XMG1.2), and PE anti-TLR7 (A94B10). Pacific Blue I-Ag7 (AG2.42.7) was made in our 
laboratory (Suri et al., 2002). 
Flow Cytometry and Cell Sorting 
Islets were harvested as described previously (Calderon et al., 2015) and dispersed using Cell 
Dissociation Solution Non-Enzymatic (Sigma-Aldrich, St. Louis, MO) for 5 min at 37°C. 
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Pancreatic lymph nodes and lungs were harvested, finely chopped with scissors, placed in 
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, Carlsbad, CA) containing 
125 ug/mL Liberase TL (Roche Life Sciences, Indianapolis, IN) and 50 ug/mL DNase I, grade II 
(Roche) and incubated at 37°C for 30 minutes and dispersed via gentle agitation. Single-cell 
suspensions incubated in PBS, pH 7.4 (Life Technologies) having 1% bovine serum albumin 
(BSA, Sigma), and 50% of 2.4G2 conditioned DMEM at 4°C for 15 min to block Fc receptors. 
Cells were stained with fluorescently labeled antibodies and sorted on a FACSAria II or analyzed 
on the FACSCanto II (BD Biosciences). Macrophages were sorted based on their expression of 
CD45, F4/80 and I-Ag7. DC were selected based on their expression of XCR1. In all cases 
CD3e+ and CD19+ events were eliminated from the sort (dump gated). For cell sorting 
experiments, approximately 500-5000 macrophages were isolated from 6-10 mice and this 
represented 1 biological sample in our analysis. At least 3 samples were used for each population 
studied by RNAseq analysis. All flow cytometry data was analyzed using FlowJo software 
version 10.2 (Tree Star Software, Ashland, OR). 
 
Intravenous LPS injection 
NOD and NOD.Rag1-/- mice were intravenously injected with 100 ng LPS in 0.1 mL of PBS. 
Mouse islets were harvested 3 hours later, dispersed, and macrophages were sorted using 
FACSAria II (BD Biosciences) after staining with antibodies to CD45, CD3, CD19, F4/80 and I-
Ag7.  
RNA isolation and Real Time PCR 
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Sorted cell RNA was isolated using the Ambion RNAqueous-Micro Kit (Life Technologies) 
following the manufacturer’s instructions. RNA was quantified by OD260 using Nanodrop 
(Thermo Fisher Scientific, Waltham, MA). Complementary DNA was synthesized using iScript 
Reverse Transcription Supermix for RT-qPCR (Bio-Rad, Hercules, CA). Quantitative RT-PCR 
was performed using the 5' nuclease (TaqMan) chemistry using iTaq Universal Probes Supermix 
(Bio-Rad). The 18S rRNA probe was obtained from Life Technologies and all other primers and 
probes were designed and obtained from IDT DNA (Coralville, IA). All qPCRs were performed 
on a StepOnePlus Real-Time PCR system (Life Technologies) running StepOne 2.3 Software 
(Life Technologies). Quality control was performed by the StepOne 2.3 software. RT-PCR data 
analysis was done using Excel (Microsoft, Redmond, WA). 
RNASeq Analysis 
Library preparation was performed with 1-50 ng of total RNA, integrity was determined using an 
Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA).  ds-cDNA was prepared using the 
SeqPlex RNA Amplification Kit (Sigma) per manufacturer’s protocol.  cDNA was blunt ended, 
had an adenosine added to the 3’ ends, and then had Illumina sequencing adapters ligated to the 
ends. Ligated fragments were then amplified for 12 cycles using primers incorporating unique 
index tags. Fragments were sequenced on an Illumina HiSeq-2500 using single reads extending 
50 bases. All RNAseq work was performed by the Genome Technology Access Center at 
Washington University School of Medicine.  
We assessed average quality of sequencing reads for base pair positions in each sample using the 
fastqс utility from fastq-tools (Droop, 2016). Samples with a quality score less than 25 (Sanger / 
Illumina 1.9 encoding) across all bases were truncated with fastx_trimmer utility, removing base 
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pairs from the end of each read in the library. All libraries were aligned to the GRCm38.p4 
assembly of the mouse genome using the STAR aligner (Dobin et al., 2013) with Gencode vM7 
(Harrow et al., 2012) transcripts included into the pre-generated reference. We generated raw 
counts of the number of tags on each gene by using htseq-count utility from HTseq package 
(Anders et al., 2015). Gencode vM7 (with –t exon option) was used as a reference GTF. DESeq2 
package (Version 1.6.3) (Love et al., 2014) was used to detect differentially expressed genes 
between the analyzed conditions (output with a P<0.05, and Benjamini–Hochberg false 
discovery rate (FDR) of 5% was used). Variance between samples was stabilized for the 
purposes of hierarchical clustering and PCA to address the problem of heteroskedasticity 
(dependence of variance on the mean counts). Pathways analysis was done using the Broad 
Institute’s GSEA software (Subramanian et al., 2005). All heat maps are in log2 scale.  
LPS, TNFα and IL-1 signature analysis 
The LPS signature consists of genes upregulated in macrophages treated with LPS for 40 min 
when compared to untreated macrophages at P-value < 0.05, LFC > 1 (GSE14769). The IL-1 
signature consists of genes upregulated in human monocyte-derived macrophages 4 h after 
stimulation with IL-1 compared to control cells (GSE8515, P-value < 0.05, LFC > 0.7). The 
donor effect for GSE8515 dataset was corrected with ComBat (Johnson et al., 2007). Limma 
package was used for differential expression analysis of microarray data (Ritchie et al., 2015). 
TNFα signaling geneset was taken from the Broad Institute Molecular Signatures Database 
(MSigDB) hallmark gene sets (Hallmark TNFα signaling via NF-κB). The Immunological 
Genome Project data set was downloaded from GEO (GSE15907)(Heng et al., 2008).  
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Intracellular Flow Cytometry 
Dispersed islet or lymph node cells were placed at 37°C in DMEM, 10% fetal bovine serum 
(FBS; bGE Healthcare Bio-Sciences, Pittsburg, PA), and 10 ug/mL Brefeldin A for 4 hours. As a 
positive control for activation, samples were pulsed with 100 ng/mL phorbol 12-myristate 13-
acetate (Sigma-Aldrich) and 500 ng/mL ionomycin (Sigma-Aldrich). Cells were washed with 
PBS, 1% BSA, cell surface stained with fluorescent antibodies for 30 minutes at 4°C, and fixed 
with PBS, 2% formaldehyde (Sigma-Aldrich) for 15 minutes at 4°C. Cells were washed with 
PBS, 1% BSA, incubated with 2% saponin (Sigma-Aldrich), PBS for 5 minutes at 4°C, and then 
with fluorescent antibodies recognizing intracellular proteins for 30 min at 4°C. Cells were 
washed with 2% saponin, PBS and then with PBS, 1% BSA. Flow cytometry was performed 
using a FACSCanto II. 
Immunofluorescence Microscopy 
For nuclear RelA detection, Islets from 6 week old NOD females were isolated and dispersed as 
described previously.  Dispersed cells were placed in chamber slides and incubated at 37°C 
overnight in 20 ng/mL IL-1β (Peprotech, Rocky Hill, NJ) DMEM (Life Technologies) 
supplemented with 10% FGE Healthcare Life Sciences, Pittsburgh, PA) or in DMEM 10% FBS 
alone (Rütti et al., 2016). Cells were washed with 1% BSA in PBS and fixed and permeabilized 
using BD Bioscience Fix/Perm kit according to manufacturer's instructions. Cells were stained 
with NF-κB p65 (D14E12) XP rabbit mAb (Cell Signaling Technology, Danvers, MA) overnight 
at 4°C. Cells were washed twice with PBS and stained with Alexa 488 anti-rabbit IgG F(ab')2 
(Cell Signaling Technology) for 2 hours at room temperature.  After washing with PBS, the 
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chamber was removed and Prolong Gold Anti-Fade Reagent with DAPI (Cell Signaling 
Technology) was applied. Slides were imaged using a Leica SPE confocal microscope. 
For pancreas immunofluorescence, frozen sections from each tissue were cut on a cryotome at 10 
µm. Sections were fixed for 5 min in ice cold acetone. Then the sections were blocked with Cas-
Block (Thermo Fisher Scientific) following the manufacturer's instructions. The sections were 
then stained with PE anti-B220 (RA3-6B2), PE anti-Siglec H (551), or PE anti-Ly6G (1A8) 
(eBioscience), and polyclonal guinea pig anti-insulin (Thermo Fisher Scientific) for 1 hour at 
room temperature. Sections were washed three times with PBS and then stained with goat anti-
guinea pig Alexa-488 (A11073, Thermo Fisher Scientific) for 1 hour at room temperature. 
Background autofluorescence was quenched with 70% ethanol supplemented with 0.5% Sudan 
Black B (Sigma-Aldrich) for 2 min at room temperature and washed with PBS. Nuclei were 
stained with bisBenzimide H 33258 (Sigma-Aldrich) at a concentration of 1 µg/mL in water for 
5 minutes at room temperature and washed three times with PBS. Sections were mounted with 
PBS containing 50% glycerol and visualized via an Olympus BX51 microscope.  
Active Caspase-1 Detection 
Islets were isolated and dispersed as described previously. Cells were incubated for 30 min at 
37°C with the fluorescent inhibitor probe FAM-YVAD-FMK (Immunochemistry Technologies, 
Bloomington, MN) to label active caspase-1 enzyme. Cells were washed and stained for cell 
surface antigens, acquired via a FACSCanto II flow cytometer, and analyzed using Flow Jo 
software.  
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Single cell sorting and qPCR 
Islet macrophages were isolated, stained ,and single cell sorted into 96 well plates containing 5 
µl Cellsdirect 2X Reaction Mix (Life Technologies) and 0.1 µl RNase inhibitor (SUPERase-In, 
Life Technologies) per well. For reverse transcription and specific cDNA pre-amplification, all 
the 96 20X Taqman assays (see Fig. S6)(IDT DNA) were mixed and diluted to 0.2X. 
Subsequently, 2.5 µl of the 0.2X Taqman assay mix, 0.2 µl of the SuperScript III RT/Platinum 
Taq (Life Technologies), and 1.2 µl PCR certified water (Life Technologies) were added 
together to the sorted single cells. Reverse transcription (15 min at 50 °C) was carried out 
followed by Taq activation (2 min at 95 °C) and 18 cycles of cDNA pre-amplification (each 
cycle: 15 sec at 95 °C, 4 min at 60 °C). The resulting cDNA product was diluted with PCR 
certified water (1:5), and submitted for single cell qPCR using the Biomark HD system 
(Fluidigm, San Francisco, CA). 
Supplemental material 
Supplemental Table 1 shows the normalized gene counts for the dataset. Because of the size of 
the table, the data is not included in this dissertation but is included in the online publication 
through JEM. Supplemental Figure 1 shows gating strategy for the isolated cells, expression of 
MHC on macrophages from Immgen, and flow cytometry of cell surface markers on islet 
macrophages.  Supplemental Figure 2 shows immunofluorescence of pancreas and lymphoid 
structures. Supplemental Figure 3 shows different islet isolation techniques and outcomes. 
Supplemental Figure 4 shows gene set enrichment analysis. Supplemental Figure 5 shows single 
cell islet macrophage qRT-PCR data.   
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Figure Legends 
Figure 1. Transcriptional profiling of islet-resident macrophages. Top expressed housekeeping 
(A) and myeloid (B) genes from NOD, NOD.Rag1-/-, and B6.g7 islet macrophages, and DC. 
Macrophages and DCs were isolated as indicated in Figure S1. (C) Сore macrophage specific 
gene signature (as defined by Gautier et al., 2012), distinguishing macrophages from DCs. 
Expression of co-stimulatory genes (D), genes encoding TLRs and adaptors (E), chemokines (F) 
and chemokine receptors (G) by islet macrophages and PLN DCs. Co-stimulatory genes 
selection was based on (Chen and Flies, 2013). TLR and TLR adaptors were based on (Chevrier 
et al., 2011). Chemokines and chemokine receptors were based on (Griffith et al., 2014). Data is 
the mean of 3-4 samples per group and is represented as the log2 global expression level. Genes 
were selected as significant by DESeq2 at a P-value <0.05, and Benjamini–Hochberg (BH) false 
discovery rate (FDR) of 5%. 
Figure 2. Analysis of islet macrophage transcriptional diversity. (A) PCA on the 5% of genes 
with the greatest variability for XCR1+ DCs, NOD CD11b+ lung macrophages, and NOD, 
NOD.Rag1-/-, and B6.g7 islet macrophages. (B) Pearson correlation matrix of macrophages and 
DCs based on all expressed RNASeq probes. (C) Hierarchical clustering of macrophages and 
DCs for the top 5% of genes with the greatest variability.  (D) Scatter plots of expression values 
of all annotated genes. (E) Heat map of differentially expressed genes taken from (D). Each dot 
represents the mean of four independent biological replicates for NOD and three for NOD.Rag1-
/- conditions. Numbers in plots indicate probes with a DESeq2 calculated fold-change between 
conditions of ≥ 2 and adj.P-val ≤ 0.05 at FDR of 5% (red, upregulated in NOD; blue, 
upregulated in NOD.Rag1-/-). (F) Gene ontology and canonical (C2) pathways hypergeometric 
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analysis of the genes differentially expressed between NOD and NOD.Rag1-/- islet macrophages. 
(G) Enrichment plots from GSEA analysis performed on differentially expressed genes using GO 
biological process (MsigDB C5BP) signature gene sets. Core enrichment genes from 
"Inflammatory Response" (H), “Behavior” (I), “Response to Oxidative Stress” (J), and 
"Oxidative Phosphorylation" (K) gene sets, identified by either GO (F) or GSEA (G). Heat maps 
show individual samples and represent the log2 row normalized expression. 
Figure 3. Early inflammatory signature during diabetogenesis. (A) Pearson correlation of 
samples from (Carrero et al., 2013) based on genes identified using DESeq2 as differentially 
upregulated in NOD vs NOD.Rag1-/- macrophages with adj.P-value ≤ 0.05 and fold change ≥ 2. 
(B) Hierarchically clustered genes from (A) in whole islet transcriptome analysis, shown in the 
upper panel. The Z-score profiles of genes expression in cluster I (red) and cluster II (green) are 
shown in the lower panel. Sample number ranged from 3-6 per group. Each column represents 
data obtained from one biological replicate each composed of all the intact islets isolated from 
one mouse of the indicated genotype. (C-D) Hypergeometric analysis of the genes identified in 
clusters I and II in Panel B using GO biological pathways and C2 canonical pathways.  
Figure 4. Islet macrophages are similar to barrier macrophages. (A) GSEA enrichment plots of 
NOD vs NOD.Rag1-/- islet macrophages differences based on LPS, TNFα and IL-1 signatures. 
The differences between NOD and NOD.Rag1-/- were compared to published signatures of LPS, 
TNFα, and IL-1β cells as described in the Methods. (B) Hierarchical clustering of Immgen 
microarray data for macrophages from different tissues. The LPS signature genes were selected 
for clustering the macrophage microarray data from Immgen. Heat-map shows the log2 row 
normalized expression. (C) LPS, TNFα, and IL1 signatures from bone marrow and lung 
(CD103negCD11b+) macrophage microarrays (ImmGen), and lung and islet macrophages from 
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the current study. All expressed genes were ranked by expression level and genes which match to 
the signatures are depicted as horizontal lines. (D) Schematic illustration of expression levels of 
the LPS, TNFα, and IL1 signatures genes in different macrophages. (E) GSEA enrichment plot 
of the Lysosome gene pathway, the top canonical (C2, MsigDB) pathway upregulated in islet 
macrophages when compared to CD11b+ lung macrophages. (F) Heat map of the core 
enrichment genes from (E). Heat map shows individual samples and represent the log2 row 
normalized expression.  
Figure 5. Flow cytometric evaluation of islet macrophages for transcriptionally identified 
markers. (A) The islets or lungs of 3 week old NOD or NOD.Rag1-/- mice were isolated and 
single cell suspensions were made. Cells were stained with antibodies against cell surface 
markers and then fixed and stained with antibodies against intracellular proform IL-1β and 
TNFα. Plots were gated on CD45+CD11c+MHCII+CD11b+F4/80+. The percentages of cells 
positive is indicated in each quadrant. Results are representative of three independent 
experiments per condition. (B) Graphs of the percent of macrophages positive for either TNFα or 
IL-1β as determined in (A). Bars show the mean+/-S.D. for at least three independent 
experiments per condition.  
Figure 6. Inflammatory status of islets before and after treatment with LPS. (A) NOD or 
NOD.Rag1-/- mouse islet macrophages were isolated and stained with the intracellular caspase-1 
substrate FAM FLICA YVAD-FMK. The black histograms are gated on the CD45-negative 
fraction of the islets and the grey histograms are gated on macrophages as in Figure S1. Mean 
fluorescent intensity (MFI) is indicated on the graphs. MFIs for active caspase-1 ranged from 
62.5-102 (mean 72.2) for the CD45neg population and from 388-884 (mean 625) for the F4/80+ 
population. Data is representative of 2-3 independent experiments per group. (B) Islets from 6 
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week old NOD mice were isolated, dispersed, and cultured overnight in chamber slides in the 
absence or presence of IL-1β. Cells were then stained with DAPI (blue) and anti-RelA/p65 (red). 
Cells were imaged by confocal microscopy. The white bar is 4 µm. Image is representative of 
three independent experiments. (C) Expression of inflammatory gene transcripts in macrophages 
isolated from islets of mice intravenously injected with LPS. The indicated mice were either 
treated with PBS (UT) or LPS IV (LPS). Then, islet macrophages were flow sorted, RNA was 
isolated, and qRT-PCR was performed on the indicated markers. Each symbol represents one 
individually sorted sample. Horizontal bars show the mean. Significance was tested using the 
Mann-Whitney U test. Asterisks indicate: *p<0.0332, **p<0.0021, ***p<0.0002. Graphs show 
all the data from at least three independent experiments performed in duplicate for each 
condition.  
Figure 7. Single cell qRT-PCR of islet macrophages reveals NOD heterogeneity. (A) PCA of the 
single cell qRT-PCR results. The samples circled in black were all Cxcl9+ while no Cxcl9+ cells 
were found in the rest of the samples. (B) Volcano plot of the fold change (log2) expression 
between NOD and NOD.Rag1-/- compared to the ANOVA p-value (log10). Genes in the upper 
right quadrant had greater than 2 fold higher expression on average in NOD versus NOD.Rag1-/- 
and were significantly differentially expressed by ANOVA at p < 0.01.  
Supplementary Figure Legends 
Figure S1. Analysis of islet macrophages. (A) Flow cytometry gating strategy for sorting of 
macrophages from 3 week old mice. Cells were gated based on forward- and side-scatter, single 
cells, CD45 expression, MHC-II, and F4/80 expression. Flow cytometry gating strategy of lung 
macrophages (B) and PLN XCR1+ DC (C) populations. Lung macrophages were gated on 
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FSC/SSC, singlets, live dead, CD45, CD11c, F4/80, and MHC-II expression. XCR1+ DC were 
gated on FSC/SSC, singlets, CD45, CD11c, MHC-II, CD11b, CD172a, CD103 and XCR1. (D) 
Expression of I-Ag7 on CD45+ CD11c+ F4/80+ macrophages isolated from islets of 2 week old 
and 4 week old NOD female mice.  (E) Expression of MHC-II complex genes, including the 
master regulator Ciita by different macrophage populations, based on ImmGen dataset 
(GSE15907). (F) Flow cytometry of CD45+ CD11c+ I-Ag7+ NOD macrophages examining for 
CD44, CD53, CD83, and TLR7. 
Figure S2. Immunofluorescence of pancreas and lymphoid tissue. (A, C, D) Pancreatic sections 
and (B) splenic sections or (D, F) peripancreatic lymphoid aggregates (LA) were stained with 
anti-insulin (Beta cells) and either (A-B) Siglec H (pDCs), (C-D) B220 (B cells), or (E-F) Ly6G 
(neutrophils). All sections were nuclear stained with bisBenzimide. (G) The indicated number of 
islets were scored for the presence of either B220+, 1A8 (Ly6G)+ or SiglecH+ cells. Results 
were obtained from NOD mice at 3 weeks and C57BL/6 mice at 8 weeks of age (three mice for 
each). 
Figure S3. Imaging of isolated islet preparations. (A-B) C57BL/6J and (C-D) NOD pancreata 
were digested without hand picking and imaged. (E-F) NOD pancreata were digested, hand 
picked under a dissection microscope, and imaged. All islet preparations were stained with 
dithizone to allow for visual separation of islets from the acinar or lymphoid aggregate structures 
that associate with pancreas digestion preparations. Arrows indicate contaminating acinar or 
leukocytic aggregate structures.  
Figure S4. There are two clusters of genes upregulated in islet NOD Macrophages when 
compared to islet NOD.Rag1-/- Macrophages. (A) Pearson correlation between all samples based 
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on genes, differentially upregulated in NOD vs NOD.Rag1-/- islet Macrophages with p-value ≤ 
0.05 and MLE moderated fold change ≥ 2. Heat maps of (B) cluster I and (C) cluster II genes. 
(D) GSEA plots of lamina propria, serosal, and CD11b+CD103neg lung macrophages comparing 
to other macrophages from Immgen dataset, based on LPS signature. 
Figure S5. Heat map of single islet macrophage qRT-PCR data. Single cell qRT-PCR data for 
NOD and NOD.Rag1-/- macrophages was hierarchically clustered using Pearson correlation. (A) 
Genes selected as significant in Figure 6B and (B) all genes were plotted by hierarchical 
clustering using Pearson correlation for grouping and Global Z score for scaling. The key on the 
bottom of the heat-map indicates the cell type examined.  
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Chapter 4 
Defining and interrogating a susceptibility period during diabetes and generation of Xcr1 
mutant mouse 
Introduction 
 Previous work has shown that there is period of time in which diabetes is at a crossroads. 
If left untreated, the NOD mouse will continue through diabetes progression. However, 
intervention using various means at weaning or earlier can prevent or delay incidence and 
penetrance of diabetes. We herein term this the diabetes susceptibility period. In previous 
studies, treatment with blocking antibodies to cytokines (Debray-Sachs et al., 1991; Li et al., 
2008; Yang et al., 1994), cell depleting antibodies (Diana et al., 2013; Hu et al., 2007; Wang et 
al., 1996; Xiu et al., 2008), or lymph node removal (Gagnerault et al., 2002) before or at weaning 
prevented or delayed diabetes. Importantly however, most of these treatments did not alter 
disease course significantly if the treatments were administered at a later time point, i.e. after 
three weeks of age. Therefore, there is a window in which disease course can be altered and it is 
at or before 3 weeks of age, the age of weaning.  
It has been determined from previous work that Batf3-dependent DCs and CD8+ T cell 
priming are critical in diabetes progression (see Chapter 3; Ferris et al., 2014; Wang et al., 1996). 
The Batf3-dependent DC is critically involved in the process. Here, we endeavor to determine 
when and where this APC is necessary. It has been shown that there are cDC1 precursors 
circulating in the blood (Grajales-Reyes et al., 2015). Our lab has shown that the CD103+ DCs 
reside within the surrounding adjacent stroma (Calderon et al., 2015). There are no current data 
on how and what cell seeds the islet CD103+ DCs. Therefore, we decided to interrogate the 
trafficking of these cells and determine the role chemotaxis plays in initiating diabetes. 
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Chemokines play a major role in trafficking diabetogenic cells to the islets of Langerhans and 
many chemokines are expressed at steady state in the beta cell and in the islet resident 
macrophage (Calderon et al., 2015; Ferris et al., 2014). Although there is little work published on 
the role chemokines play in diabetes progression, there are several studies showing an increase 
or decrease in disease penetrance depending on the chemokine targeted. Absence of CXCR3, for 
instance, accelerates diabetes (Yamada et al., 2012). CXCR3 binds the chemokines CXCL9, 
CXCL10, and CXCL11, and is expressed on FOXP3+ Tregs and effector T cell subsets (Lacotte 
et al., 2009). We have shown that CXCL9 transcript induction occurs very early in diabetes 
progression (Carrero et al., 2013; Ferris et al., 2014). Therefore, an attempt at regulation and/or 
the beginning of inflammation is occurring early. The absence of CXCR3 in the NOD mouse, 
however, may have a greater effect on Treg trafficking rather than effector cell trafficking as 
these mice become diabetic with increased kinetics.  Another example of a chemokine receptor 
deficiency accelerating diabetes is that of CCR5. CCR5 plays a role in recruiting monocytes and 
its absence in the NOD mouse enhances diabetes penetrance (Solomon autoimmunity 2010). On 
the other hand, absence of another monocyte recruiting receptor, CCR2, reduces the incidence of 
diabetes (Solomon et al., 2010). Furthermore, blocking chemokines by transgenically expressing 
a decoy chemokine receptor on the beta cell reduced diabetes penetrance (Lin et al., 2011). 
Therefore, trafficking to the islets is a tightly choreographed affair. We decided to ask two 
questions: (1) can we block entry to islets by broadly inhibiting chemotaxis and (2) when is the 
susceptibility period and how is it established? To test the chemotaxis inhibition, we determined 
to block chemokine mediated entrance to the islets via g-protein coupled receptor inhibition by 
pertussis toxin (PTX). PTX inhibition of g-coupled protein receptors is mediated by 
nicotinamide adenine dinucleotide (NAD)- dependent ADP-ribosylation of g-proteins (Katada, 
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2012).  The carboxy-terminal domain of the g-protein containing the PTX site is important for 
interacting with receptor molecule G-coupled protein receptors (GPCRs). ADP-ribosylation by 
PTX results in uncoupling of the G proteins from GPCRs. Thus, the downstream signaling of the 
GPCR is abolished upon treatment with PTX (Katada et al., 1986). Of the known chemokine 
receptors, all are GPCRs (Broxmeyer et al., 2001). Therefore, we determined to inhibit all GPCR 
mediated chemotaxis by treating NOD mice at various time points with PTX to test our 
hypotheses.  
Treatment of PTX or CD8 depleting antibodies at 3 weeks of age for three weeks 
inhibited incidence of diabetes to 10% as compared to 90% incidence seen in control treated 
mice. These treatments altered and delayed infiltration of diabteogenic T cells and DCs into the 
islets when assayed a various weeks post treatment. However, islets isolated from PTX treated 
mice at over 40 weeks of age displayed substantial autoimmune infiltrate, whereas CD8+ T cell 
depleted mice at 40 weeks of age had minor infiltration. Delaying treatment initiation post 3 
weeks of age had a similar but much reduced effect on diabetes progression. Starting PTX 
treatment at 6 weeks of age for three weeks rendered a reduction of incidence to 50% and 
starting PTX treatment at 12 weeks of age for three weeks had little effect on disease 
progression. The PTX treatment at 6 weeks of age delayed infiltration for a period of time but 
rapidly the infiltration progressed to control levels. Our PTX treatments led us to hypothesize 
that the XCR1 chemokine receptor expressed on the crucial cDC1 subset drives diabetogenesis 
through interacting with XCL1 produced by T cells (Dorner et al., 2009; Ferris et al., 2014). 
However, we report here that genetic ablation of the Batf3-dependent chemokine receptor XCR1 
does not alter diabetes incidence or progression. Autoimmune infiltration to the islets was not 
delayed or reduced. Our results show two findings: (1) there is little way to alter diabetes 
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progression after a certain time period and this is earlier than clinical diagnosis in patients and 
(2) the chemotactic protein XCR1, while being a biomarker for the Batf3-dependent DC, is 
dispensable in diabetes progression.  
Results 
Pertussis toxin treatment at 3 weeks of age protects NOD mice from diabetes 
 In order to investigate the effect inhibition of chemotaxis has on the initiation of diabetes 
in NOD mice, we treated mice with PTX beginning at 3 weeks of age. Injections were given at 
1week intervals until three injections were accumulated. Mice were monitored for diabetes for a 
year or sacrificed at 6, 8, and 12 weeks of age to examine the progression of disease by islet 
infiltration or autoimmune T cell priming. The dose of PTX was chosen by calculating the total 
PTX administered during induction of the mouse model of Multiple Sclerosis, Experimental 
Autoimmune Encephalomyelitis (EAE).  In EAE, intraperitoneal (i.p.) PTX is injected at a dose 
of 300 ng twice along with Myelin Oligodendrocyte Glycoprotein (MOG) peptide emulsified in 
Complete Freund’s Adjuvant (CFA) to induce disease (Lin et al., 2016). Therefore, we decided 
to have the equivalent dose spread over three weeks and inject 200 ng i.p. at 1 week intervals to 
accumulate 600 ng total. In this manner, we derived a relevant published dose of PTX. The 
overall experimental schematic is shown in Figure 1A. We also delayed the initiation of the 
treatment from 3 weeks of age to 6 weeks or 12 weeks of age in order to test the susceptibility 
period hypothesis.  
 Treatment of 3 week old NOD mice with our PTX protocol protected mice from diabetes 
(Figure 1B). Two out of twenty mice became diabetic. In contrast, delaying the treatment three 
weeks was unable to produce protection in >50% of the animals (Figure 1B). Finally, delaying 
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treatment until mice were 12 weeks of age had no significant effect on diabetes progression 
(Figure 1B). Control mice treated with mutant PTX or PBS succumbed to diabetes at normal 
incidence and penetrance (Figure 1B). In 3 week old NOD mice, their islet CD45+ cellular 
population contains over 90% macrophage and very few if any infiltrating T cells or dendritic 
cells (Ferris et al., 2014). The CD45% is <3%.  As the mice age, autoimmune T cells and 
dendritic cells accumulate within their islets culminating in islets that contain >50% CD45+ 
cellularity by disease onset (Ferris et al., 2014).  A representative 6 week old NOD mouse islet is 
shown by flow cytometry in Figure 1C.  Gates illustrated in Figures 1C and 1D are 
representative gating strategy to determine populations within islets as the mice aged. At 6 weeks 
of age, NOD islets contain up to 20% CD45+ cellular infiltration with autoimmune T cell 
infiltrates representing almost half of the total CD45+ cellularity (Figure 1C bottom left 
histogram).  The myeloid compartment, outlined by the bottom middle and right histograms of 
Figure 2C, shows a major population of macrophages with cDC1 CD103+ DCs infiltrating. In 
contrast, a representative PTX treated animal (started PTX at 3 weeks) islets are outlined in the 
gating strategy in Figure 1D. The CD45% does not exceed 5% and T cell infiltration is reduced. 
The myeloid compartment, the vast majority of cells, has <1% cDC1 DCs and consists of >95% 
macrophages. The PTX treated islets at 6 weeks of age is identical in CD45+ cellularity as is 
evidenced in a 3 week old NOD mouse (Figure 1D).  Essentially, PTX treatment halts islet 
infiltration by autoimmune cells.  
Pertussis toxin treatment initiated in 3 week old mice delays islet infiltration  
Isolation of islets from PTX treated mice with initiation of treatment at 3 weeks of age 
showed minor islet infiltration. We harvested islets from 6 week old, 8 week old, and 12 week 
old treated mice to determine the extent of autoimmune infiltrate. Islet CD45+ cellularity did not 
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exceed 8% at any of the ages examined. In contrast, CD45+ cells exceeded 50% at 12 weeks of 
age when isolated from control treated mice. Even at 6 weeks of age, the CD45+ cellular 
percentage evidenced from control islets exceeded all ages examined in the PTX treated animals 
(Figure 2A).  PTX treatment significantly inhibited autoimmune T cell infiltration at 6 weeks of 
age.  T cell percentage as a percentage of CD45+ infiltrating cells did not exceed 10% and 
because the CD45+ cellularity was <5%, the total infiltration was almost negligible (Figure 2A-
B). T cell infiltration did increase over the time course examined albeit much slower and at a 
lower percentage when compared to the control treated animals. Indeed, 4 of the samples 
examined at 8 weeks did not show an increase in T cell infiltration from 6 to 8 weeks. At 12 
weeks of age, the percent T cell infiltration was still significantly less than that of the control 
treated mice (Figure 2B). As a comparison, when T cell infiltration is present, the myeloid 
compartment (CD11c+ MHCII+) percentage decreases (Figure 2C). This does not mean that 
myeloid cells did not enter, it simply shows that T cell infiltration, as a percentage of the 
infiltration, is more accelerated than that of the myeloid population. Indeed, examination of the 
PTX islets showed a higher percentage of myeloid cells at every time point examined indicating 
that the islet is maintained in a quiescent state (Figure 2C). Finally, an indication that diabetes is 
progressing is an increase of CD103+ DCs within the islets beginning at 3 weeks of age (Ferris 
et al., 2014). In the PTX treated mice, the population of CD103+ DCs as a function of the 
myeloid cells was not seen at 6 weeks of age. However, CD103+ DCs were found to be entering 
at 8 weeks, albeit much reduced from the control treated mice.  In the PTX treated mice at 12 
weeks of age, the CD103+ DC population resembled the population found in 6 week old control 
treated animals (Figure 2D). PTX treatment halted islet infiltration of both T cells and DCs. This 
treatment was the most efficacious one week post the last injection as evidenced by the 
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infiltration of islets isolated from 6 week old animals (Figure 2). However, even though 90% of 
the mice are protected from diabetes, their islets do become infiltrated despite the infiltration 
being much lower than control treated animals. The susceptibility window seems to fall at 
approximately 3 weeks of age and this experiment could possibly be on the latest precipice of the 
treatment period. Therefore, this could explain the propensity for some mice to still become 
diabetic.  
Pertussis toxin treatment initiated in 6 week old mice delays islet infiltration for a brief 
period of time 
 Isolation of islets from mice treated with PTX initiated at 6 weeks of age showed delayed 
islet infiltration but the infiltrate quickly returns at later timepoints. Islet infiltration of CD45+ 
cells at one week post treatment, 9 weeks of age, showed substantial reduction in islet infiltration 
(Figure 3A). The control treated islet CD45+ cellularity at 9 weeks of age showed an average of 
25% infiltration. This was in contrast to the PTX treated animals, which showed islet infiltration 
comparable to 6 week old NOD mice treated with PTX initiated at 3 weeks (Figures 2A, 3A).  
However, when PTX treated mice islets were examined at 12 weeks of age, 4 weeks post last 
PTX injection, islet CD45+ infiltration had reached ~25% (Figure 3A). This was modestly less 
than the control treated mice at 12 weeks, but greater than 12 week old islets sampled from mice 
initiated with PTX treatment at 3 weeks of age (Figures 2A, 3A).  Correspondingly, islet CD3ε+ 
T cell percentage as a proportion of CD45+ cells was also reduced at 9 weeks of age in PTX 
treated animals when compared to control treated animals (Figure 3B). Again, islet infiltration 
returned at 12 weeks of age showing no difference of CD3ε+ percentage when compared to 
control treated animals (Figure 3B). Myeloid percentage as a proportion of CD45+ cells 
remained at ~90%, comparable to all the myeloid percentages examined from mice initiated with 
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PTX treatment at 3 weeks of age (Figures 2C, 3C).  A quick return to control levels occurred at 
12 weeks of age, however, with islet myeloid percentage rapidly falling due to T cell infiltration 
(Figure 3C). Finally, islet cDC1 CD103+ DCs are briefly delayed in entering islets, but again, 
quickly return to control percentages at 12 weeks of age (Figure 3D). Because young, 
uninfiltrated mouse islets display solely the islet resident macrophage, PTX treatment “freezes” 
the islets in a quiescent state for a period of time, see figure 1. However, once a portion of islets 
are infiltrated by the primed adaptive immune cells, i.e. 6 week old NOD mouse islets, a quick 
relapse into diabetes progression occurs following PTX treatment. If however, PTX treatment 
can be initiated before overt islet infiltration and subsequent adaptive immune system activation, 
diabetes progression can be substantially delayed leading to diabetes blockade. 
Pertussis toxin treatment inhibits T cell priming in the draining pancreatic lymph node 
It has been shown that the increase in overall islet infiltration is orchestrated by the cDC1 
and T cell infiltrates (Ferris et al., 2014).  Due to the inherent nature of the cDC1 subset’s ability 
to prime CD8+ T cells and its relative absence in the islets of PTX treated mice, we assayed the 
priming of a CD8+ TCR transgenic (tg) T cell in the draining pancreatic lymph node of PTX 
treated mice. The CD8+ TCR transgenic cells were harvested from 8.3 TCR tg CD45.2 NOD 
mice. The 8.3 TCR tg (8.3 CD8+) T cells react to the 206-214 peptide derived from islet-specific 
glucose-6-phosphatase catalytic subunit related protein (IGRP) presented by Kd (Lieberman et 
al., 2003). IGRP is exclusively expressed by the islet Beta cell and, therefore, is presented solely 
in the draining pancreatic lymph node and not other lymph nodes (Ferris et al., 2014). The 
harvested 8.3 CD8+ T cells were CFSE labeled and transferred intravenously into 6 week old 
(one week post last PTX injection) or 8 week old (3 weeks post last PTX injection) CD45.1 
NOD mice that were PTX treated according to the 3 week initiation protocol, see figure 1A. 
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Recipient mouse draining pancreatic lymph nodes and control inguinal lymph nodes were 
harvested three days post transfer and assayed for CFSE dilution via flow cytometry to ascertain 
the degree of T cell priming.  
 CFSE labeled 8.3 CD8+ T cells did not proliferate in an non-pancreas draining lymph 
node, the inguinal lymph node, as expected (Figure 4A-B)(Ferris et al., 2014). To calculate the 
degree of priming, a calculation of division index was used to determine the average number of 
cell divisions occurring in the transferred cells (Roederer, 2011). Thus, the division index gives 
us the average priming occurring in the transferred CFSE labeled 8.3 CD8+ T cells.  8.3 CD8+ T 
cell CFSE division index in the draining pancreatic lymph node of control mice at 6 weeks of 
age averaged to approximately 12 (Figure 4A). The division index of CFSE labeled 8.3 CD8+ T 
cells isolated from the draining pancreatic lymph nodes of PTX treated mice at 6 weeks of age 
averaged to approximately 5 (Figure 4A).  This was only 4-fold above background inguinal 
lymph node division indexes and approximately 2-fold less than the control pancreatic lymph 
node division index (Figure 4A). Division indexes increased when CFSE 8.3 CD8+ T cells were 
transferred into 8 week old recipients (Figure 4B). We attribute this increase to an increase in 
inflammation within the islets and an increase in cross-priming cDC1 DCs within the islets as 
well. Nevertheless, the average division index of draining pancreatic lymph node CFSE 8.3 
CD8+ T cells transferred into PTX treated 8 week old mice was still approximately 2-fold less 
than the cells transferred into the control recipients (Figure 4B). These assays show that the PTX 
treatment inhibits T cell priming within the draining lymph node for an extended period of time 
even after PTX injections. PTX treatment may play a role in the ability of the islet antigen 
presenting cells (APCs) to present to islet infiltrating T cells. To test this, we isolated islets after 
treating mice with 200 ng PTX or mutant PTX intraperitoneally and assayed their ability to 
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present to diabetogenic T cells. Islets isolated from PTX and mutant PTX treated mice presented 
equally well to insulin reactive T cells (Figure 4C). PTX treatment also could alter the pancreatic 
draining lymph DC populations. To determine if PTX treatment changed the relative population 
frequency of the draining pancreatic lymph node (PLN) DCs, we flowed the PLN DC fractions at 
6 weeks of age, one week post last PTX injection. PLN DC populations assayed were determined 
by resident or migratory DC gating (Crozat et al. 2011). The migratory DC population found in 
the PLN of PTX treated mice showed a significant decrease when compared to control treated 
mice (Figure 4D). However, both the resident DC fractions of the control and PTX treated PLNs 
were assayed and no differences were identified (Figure 4D). Therefore, the inhibitory effect on 
T cell priming could be mediated by a loss of migration from the islets of the pancreas to the 
draining PLN and not by inhibiting antigen presentation within the islets.  
CD8+ and CD4+ T cell depletion at three weeks of age inhibits islet infiltration but only 
CD8+ T cell depletion prevents diabetes 
 Because we saw decreased migratory DC percentages and an impairment of CD8+ T cell 
priming in our PTX treatment assay, we hypothesized that manipulation of the CD8+ T cell 
during the susceptibility period would alter disease course. It has been shown that CD8+ T cells 
are required for diabetes (Serreze et al., 1994) and that depletion at an early age in the NOD 
mouse can prevent insulitis (Wang et al., 1996). In the latter paper, CD8+ T cells were depleted 
by antibody treatment at 2 weeks of age and assayed for insulitis at various ages.  Here we tried 
to replicate their study with minor changes. In our study, we followed the same protocol for 
treating mice as we did with pertussis toxin. We started our antibody treatments in mice at 3 
weeks of age with either YTS191.1 or YTS 196.4 antibodies that deplete CD4+ and CD8+ T 
cells respectively (Cobbold et al., 1984). It has been shown that depleting CD4+ T cells 
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throughout the life of the mouse can protect from diabetes, however if CD4+ T cells are depleted 
early during diabetes and allowed to return, diabetes still develops (Miller et al., 1988). 
Therefore, we decided to try and replicate the findings to test the susceptibility period. We 
carried out the same protocol of treatment as the PTX protocol with subsequent weekly 
injections for a total of 3 weeks of injections, see Figure 1A.  Control mice were injected with rat 
IgG following the same timeline. Cohorts of mice were either followed for diabetes or sacrificed 
at 6 weeks of age or 8 weeks of age and islets were examined for autoimmune infiltration. The 
control IgG treated mice and the mice treated with CD4+ T cell depleting antibodies showed 
normal kinetics and penetrance of diabetes (Figure 5A). However, corroborating earlier studies, 
the CD8+ T cell depleting antibody treatment protected mice from succumbing to diabetes 
(Figure 5B). To understand the islet infiltration kinetics, CD45+ cellular fractions were assayed 
by flow cytometry as were studied in the PTX treatment assays.  Notably, both CD4+ and CD8+ 
T cell depletion inhibited islet CD45+ cellular infiltration at both 6 and 8 weeks of age (Figure 
5B). This CD45+ fraction found in the islets from both the depletion studies had a similar 
percentage of islet infiltrating T cells at both 6 and 8 weeks of age. When compared to control 
IgG treated mice, the CD3ε+ T cell percentages isolated from T cell depleted mice were 
drastically reduced (Figure 5C). The myeloid fraction of the CD45+ cells remained consistently 
at ~90% in the T cell depleted mouse islets thus showing that islets remained with the islet 
resident macrophage as essentially the sole CD45+ inhabitant (Figure 5D). This was in contrast 
to the control IgG treated mice which showed a dramatic reduction in the islet resident myeloid 
fraction over time (Figure 5D). Finally, islet infiltrating cDC1 DCs remained at low percentages 
when compared to the IgG control islets (Figure 5E). It is interesting to note that CD4+ T cell 
depletion inhibits entry of islet infiltration out to 8 weeks and yet the mice still become diabetic 
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along similar kinetics when compared with the control IgG treated mice. These results do 
corroborate, however, that the early susceptibility period can be altered through manipulation of 
CD8+ T cell priming as shown by the PTX treatment. The result of the CD4+ T cell depletion 
can be explained two ways: (1) CD4+ T cells are needed to initiate islet infiltration, however, 
they are able to do so at any point during the life of the NOD mouse or (2) there are CD4+ T 
cells entering early at 3 weeks of age (Ferris e al. 2014), these cells activate cDC1 DCs and 
therefore the immune response is activated but without CD4+ T cell help, the CD8+ T cells are 
unable to progress diabetes until the CD4+ T cells return.  Nevertheless, downstream effector 
killing and epitope spreading is generated by the CD8+ T cells. Without CD8+ T cell mediated 
beta cell death, the islets become less receptive to autoimmune islet infiltration and a general 
regulatory phenotype is produced. 
CD8 depleted NOD mice aged past 40 weeks have infiltration similar to 8 week aged NOD 
wildtype mice 
 To examine the extent of protection of PTX and CD8 T cell depletion at an early age, we 
harvested islets from 40 week old NOD mice treated with PTX or CD8+ T cell depleting 
antibodies for three weeks at age of weaning (see Figure 1A). Examining the islets at this age 
would allow us to examine the degree of infiltration. Even though the mice are not diabetic, the 
degree of infiltration will allow us to understand the ability of each treatment to prevent 
autoimmune infiltrate to occur, even though they are both capable of preventing diabetes onset. 
When non-diabetic control rat IgG treated mice islets were examined at 40 weeks of age, the 
CD45+ cellular percentage was 60%. (Figure 6) Of this fraction, 66% of these cells were CD3ε+ 
T cells. These T cells were fractionated into 60% CD4+ T cells, 11% CD8α, and 25% double 
negative (DN) T cells. These DN T cells are presumably γδT cells. The myeloid fraction 
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(CD11c+ MHCII+) was relatively small representing 18% of the total CD45+ cells. Of this 
fraction, a large percentage (~30%) was represented by the CD103+ cDC1 DCs (Figure 6 top 
right). This data represents the infiltration of a non-diabetic mouse that has yet to succumb to 
diabetes. It is possible that the mouse would become diabetic at some point. The amount of 
infiltrating leukocytes into the islet is remarkable and we would theorize that if these mice were 
followed for a short period of time that they would become diabetic. Next, we examined non-
diabetic PTX treated mice islets. The extent of inflammation was striking. Handpicking the islets 
under the microscope showed that all islets had infiltrates. This exceedingly high infiltrate was 
evident by flow cytometry as well. The CD45+ percentage of total islet cells was ~90%. This 
meant that the endocrine cells represented only 10% of the total cellularity. These islets consisted 
of 60% CD3ε+ T cells and 10% myeloid cells (Figure 6 top right). In short, these islets were 
heavily infiltrated and it is noteworthy that the mice were not yet diabetic. Finally, we examined 
islets of the mice treated with CD8α+ T cell depleting antibodies at weaning for 3 weeks (see 
Figure 1A).  These mice islets exhibited low infiltrating leukocytes with the CD45+ percentage 
of cells representing only 3-10% of the total cells. Further evidencing the lack of infiltration was 
the fact that the largest population of cells within the islets remained the tissue-resident islet 
macrophage (Figure 6 bottom panels). Between the samples, the infiltration varied. However, 
both samples showed infiltration at similar levels as islets isolated from 6 week old NOD mice 
(Figure 6, see figure 2A-D). Therefore, although both the PTX and CD8+ T cell depletion 
treatments resulted in protection from diabetes, the CD8+ T cell depletion treatment reduced 
overall islet infiltration.  
XCR1 protein expressed on the Batf3-dependent DC lineage is not required for diabetes. 
 
 
140 
 The chemokine receptor XCR1 is solely expressed by the cDC1 DC lineage (Crozat et 
al., 2011).  XCR1 binds the chemokine XCL1 and it has been reported to be the only binding 
partner (Kelner et al., 1994; Yoshida et al., 1998, 1999). In previous data, qRT-PCR was 
performed on sorted islet cell populations in order to see if any relevant chemoattractants could 
be discovered. Chemokine analysis of the NOD.Rag1-/- and NOD.Batf3 mice was done to see if 
any chemokines were being produced before inflammatory infiltrates occur and therefore could 
shed light on the entrance of the CD103+ DC into the islets (Ferris et al. 2014). Our studies led 
us to use the 12 week old mouse islets also because, at this time, the inflammatory process is 
passed the early interferon gene signature stage and has moved on to destruction of the islet 
resident beta cell. In this manner, we could detect which cells were producing chemoattractants 
that may be responsible for the burst of CD103+ DCs. Purity of the sorting was confirmed by 
gene transcript expression of Cd3e, Emr1, Ins1, and Xcr1. In short, no Xcl1 transcript was 
detectable (Ferris et al., 2014). However, there was expression of Ccl19 and Ccl21. These 
chemokines coordinate DC and T cell trafficking to the T cell zones within secondary lymphoid 
organs (Bouma et al., 2005; Förster et al., 1999, 2008; Hauser and Legler, 2016). To determine 
chemokine and cytokine transcript expression in an inflamed setting, 12 week old NOD islet 
cells were sorted. To ensure cleanliness, Cd3e, Cd19, Emr1, Ins1, and Xcr1 gene transcripts 
expressed in T cells, B cells, macrophages, beta cells, and CD103+ DCs, respectively, were 
assayed. The most notable changes in cytokine and chemokine patterns was the T cell production 
of Ifnγ, the CD8+ T cell production of Ccl5 and Xcl1 (Ferris et al., 2014). Of note, the 
chemokines that are thought to be responsible solely for DC homing correspond to CCL2, CCL5, 
CCL19, and XCL1 (Johnson and Jackson, 2014; Lukacs-Kornek et al., 2008). Because CCL2 
and CCL5 are promiscuous chemoattractants binding to varying chemokine receptors and 
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because CCL19 is involved in lymphoid architecture and T cell homing, we discarded these as 
potential targets for disruption. However, the XCL1 production by the CD8+ T cell population 
was intriguing because the XCR1 chemokine receptor, as stated previously, is expressed on the 
Batf3-dependent lineage of DCs (Crozat et al., 2010, 2011; Dorner et al., 2009). Taking that into 
consideration, and knowing the intimate relationship between the CD8α /CD103+ DCs and the 
CD8+ T cells, we decided to pursue disruption of this chemokine receptor. This enabled us to 
test the receptor XCR1 in (A) attracting the CD103+ DCs over time and (B) interacting with the 
XCL1 producing T cells, whether that is within the islet or the draining pLNs.  
Therefore, we resolved to disrupt the XCR1 protein by genetically mutating the Xcr1 
gene. To do this, we utilized the CRISPR-cas9 system of genomic engineering. The Xcr1 gene 
consists of two exons, the first transcribes a small 5 amino acid span and the second comprises 
the other 325 amino acids. We targeted the last amino acid in the first exon to generate an 
essentially null protein, leaving only 4 amino acids. Microinjection of the gRNA and cas9 
protein yielded 3 founding lines herein termed NOD.Xcr1.5nt, NOD.Xcr1.6nt, and 
NOD.Xcr1.1nt. The NOD.Xcr1.5nt has a 5 nucleotide truncation before the intron spanning 
region; altering the amino acid sequence at the intron junction presumably yields an out-of-frame 
protein. Similarly, the NOD.Xcr1.6nt has a 6 nucleotide truncation before the intron spanning 
region; altering the amino acid sequence at the intron junction presumably yields an out-of-frame 
protein, as well. Finally, the NOD.Xcr1.1nt founder has a one nucleotide insertion before the 
PAM sequence yielding a stop codon (Figure 7A). Each has yielded a null protein as evidenced 
by flow cytometry and the Batf3-dependent DC lineage is not absent in these mice (shown is 
NOD.Xcr1.1nt and NOD.Xcr1.5nt, Figure 7B). For ease, all mice used for flow cytometry are 
NOD.Xcr1.1nt. However, as evidenced by flow cytometry of islets, the disease course and islet 
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infiltration is unaltered. When islets are isolated and compared to age matched control infiltrates 
at 16 weeks of age, the CD45+ infiltration is similar to the Xcr1-null islet infiltrate. (Figure 7C).  
Noticeably, the Batf3-dependent cDC1 population is still entering, but, as shown before, they are 
not expressing the XCR1 protein (Figure 7C). We followed two founding lines for diabetes, the 
NOD.Xcr1.5nt mouse harboring the 5 nucleotide deletion yielding nonsense mediated decay of 
the XCR1 protein and the NOD.Xcr1.1nt harboring the 1 nucleotide insertion yielding a 
premature stop codon, see figure 6A. When followed for disease, the kinetics and penetrance are 
not reduced (Figure 7D). Therefore, although it was a promising candidate for disruption, it 
appears as though the chemokine receptor XCR1 is not necessary for the cDC1 lineage in 
promoting disease progression.   
Discussion 
 Herein, we have described a window of disease susceptibility that is quite narrow in the 
NOD mouse. The period for intervention seems to range from approximately 2 to 6 weeks of 
age. During this period, altering chemotaxis via pertussis toxin (PTX) allowed for significant 
delay of diabetogenesis (see Figure 1). While we conjecture that PTX is inhibiting trafficking of 
the cDC1 DCs to the draining lymph node and inhibiting their ability to prime CD8+ T cells, the 
data is not complete enough to be certain of that hypothesis. We have reason to believe that the 
lack of CD8+ T cell priming is at least partially contributing to the lack of disease because of the 
paucity of migratory DCs within the draining lymph node and inhibition of CD8+ T cell priming 
within the lymph node after PTX treatment (see Figure 4). However, because PTX inhibits all 
Gαi protein coupled receptors, we cannot conclusively link PTX treatment solely to chemotaxis, 
although we strongly believe that chemokines are playing a major role in disease development. 
We have also shown here that depleting CD8+ T cells allowed for less infiltration into islets 
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when mice were assayed at 40 weeks of age, albeit the incidence of diabetes in these mice was 
the same as the PTX treated mice. We hypothesize that lacking CD8+ T cells during the critical 
susceptibility window does not allow for Beta cell death. Because of the lack of death and 
subsequent inflammation, there is less antigen draining/trafficking to the pancreatic lymph node 
and less overall T cell priming. This lack of beta cell death and islet specific inflammation 
therefore may skew the autoreactive population of CD4+ T cells from inflammatory to tolerant. 
This hypothesis fits well with the PTX data in that inhibiting autoimmune CD8+ T cell priming 
via PTX allows for CD4+ T cells to be skewed towards tolerance.   
However, CD4+ T cell depletion during the susceptibility period did not alter disease 
progression, even though we evidenced a robust inhibition of islet infiltrating cells. If CD8+ T 
cells need CD4+ T cell help, why are we not seeing protection? There are two not mutually 
exclusive possibilities for the lack of diabetes protection witnessed by CD4+ T cell depletion 
during the susceptibility window:  
(i) We missed the susceptibility window for CD4+ T cells. The possibility that autoimmunity 
within the NOD mice is occurring much earlier than thought is very probable. Indeed, the 
original description of regulatory T cells was shown by surgically removing thymuses from 3 
day old C57Bl/6 (B6) mice. If the thymus was removed before 3 days the mice had fulminant 
multi-organ autoimmunity, but if the thymus was removed after 3 days of age, the mice had no 
apparent autoimmune symptoms (Nishizuka and Sakakura, 1969; Sakaguchi and Sakaguchi, 
1992). This has been known for some time, but when pertaining to the autoimmune-prone NOD 
mouse, this knowledge is overlooked. Is it possible that the role of the autoimmune CD4+ T cell 
is occurring much earlier and their role is largely irrelevant after a certain time period other than 
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for CD8+ T cell help. Therefore, letting the CD4+ T cells return allows for the disease to 
continue.  
 (ii) CD4+ T cell help is occurring constantly throughout the diabetes process and depleting the 
cells for a short period does not alter their autoimmune propensity nor does it skew their 
phenotype towards regulation. This would imply that CD4+ T cell help for the CD8+ T cells is a 
continuous process, however, the CD4+ T cells are necessary for other autoimmune cells to enter 
the islets. Because we saw little infiltration after CD4+ T cell depletion, we conjectured that 
there would be a break in disease progression. However, this was not the case. This points to 
CD8+ T cell activation still occurring, but the cells were unable to enter into islets. Once the 
depletion of the CD4+ T cell was halted, the already primed CD8+ T cell could enter and kill the 
islet Beta cells via CD4+ T cell help. This hypothesis, while reasonable, does not explain why 
the returning CD4+ T cells are not becoming regulatory, as is the probable case happening in the 
PTX treatment. There is an overall lack of infiltration into the islets of the CD4+ T cell depleted 
mice and, therefore, less islet inflammation and less beta cell death. However, the lack of beta 
cell death and overall tolerizing milieu seen in the PTX treated mice cannot have an effect on the 
autoimmune CD4+ T cells because they are missing. The lack of the cell that is pushed towards 
being regulatory during the time period when there is a lack of inflammation could be the reason 
for why a short course of CD4+ T cell depletion is not protective. These two non-mutually 
exclusive hypotheses could explain the CD4+ T cell depletion data.  
 We have also shown that the chemokine receptor XCR1, while being a specific marker 
for the cDC1 subset of DCs, is unnecessary for the initiation and progression of diabetes. The 
XCL1/XCR1 axis has been shown to be involved in activation and priming of CD8+ T cells 
(Dorner et al. 2012) and we have shown that the activated T cells entering islets produce 
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abundant amount of XCL1 transcript (see Chapter 2). Therefore, having this information we 
decided to utilize CRISPR-Cas9 targeting of XCR1 to generate NOD mutant mice. The mutant 
mice were viable and had no overt signs of abnormal development. As stated before, we 
developed 3 founders all lacking XCR1 protein expression by flow cytometry. The Batf3-
dependent DC population was not missing; they merely lacked XCR1 expression. However, the 
XCR1 mutant mice all succumbed to diabetes with similar kinetics and penetration (see Figure 
7). When isolated, the islet infiltrating cDC1 DCs were not altered in terms of numbers or 
percentages (see Figure 7). Therefore, we conclude that the XCR1 chemokine receptor is not 
necessary for diabetes progression. There are two possibilities as to why the XCR1 mutation did 
not alter diabetes:  
(i) The XCR1/XCL1 axis is not as monogamous as previously published. There may be another 
as of yet unidentified chemokine receptor expressed by the cDC1 subset of DCs that is capable 
of binding XCL1. Since XCL1 null mice have been shown to exhibit a lack of CD8+ T cell 
priming (Dorner et al. 2012), this would explain the similarities of incidence and penetrance 
witnessed between wildtype NOD and the XCR1 mutant mice. Essentially, XCL1 is still capable 
of fostering interaction between CD8+ T cells and the cDC1 DCs via another chemokine 
receptor.  
(ii) The XCR1 chemokine receptor, while being an excellent subset marker for the cDC1 DCs, is 
not playing any role in their behavior during diabetes. This is the most likely explanation if 
XCL1 is the sole chemokine bound by XCR1. If there is not another chemokine receptor that can 
bind XCL1, than the only explanation is that the XCR1/XCL1 axis has no role in diabetes 
progression. The chemotaxis to the islets would be due to another chemokine and we were 
incorrect in targeting the XCR1/XCL1 pairing.  
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We have found an orphan GPCR, GPR33, which is expressed solely on the cDC1 subset of DCs. 
This receptor could possibly bind XCL1 or another chemokine being expressed in islets to attract 
these cells. As of writing this thesis, we have generated GPR33 null NOD mice. Some 
preliminary data has shown that these mice succumb to diabetes with normal kinetics and 
penetrance, however the XCR1 protein is still in tact. Therefore, we are beginning to cross this 
line to the XCR1 mutant to generated double knock-out mice to test if XCL1 binding to the 
cDC1 DC is necessary for disease progression.  
 In conclusion, we have shown that by inhibiting CD8+ T cell priming via PTX or by 
ablating them through antibody depletion, we can severely inhibit diabetes incidence. We have 
outlined a theory as to why there is only a brief window for inducing protection. Once priming 
and activation of T cells occurs in the draining pancreatic lymph node, rapid beta cell death 
occurs and memory cells are formed. Any attempt at control of diabetes or reversal at this point 
is extremely difficult.  Therefore, we propose that intervention or reversal strategies past a 
certain timepoint are futile in blocking autoimmune diabetes. To truly prevent this autoimmune 
disease, intervention must occur before the adaptive immune system has been activated and 
memory cells have been formed. We propose that inducing tolerogenic macrophages and DCs 
before the adaptive arm of the immune system can become activated will prevent diabetes onset. 
Currently, we are developing strategies to delete the cDC1 DCs via antibody depletion at various 
timepoints to further test the susceptibility period hypothesis.  
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Materials and Methods 
Mice 
NOD/ShiLtJ (NOD) and NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ (8.3) mice were obtained 
from the Jackson Laboratory and bred in our colony under specific pathogen free conditions. 
NOD.Xcr1 mutant mice were generated using CRISPR-cas9 targeted genetic mutation. All 
mouse experiments were approved by the Division of Comparative Medicine of Washington 
University School of Medicine (Association for Assessment & Accreditation of Laboratory 
Animal Care [AAALAC] accreditation number A3381-01).  
Islet Isolation 
Pancreata were perfused in 5 mL Hanks Buffered Salt Solution (HBSS) without calcium 
supplemented but with collagenase, removed from mouse, and digested in a 37 °C waterbath for 
~12-15 min. Younger mice had a shorter incubation time due to their smaller pancreatic mass. 
After shaking for 90 seconds, the pancreata were washed 3 times in HBSS and passed through a 
70 µm filter. The remains were flushed from the filter and islets were handpicked using the zinc-
chelating dye dithizone (Sigma-Aldrich; 200 µg/mL 10% DMSO PBS) as a marker of islets.  
Flow Cytometry 
Flow cytometry was performed using a FACSCanto II (BD Biosciences, Franklin Lakes, New 
Jersey) and data was analyzed using FlowJo software (Tree Star Software, Ashland, OR).  Islets 
were harvested as described previously and dispersed via Cell Dissociation Solution Non-
Enzymatic (Sigma-Aldrich) for 5 min at 37°C. Single cell suspensions were treated with 2.4G2 
conditioned media (PBS, 1% bovine serum albumin, and 50% 2.4G2 in DMEM) at 4 °C for 15 
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min to block FC receptors. Cells were then stained with fluorescent antibodies and assayed via 
flow cytometry.  
PTX Toxin and Antibody Injections 
For the 3 week initiation treatment, NOD mice at 3 weeks of age were intraperitoneally (IP) 
injected with 200 ng PTX (List Biological Laboratories) or mutant PTX (List Biological 
Laboratories). The mice were IP injected with the same amount of either PTX or mutant PTX at 
4 weeks of age and 5 weeks of age. For the 6 week initiation treatment, NOD mice at 6 weeks of 
age were injected with 200 ng PTX or mutant PTX. The mice were IP injected with the same 
amount of either PTX or mutant PTX at 7 weeks of age and 8 weeks of age. For the 12 week 
initiation treatment, NOD mice at 12 weeks of age were injected with 200 ng PTX or mutant 
PTX. The mice were IP injected with the same amount of either PTX or mutant PTX at 13 weeks 
of age and 14 weeks of age. For the T cell depleting antibody treatments, we used YTS191.1 
(anti-CD4) and YTS196.4 (anti- CD8α) kindly provided by the Protein Production Facility at 
Washington University in St. Louis. NOD mice at 3 weeks of age were IP injected with 500 µg 
of depleting antibody. The mice were IP injected with 250 µg at 4 weeks of age and at 5 weeks 
of age.  
Diabetes Monitoring 
Blood glucose was monitored daily or weekly and after two consecutive readings of ≥250 mg/dL 
mice were considered diabetic (Chemstrip 2GP, Roche Diagnostics, Indianapolis, IN).  
In Vivo T Cell Proliferation and Antigen Presentation Assays 
8.3 TCR transgenic mouse spleens and lymph nodes were harvested and dispersed into single 
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cell suspensions. CD8 positive cells were selected via magnetic microbead cell separation 
(Miltenyi Biotech, San Diego, CA) according to the manufacturer’s protocol. The cells were then 
stained with 1 µM CFDA SE (Life Technologies) for 10 min at 37 °C and immediately quenched 
with 4 °C DMEM supplemented with 10% FCS. 5 x 106 cells were transferred via intravenous 
injection into recipient mice. After 3-7 days, islets, draining pancreatic lymph nodes, and 
inguinal lymph nodes were harvested, dispersed into single cell populations, and stained with 
fluorescent antibodies.  Flow cytometry was performed and analyzed as described above.  For 
antigen presentation assays, T cell hybridomas (5 x 104 per well) were cultured with dispersed 
islet cells (5 x 104 per well) and with peptide pulsed APC (5 x 104 or 105 per well) as controls. 
After incubating for 18 hours, the culture supernatant of each well was assayed for IL-2 
production through use of the IL-2 dependent cell line CTLL-2. Proliferation of CTLL-2 was 
assessed by [3H] thymidine incorporation.  
Antibodies 
The following antibodies were purchased from BioLegend (San Diego, CA): FITC/PE/PerCP-
Cy5.5 anti-B220 (RA3-6B2), PE anti-CD103 (2E7), PE-Cy7 anti-CD11b (M1/70), APC-Cy7 
anti-CD11c (N418), APC anti-CD205 (NLDC-145), PE-Cy7 anti-CD4 (RM4-5), BV510/APC 
anti-CD45 (30-F11), Pacific Blue anti-CD45.2 (104), FITC/PerCP-Cy5.5 anti- CD8α (53-6.7), 
PerCP-Cy5.5/APC anti-F4/80 (BM8), Alexa Fluor 488 anti-I-Ak (40F), Alexa Fluor 647 anti-
Siglec H (ebio440c), and PE anti-VB8.1/8.2 (KJ16-133.18). The following antibodies were 
purchased from eBioscience (San Diego, CA): APC anti-CCR7 (4B12), FITC/V450 anti-CD19 
(1D3), APC anti-CD25 (PC61.5), PerCP-Cy5.5 anti-CD45.1 (A20), PerCP-Cy5.5 anti-CD45.2 
(1D4), and PE anti-FoxP3 (FJK-16s). The following antibodies were purchased from BD 
Biosciences:  FITC/APC anti-CD3e (145-2C11), V450 anti-CD45.1 (A20), FITC anti-I-AKß 
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(10-3.62), and PE anti-Vß4 (KT4). Pacific Blue I-Ag7 (AG2.42.7) was made in our laboratory. 
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Figure Legends 
Figure 1. Inhibition of Diabetes in PTX treated young NOD mice. (A) Schematic of PTX and 
depleting antibody protocol. (B) Diabetes incidence of PBS (black circles, n=12), PTX treatment 
initiated at 3 weeks of age (blue squares, n=20), PTX treatment initiated at 6 weeks of age (red 
triangles, n=10) and PTX treatment initiated at 12 weeks of age (green diamonds, n=10). 
Representative flow plots of (C) Control PBS treated mice or (D) PTX treated NOD mice at 6 
weeks of age. PTX treatment initiated at 3 weeks of age. 
Figure 2. PTX treatment initiated at 3 weeks inhibits islet infiltration. Representative graphs of 
data from flow plots of islets isolated from NOD mice treated with control PBS or PTX at 3 
weeks of age (see Figure 1A). Ages and treatment of mice are displayed on the X-axis.  Gating 
strategy for the graphs is shown in Figures 1C-D. (A) Percent of CD45+ cells in isolated islets. 
(B) Percent CD3ε+ cells of total CD45+ cells in isolated islets (C) Percent CD11c+ MHCII+ 
cells of total CD45+ cells in isolated islets. (D) Percent CD103+ cells of total CD11c+ MHCII+ 
cells in isolated islets. 
Figure 3.  PTX treatment initiated at 6 weeks inhibits islet infiltration for a short period but 
quickly reverts to control treated levels. Representative graphs of data from flow plots of islets 
isolated from NOD mice treated with control PBS or PTX at 6 weeks of age (see Figure 1A). 
Ages and treatment of mice are displayed on the X-axis.  Gating strategy for the graphs is shown 
in Figures 1C-D. (A) Percent of CD45+ cells in isolated islets. (B) Percent CD3ε+ cells of total 
CD45+ cells in isolated islets (C) Percent CD11c+ MHCII+ cells of total CD45+ cells in isolated 
islets. (D) Percent CD103+ cells of total CD11c+ MHCII+ cells in isolated islets. 
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Figure 4. PTX treatment inhibits CD8+ T cell priming in the draining pancreatic lymph node. 
CFSE dilution of transferred 8.3 NOD CD8+ T cells into (A) 6 week old PTX treated mice and 
(B) 8 week old PTX treated mice. Cells were isolated from the pancreatic lymph nodes and 
inguinal lymph nodes from recipient mice. Cells were assayed 3 days post transfer. 
Representative graphs are shown on the right. Dots represent individual mice. (C) Islets isolated 
from PBS or PTX treated mice were dispersed and incubated O/N with an insulin reactive 
hybridoma. The supernatant was then assayed for IL-2 production as described in the main 
methods.  Islets were either left untreated (left) or pulsed with 10µM Ins B:9-23 (right). (D) 
Percentage of migratory or resident DC populations as shown in gating strategy in Figure S1.  
All PTX treatments were initiated at 3 weeks of age (see Figure 1A). P values were calculated 
using Mann-Whitney U test (** P < 0.005). 
Figure 5. T cell depletion early inhibits islet infiltration for a period but only CD8+ T cell 
depletion protects from diabetes. (A) Diabetes incidence of mice treated with control IgG (black 
circles), CD4+ T cell depleting antibodies (red triangles), and CD8+ T cell depleting antibodies 
(blue squares). Representative graphs of data from flow plots of islets isolated from NOD mice 
treated with control IgG, YTS191.1 (anti-CD4), or YTS169.4 (anti-CD8α) at 3 weeks of age (see 
Figure 1A). Ages and treatment of mice are displayed on the X-axis.  Gating strategy for the 
graphs is shown in Figures 1C-D. (B) Percent of CD45+ cells in isolated islets. (C) Percent 
CD3ε+ cells of total CD45+ cells in isolated islets (D) Percent CD11c+ MHCII+ cells of total 
CD45+ cells in isolated islets. (E) Percent CD103+ cells of total CD11c+ MHCII+ cells in 
isolated islets. 
Figure 6. CD8+ T cell depletion during the susceptibility period inhibits islet infiltration for the 
life of the mouse. Flow cytometry plots of islets isolated from control IgG (top left), PTX (top 
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right), and YTS169.4 (anti-CD8, bottom panels) treated NOD mice. Pooled islets from 2 mice 
were isolated from NOD mice treated with control IgG, YTS191.1 (anti-CD4), or YTS169.4 
(anti-CD8α) at 3 weeks of age (see Figure 1A). 
Figure 7. Loss of the chemokine receptor XCR1 does not inhibit islet infiltration or diabetes in 
NOD mice. (A) Schematic of CRISPR-Cas9 targeted deletions of the three founding XCR1 
mutant mouse lines. (B) Flow cytometry plots of pancreatic lymph nodes isolated from NOD 
(top) or NOD.Xcr1.1nt (bottom) mice. (C) Flow cytometry plots of islets isolated from NOD 
(top) or NOD.Xcr1.1nt (bottom) mice at 16 weeks of age. (D) Diabetes incidence of 
NOD.Xcr1.1nt (blue circles) and NOD.Xcr1.5nt (black squares). Numbers of mice followed for 
diabetes are indicated in Figure 7D.  
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Chapter 5 
Discussion and Future Directions 
Parts of Chapter 5 are taken from a review derived from this thesis. It was published in 
the Journal of Autoimmunity in July of 2016.  The authors were Stephen T. Ferris, Javier A. 
Carrero, and Emil R. Unanue. 
The APC of the islets: the macrophages 
The presence of APC in islets of non-diabetic animals was described in early histological 
studies as well as in the analysis of isolated islets. The most recent studies were reviewed by 
Calderon et al. 2014 which contains references to the initial reports (Calderon et al., 2014). The 
APCs in normal islets, i.e. from non-diabetic mice, were initially identified as F4/80 positive 
cells, a marker of macrophages (Calderon et al., 2014). When islets were isolated and examined, 
the myeloid cells were referred to as dendritic cells (DCs) based on their expression of the 
CD11c marker (Calderon et al., 2008; Melli et al., 2009; Tang et al., 2006). However, more in-
depth examination, including the testing of various cell markers combined with gene expression 
patterns and developmental studies, identify them as macrophages (Calderon et al., 2015; Ferris 
et al., 2014).  
These resident macrophages of the pancreas have distinct features (Calderon et al., 
2015)(Figure 1). The islet macrophages in non-diabetic strains are monolithic, representing only 
one population based on flow cytometric evaluation (Table 1). The pancreatic stromal 
macrophages parse into two populations based mainly on their expression of CD206 (mannose 
receptor) and CD301 (CLEC10A). The islet macrophages are present within the islets since birth 
 
 
165 
and derive from definitive hematopoiesis. Under steady state, the islet macrophages do not 
exchange with monocytes, but proliferate in situ, albeit slowly. In striking contrast to the islet 
resident macrophages, are those found in the inter-acinar stroma. The CD206/CD301-negative 
stromal macrophage population is derived from blood monocytes and in constant turnover, and 
the CD206/CD301+ stromal macrophage is derived from yolk-sac hematopoiesis. The latter tend 
to concentrate around the pancreatic ducts.  
The turnover of these macrophages was examined by the technique of parabiosis of mice 
differing in the myeloid marker CD45, i.e. one mouse expressing CD45.1 was parabiosed to 
another expressing CD45.2. After several weeks of blood exchange, analysis of the islets or the 
stromal yolk-sac derived cells showed no interchange between the two parabionts. The islet 
macrophages and stromal yolk-sac derived macrophages, in contrast to monocytes and 
lymphocytes in the spleen, maintained their initial distribution prior to the parabiosis (Calderon 
et al., 2015). Therefore, these resident macrophages are maintained by a low level of replication. 
Furthermore, there are differences in gene expression and function between the stromal 
and islet macrophages. The islet-resident macrophages display a gene expression profile 
consistent with an M1 activation pattern, while the stromal macrophages exhibit transcripts 
consistent with an alternative activation pattern, or M2. Additionally, the islet resident and 
CD206/CD301-negative stromal populations of macrophages express a high-level of MHC-II 
even under steady state conditions. The macrophages that do not express CD206/CD301 can 
present exogenous antigen to T cells ex vivo, whereas the CD206/CD301+ macrophages present 
very weakly. Macrophages in other tissues also differ in origin and properties (reviewed in 
Murray et al., 2014; Wynn et al., 2013). 
 
 
166 
When mice were lethally irradiated and reconstituted with bone marrow stem cells, the 
reconstituted macrophages found in the islets and the stroma were still M1 or M2 in their gene 
expression signatures respectively. From these series of findings, we concluded that the 
“pancreas anatomy conditions the origin and properties of the resident macrophages” (Calderon 
et al., 2015). How each tissue conditions the biology of their resident cells is an important issue 
for future investigations. 
The islet macrophages have a homeostatic or trophic role. This role became apparent in 
studies from Pollard’s group examining the op/op mouse (Banaei-Bouchareb et al., 2004). This 
mouse has a natural mutation in the Csf-1 gene and consequently lacks macrophages in many 
tissues. Their islets are of small size and a number of mice have an abnormal glucose tolerance 
test (Calderon et al., 2015). Calderon, et al. showed that most of the op/op mouse islets lack 
macrophages or contain no more than two per islet. In contrast, islets of normal mice have 
macrophages ranging in number from 2 to about 20, depending on their size, with a mean of 
about 10 per islet (Calderon et al., 2008). The basis of this trophic supportive role of the islet 
macrophage is not known, but clearly beta cells and the resident macrophages are 
communicating with each other in a homeostatic relationship. 
The islet resident macrophages have a close interaction with blood vessels. Live images 
of islets isolated from CX3CR1-GFP mice show them extending long dendrites amongst the beta 
cells. Moreover, some of the dendrites penetrate the lumen of the blood vessels (Calderon et al., 
2008). Finally, islet macrophages, as discussed below, have taken up insulin containing granules, 
on the average of about 3 granules per cell (Vomund et al., 2015). 
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In Chapter 3, it was shown that the islet macrophage is “resting” in an enhanced 
inflammatory state. This data further expanded upon the original finding that the islet 
macrophage was M1 skewed (Calderon et al., 2015). This chapter delved deeper into the islet 
macrophage gene signature and showed that it was producing high levels of inflammatory 
protein even at steady state (see Chapter 3 Figure 5). Therefore, why is the islet macrophage, 
even in non-diabetic strains, in a resting inflammatory state? There are three ways in which the 
islet macrophage could gain this phenotype: 
(i) The islet macrophage inherits this signature during islet development. The pancreas and the 
gut are derived from developmentally similar structures during organogenesis (Hebrok, 2003; 
Kim and MacDonald, 2002). Thus, the macrophages that seed these structures will be exposed to 
similar tissue states as they develop within the organ, whether that be the developing pancreas or 
gut tissue. Therefore, the developing state of the pancreas and the gut could initiate the 
phenotype of the islet macrophage and this inflammatory state persists through the life of the 
mouse.  
(ii) The islet macrophage is exposed to gut microbes or their byproducts. It is known that the 
microbiome alters the development of diabetes. Germ free mice become diabetic more quickly 
and with greater penetrance (Wen et al., 2008).  Mice treated with varying cocktails of 
antibiotics, drastically reducing the gut microbial species variance and overall numbers, 
enhances diabetes penetrance and incidence (Candon et al., 2015; Livanos et al., 2016). Thus, as 
the species variation and overall number of microbes residing within the gut decreases, the 
propensity for developing diabetes increases. It is likely that the commensal microbes are 
damping the autoimmune process through innate signaling. Indeed in another study, Myd88 
deficiency, an adaptor involved in signaling through many TLRs, in NOD mice led to a 
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protection in disease (Burrows et al., 2015). Here, the authors postulated that signaling through 
TLR4 via TRIF was protective, while signaling through Myd88 led to autoimmunity. They put 
forth a “balance of signaling” hypothesis stating that the activation signaling going through the 
Myd88 adaptor has a more prominent effect on diabetogenesis. Therefore, the microbiome could 
be interacting with the islet macrophage via the gut or via the blood stream to initiate or dampen 
the autoimmune process.  
(iii) Products of the beta cell influence the phenotype of the islet macrophage. The islet 
macrophage is in close contact with beta cells. These beta cells are constitutively producing large 
amounts of insulin within their granules. The beta cell can pass these granules to the islet 
macrophage (Vomund et al., 2015). The islet APCs are the only cells capable of presenting 
antigen at sufficient quantities to signal T cell hybridomas against insulin or the degradative 
products of insulin (Ferris et al., 2014; Vomund et al., 2015). These granules not only contain 
insulin, but many other trafficking and granule forming proteins, high amounts of ATP, calcium, 
zinc, and sulfur (Brunner et al., 2007; Foster et al., 1993). Because the whole dense core granule 
can be taken up by the macrophage, it is feasible that the relative concentration of any of the 
granule contents, once ingested, would render its concentration fairly high within the 
macrophage itself. Therefore, the basal capturing of beta cell granules could stimulate the 
macrophage, and thus produce the phenotype we observed in chapter 3.  
 Current experiments testing these three hypotheses are ongoing in the lab. To test point 
(ii), we have begun treatment of NOD or NOD.Rag1-/- mice with vancomycin, neomycin, 
ampicillin, and metronidazole (VNAM); broad-spectrum antibiotics. However, the VNAM 
treatment did not dampen the observed islet macrophage phenotype (data not shown). If 
anything, the depletion of the microbiome increased the intracellular production of pro-IL-1β and 
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TNFα by the islet macrophage. This data is preliminary, but it appears as though the microbiome 
is more than likely having an anti-inflammatory effect on the overall islet macrophage 
phenotype. Based upon the work by Burrows et al. 2015, we have obtained Myd88 deficient 
mice and are beginning to examine their islet macrophage phenotype. Our hypothesis is that we 
should see a dampening of the inflammatory phenotype observed in the normal islet macrophage.  
Finally, to test hypothesis (iii), Dr. Derrick McCarthy has incubated bone marrow derived 
macrophages (BMDM) with insulinoma cell lines. Because BMDMs do not express high levels 
of MHC class II, his read-out for the islet phenotype was expression of MHC class II. As of 
writing this thesis, it appears as though placing differentiated macrophages on insulinoma cell 
lines does not recapitulate the islet macrophage phenotype. However, culturing the BMDMs with 
insulinomas during the differentiation process of the macrophages induced MHC class II 
expression. Therefore, although these findings are preliminary, the islet macrophage phenotype 
observed may be partially or wholly shaped by the surrounding beta cells.  
The APCs of the islets: the CD103+ DCs. 
In NOD mice, at 3-6 weeks of age, another APC is found within the islet in small 
numbers but which increases as diabetes progresses (Ferris et al., 2014). This minor population is 
a DC that expresses CD103 (Figure 2). It belongs to the lineage of DC characterized by being 
efficient in cross presentation, i.e. capable of presenting to CD8+ T cells when taking up proteins 
or cellular material, i.e. cDC1 DCs (Shortman and Heath, 2010). At the same time that the 
CD103+ DC enter the islets, a few CD4+ T cells are also found. It is striking that most of the T 
cells are found in contact with the islet APCs. There is a correlation in presence of the CD4+ T 
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cells, the CD103+ DC, and the interferon-inducible gene signature of inflammation (Ferris et al., 
2014).  
We have paid attention to T cells found in isolated islets. The islets of non-diabetic mice 
have a small number of CD45+ cells, ~2-5%, mostly represented by the macrophages described 
above. However, up to 5% of these CD45+ cells are T cells. We consider this small number as 
“passenger” T cells, but could be tissue resident memory cells or the first cells to be instigating 
the autoimmune response. By direct microscopy, T cells are not found in islets (Calderon et al., 
2011). Finally, also to note, is the importance of isolating the islets free of stromal cells or the 
perilobular lymphoid aggregates. These represent the bulk of cells in a pancreas and 
contamination with them can be a serious problem when examining islets (see Chapter 3 
supplemental Figures 2&3). 
To examine the role that the CD103+ DC is playing in diabetogenesis, we crossed the 
Batf3 gene knockout mouse onto the NOD background. The Batf3-deficient mice were generated 
by Dr. Kenneth Murphy. His laboratory found that the Batf3 transcription factor is critical in the 
differentiation of the common DC precursor to the CD103/CD8α+ alpha lineage (Hildner et al., 
2008). The absence of this DC lineage renders the mouse incapable of cross-presenting antigens 
to CD8+ T cells. Thus, these mice are susceptible to viral infections and do not reject 
immunogenic syngeneic tumor cells. We performed microsatellite marker analysis to confirm 
full backcrossing and SNP analysis on the IDD loci to ensure NOD purity (see Chapter 2 
Supplemental Tables 1&2). The Batf3 null mouse (NOD.Batf3-/-), in brief, lacks the 
CD103/CD8α+ DC lineage of DCs in all lymphoid tissues, confirming the findings made by the 
Murphy laboratory (Edelson et al., 2010; Ferris et al., 2014; Hildner et al., 2008).  
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The NOD.Batf3-/- mice did not become diabetic when followed for more than a year. 
Moreover, by histology and flow cytometry, there was no infiltration of hematopoietic cells at 
any time. As a side note, there is no other NOD model besides genetic depletion of T cells such 
as the NOD.SCID or NOD.Rag1-/- mice that have as “healthy” islets as those found within the 
NOD.Batf3-/- mice. Gene expression analysis of the isolated islets did not show the signatures of 
inflammation that develop in the NOD by the 4th to 8th week of life. In fact, the gene expression 
analysis of NOD.Rag1-/- and the NOD.Batf3-/- were practically identical (Ferris et al., 2014). 
Where is the defect in the NOD.Batf3-/- mice, in the autoreactive T cells or in the APCs? 
To test these issues, NOD.Batf3-/- mice were lightly irradiated and partially reconstituted with 
NOD.Rag1-/- bone marrow cells. A few weeks later, the islets and lymphoid tissues now 
contained the CD103+ DC. The transplant had replaced the defective DC lineage. T cells now 
entered the islets of these mice resulting in diabetes. As a control, NOD.Batf3-/- reconstituted 
with bone marrow from a NOD.Rag1-/-xBatf3-/- was ineffective at replacing the DC lineage or 
causing inflammation within the islets. The key finding here is that the absence of diabetes in the 
Batf3-deficient mice was caused by the lack of the CD103+ DCs, and that Batf3-deficient T cells 
are fully competent but unable to initiate diabetogenesis without said DCs. Indeed, in other 
experiments, T cells isolated from the NOD.Batf3-/- were able to transfer diabetes when injected 
into NOD.Rag1-/- mice (Ferris et al., 2014). 
To further test the requirement of T cell infiltration on the accumulation of the Batf3-
dependent DC within the islet, we examined three congenic strains of mice: NOD.B16A, 
NOD.H4, and NOD.Rag1-/-. NOD.B16A mice, generated by the Eisenbarth laboratory 
(Nakayama et al., 2005, 2007), are homozygous null for the Ins1 and Ins2 genes. Under control 
of the rat insulin promoter, a mutated for of insulin is expressed. The mutated insulin was 
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engineered with an amino acid change from alanine to tyrosine at position 16 of the B chain, 
hence B16A. These mice did not become diabetic, and it is generally thought that the change 
from alanine to tyrosine renders the insulin non-immunogenic to T cells.  Indeed, most anti-
insulin CD4+ T cells did not react with the modified insulin. The NOD.H4 mouse is I-Ak and, 
therefore, does not have the diabetogenic MHC class II allele I-Ag7. This strain does not become 
diabetic. Finally, the NOD.Rag1-/- mouse is deficient in lymphocytes due to their inability to 
rearrange their antigen receptors during development.  
In the islets of NOD mice at 12 weeks of age, there is ~20% CD103+ DCs within the 
CD11c+ MHCII+ gate. This time point was used as a reference to examine the accumulation of 
CD103+ DCs in the congenic strains. The NOD.Rag1-/- mice had the basal 5% CD103+ DC. 
This 5% can be seen at 4-6 weeks of age in wild-type NOD mice. Therefore, T cells are not 
needed for the initial seeding of the islet by the CD103+ DCs. However, they are necessary for 
the burst over time. The NOD.H4 was examined to ascertain if non-diabetogenic T cells could 
initiate a burst of CD103+ DCs within the islet. The percentage of T cells was ~3-4% of the 
CD45+ population and considered passengers. The CD103+ DCs were at 5% and considered 
basal. We concluded that non-immunogenic T cells could not drive the expansion of the DCs 
within the islets (Ferris et al., 2014 see Chapter 2 Figure 3).  
Finally, to test if insulin reactive T cells, which are generally thought to be the driver or 
initiating T cells in diabetes, we examined the islets of the NOD.B16A mice. Similar to the 
NOD.H4 mice, at 12 weeks, the T cell percentage was ~3-4% of the CD45+ cells and the 
CD103+ DC percentage was 5% of the APCs (Ferris et al., 2014, see Chapter 2 Figure 3). 
Therefore, the congenic mouse studies showed that T cells are unnecessary for the initial seeding 
of the islets by the Batf3-dependent DCs and that the accumulation of these DCs requires an 
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autoreactive T cell population and, more specifically, an insulin autoreactive T cell population. 
Taken together, these experiments point to the requirement of CD103+ DCs, insulin reactive T 
cells, and the expression of the MHC class II IAg7 molecule to initiate the diabetogenic process.  
In the absence of the CD103+ DC, the presentation of beta cell epitopes in the pancreatic 
lymph node was decreased. While presentation of the islet specific glucose-6-phosphotase 
related protein (IGRP) MHC class I epitope was undetectable, presentation of the BDC2.5 MHC 
class II epitope was reduced by about half. Importantly the entry of insulin reactive T cells or the 
BDC2.5 T cells into islets was not detected (Ferris et al., 2014 see Chapter 2 Figure 6). Thus, the 
CD103+ DC controls the entry as well as the priming of T cells.  
The manner in which the CD103+ DC regulates the initiation of diabetes is an issue of 
continuing investigations. There are several questions left unanswered and current work within 
the laboratory is working to address these questions. The questions are:  
(i) Why are the cDC1 DCs entering islets in the NOD strain but not in non-diabetic strains and is 
this anomaly a trigger for diabetes? 
(ii) Are the cDC1 DCs controlling antigen traffic to the draining pancreatic lymph node? 
(iii) How are these DCs entering the islets, are they precursors entering from the blood or are 
they entering from the surrounding acinar tissue into the islets? 
(iv) Is there a way to inhibit traffic of these cells, either to the islets or their traffic to the nodes? 
 These questions were addressed in some respects and explained in Chapter 4. In brief, we 
tried to halt cellular trafficking by inhibiting chemotaxis using pertussis toxin (PTX). In some 
respects, we utilized a “hammer” inhibiting all g-coupled protein receptor signaling to address 
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cellular trafficking and so may have been heavy handed in our design. We also were not able to 
address the direction of the trafficking although it is pointing to a block in trafficking to the 
draining lymph node. We were able to block entry for a period of time of cells into the islets, 
therefore we believe that the majority of trafficking, whether it is the early cDC1 entry or the 
later burst produced by T cell infiltration, is controlled by chemokine trafficking.  
 Because we had the PTX data and the knowledge that the cDC1 subset is marked by a 
specific chemokine receptor XCR1 involved in CD8+ T cell interactions (Dorner et al., 2009), 
we attempted to inhibit chemotaxis to the islets by genetically ablating the XCR1 chemokine 
receptor. We generated three founding lines of Xcr1-deficient NOD mice as explained in Chapter 
4. These lines showed absence of the chemokine receptor by fluorescence-activated cell sorting 
(FACs) analysis. Nevertheless, the mice succumbed to diabetes with similar disease incidence 
and penetrance (see Chapter 4 Figure 7). However, this does provide us with evidence that the 
XCR1 chemokine receptor is dispensable for disease progression. We are currently attempting to 
address the entry of these cells by generating an XCR1-mOrange-DTR reporter mouse. In this 
manner, we can visualize whole pancreata by 2-photon and image the trafficking of these cells. 
We are placing the gene for diphtheria toxin receptor (DTR) in the construct in order to ablate 
these cells with diphtheria toxin as a means of testing when they are needed in the development 
of diabetes. Along these lines, we are also immunizing our Xcr1-deficient mice with XCR1 
expressing cDC1 cells in order to generate a depleting antibody that would be more translatable 
to the clinic. Finally, we have generated CXCL14 and CXCL16 deficient mice. These 
chemokines are highly expressed by the islet resident macrophage (see Chapter 3). In the case of 
CXCL14, it is expressed solely in the NOD islet macrophage and not expressed in non-diabetic 
strain islet macrophages. This chemokine is a promising candidate for disruption because it has 
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been shown to be involved in chemotaxis of DCs (Hara and Tanegashima, 2012; Shellenberger 
et al., 2004; Shurin et al., 2005). Therefore, we hypothesize that the original seeding of the islets 
by the cDC1 DCs is caused by the abnormal expression of CXCL14 by the NOD islet 
macrophage. In deleting this chemokine, we will be able to test this hypothesis directly and 
interrogate the trafficking of these DCs to the islets.  
 In conclusion, we have described the islet APC landscape as it pertains to not only 
diabetes, in the NOD mouse, but also across non-diabetic strains. The abnormal accumulation of 
cDC1 DCs within the islets of NOD mice is intriguing considering we have evidence that a small 
number of T cells are always present in islets. We term these T cells “passenger” T cells, but it is 
possible that these could be tissue resident memory cells. These T cells may not able to initiate 
diabetes due to (a) the inherent genetics governing T cell signaling, (b) an incorrect MHC class II 
molecule, or (c) the absence of the trafficking cDC1 DC within the islets. The perfect example of 
a combination of all three of these possibilities is the B6.g7 mouse (see Chapter 3). This mouse 
is genetically C57Bl/6 but has the diabetic MHC II locus. These mice do not become diabetic. 
They harbor the correct MHC class II molecule but the levels of T cell infiltrate do not exceed 
that of “passenger” level. These islets also do not contain cDC1 DCs at any time period 
examined and the islet macrophage does not express CXCL14. It is possible that the T cells are 
becoming abnormally activated within the islet by the resident macrophage but cannot generate 
CD8+ T cell help without the presence of the cDC1 subset of DC. A general schematic of our 
current model of diabetes progression is represented in Figure 3.  In short, we believe that the 
interplay between the highly activated islet macrophage, the cDC1 CD103+ DC, and the 
autoreactive CD4+ T cells coordinate the initiation of diabetes. Once this process has begun, it is 
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propagated to the draining lymph node and is difficult to inhibit. This thesis provides the 
groundwork for further studies to pursue the initiation of diabetes.  
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Figure Legends 
Figure 1. The multiple origins of pancreatic macrophages and their maintenance. The illustration 
depicts the origin of islet-resident macrophages (adult HSC derived, shown in green) and their 
self-maintenance by in situ proliferation. These show basal M1 features. In contrast, the exocrine 
pancreatic (stroma) macrophages are composed of two subsets: one in continual replacement by 
circulating monocytes (adult HSC derived) and not self-maintained and the second derived from 
yolk sac and fetal liver monocytes (shown in red) and self-maintained. Half the interacinar 
macrophages expressed CD206 and CD301 and were preferentially situated among pancreatic 
ducts. The second set derives from circulating monocytes and did not express CD206 or CD301. 
All macrophages in the interacinar stroma have M2 features. From Calderon et al. 2015 with 
permission. 
Figure 2. Islet APC composition differs between the NOD and NOD.Batf3-/- mice. Scatter plots 
represent the flow cytometry of dispersed islets from two NOD (top) or NOD.Batf3-/- (bottom) 
mice at 12 weeks of age. Each gate is predicated upon the panel to the left, e.g. CD11c+ MHCII+ 
gate displays cells from the CD45+ gate. The NOD shows two APCS, the F4/80+ macrophage 
and the CD103+ DC, whereas the NOD.Batf3-/- is missing the CD103+ DCs. 
Figure 3. Current model of diabetes progression. 
1) Type B insulin autoreactive CD4+ T cells enter the islets. Those islets that are absent of Batf3-
dependent dendritic cells are unable to recruit and/or retain the autoreactive T cells and the 
diabetogenic process is never established. Hence, the “healthy” islets that are evidenced in the 
NOD.Batf3-/- mouse.  
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2) An as of yet unknown interaction amongst the resident macrophage, the CD103+ DC, and the 
autoreactive T cell occurs, activating the CD4+ T cell. 
3) Once the CD4+ T cell gets activated, either by the macrophage or the CD103+ DC, the 
trafficking DC, presumably the CD103 DC, becomes activated and exits the islets. 
4) The draining pancreatic lymph node, upon receiving an activating and inflammatory signal 
from the trafficking DC, switches from a regulatory depot, to an amplification and priming 
source for islet autoreactive T cells.  
5) Primed autoreactive T cells enter islets and destroy beta cells releasing more antigen and 
providing expansion of the autoimmune process.  
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Table 1. Pancreatic macrophage profile under steady state 
Expression 
marker 
Islet 
macrophage 
Stroma 
CD206+ 
macrophage 
Stroma 
CD206- 
macrophage 
F4/80 + + + 
CD11b + + + 
CD11c + + + 
MHC-II + +/- + 
CD64 + + + 
CD68 + + + 
LyzM + + + 
Cx3cr1 + +/- +/- 
CD206 - + - 
CD301 - + - 
Ly6C - - - 
CD103 - - - 
Zbtb46 - - - 
Il1b + - - 
Tnfa + - - 
Nos2 - - - 
Arg1 - +/- +/- 
Il10 - + - 
Ym1 - - + 
Fizz1 - + + 
+ , high expression; +/-, low expression; -, negative expression 
